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ABSTRACT
Despite progress in detection and treatment, lung cancer remains the leading
cause of cancer-related death in the United States. The United States Preventive Services
Task Force (USPSTF) recommends adults at high risk for lung cancer undergo annual
low-dose computed tomography (LDCT) screening, however, lung cancer screening
(LCS) uptake remains low. Qualitative research on family physician (FP) perceptions
and experiences with LCS has been limited since USPSTF publication and Centers for
Medicare and Medicaid Services (CMS) decision memo. We conducted a qualitative
study to assess FP knowledge and perceptions of LCS and gain insight into their current
experiences with LDCT. A convenience sample of FPs were asked to participate in
Skype audio interviews. A semi-structured interview guide was used to navigate the
interviews. A theme codebook was developed using the constant comparison technique.
All interviews were coded by two reviewers.
We found that FP knowledge about the scientific evidence and patient eligibility
criteria for LDCT was suboptimal. Age and smoking history were the primary drivers of
a FPs decision to discuss LCS. Most FPs knew that they should initiate LDCT
discussions with high risk patients, however, they indicated that they would be willing to
screen patients outside of the specified criteria. LDCT cost and lack of time were cited as
barriers. Facilitators included screening tools in the clinic waiting room and electronic
medical record notifications. These results indicate a need for FP education about LCS,
as well as tools to assist providers in the clinic.
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As LCS becomes more widely adopted, more lung cancers will be detected at an
earlier stage. While tumor molecular testing (MT) is currently recommended for patients
with metastatic disease, MT could increasingly be used in early stage patients to guide
initial treatment decisions. Disparities in MT and targeted therapy utilization may exist.
We quantitatively evaluated factors related to MT and erlotinib utilization and the impact
of these on overall survival (OS).
Stage IIIB/IV non-small cell lung cancer (NSCLC) cases diagnosed between
January 1, 2002 and December 31, 2012 and available through the South Carolina
Central Cancer Registry were linked to SC State Employee Health Plan (SCSEHP) and
Medicaid administrative claims data. MT and erlotinib utilization were independently
categorized as “yes” or “no” based on claims data. We found several characteristics
associated with MT, including younger age, having an out-of-state provider, being
diagnosed in 2010 or later, adenocarcinoma histology, and low tumor grade. Risk of
death was reduced and OS was longer for patients with MT. Younger age, female sex,
SCSHEP insurance, having an out-of-state provider, adenocarcinoma histology, and
having molecular testing were associated with erlotinib utilization. Risk of death was
lower for patients treated with erlotinib and OS was longer. These results suggest that
tumor MT and erlotinib utilization lead to improved patient survival. Additional research
should evaluate these important factors in nationally representative datasets.
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CHAPTER I:
INTRODUCTION
Statement of the Problem
In the United States, an estimated 1,688,780 new cases of cancer will be
diagnosed in 2017.1 Of these, approximately 222,500 cases of lung cancer will be
diagnosed and an estimated 155,870 individuals will die from the disease.1 In North
Carolina and South Carolina, collectively, 12,261 new cases are estimated (NC: 7,940;
SC: 4,321) and deaths are estimated.1 Lung cancer is the second most frequently
diagnosed cancer and is the leading cause of cancer mortality among both males and
females, with five-year survival rates of 18% among all races.1 Over half (57%) of cases
are diagnosed with distant disease, meaning the patient has advanced or metastatic
disease at the time of diagnosis.1 Only 22% of cases are diagnosed with localized or
regional disease.1 Five year survival is better for those diagnosed with local disease
(54%) compared to those with regional or distant disease (27% and 4%, respectively).2
Since 1990, a decrease in the lung cancer mortality rate has been observed in both
males and females, but the decline has been greater for males.1 Hopefully, this
decreasing trend will remain stable or improve in future decades, as improvements in
lung cancer detection and treatments are made. Lung cancer screening with low-dose
computed tomography (LDCT) and treatment with molecularly targeted therapies are two
approaches to the control of lung cancer in the United States, both of which have become
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popularized within the last two decades. The goal of LDCT is to identify lung cancer in
earlier stages, when the disease is more treatable, while the goal of molecularly targeted
treatment is to improve survival and quality of life (QOL).
This dissertation will consist of three lung cancer research manuscripts. The first
will focus on family physician (FP) lung cancer screening perceptions and practices
(Chapter IV). The second and third manuscripts will focus on: 1) factors related to
molecular testing and its impact on survival (Chapter V); and 2) factors related to
utilization of erlotinib and erlotinib’s impact on survival (Chapter VI).
Lung Cancer Background
Lung cancer is among the most commonly diagnosed cancers and is the number
one cause of cancer death among adults in the United States.1 Broadly, lung cancer can
be divided into two subtypes: non-small cell lung cancer (NSCLC) and small cell lung
cancer. NSCLC can be further sub-categorized as adenocarcinoma, squamous, or large
cell carcinoma. NSCLC is the most common type, comprising 85% of cases. A new lung
cancer screening approach, low-dose computed tomography, allows for detection of early
stage lung cancer that can be curable3. For patients diagnosed with early stage NSCLC,
surgical resection is the cornerstone of their treatment, however, approximately 70% of
patients diagnosed with NSCLC present to the clinic with late stage disease.1 Patients
with late stage NSCLC experience widespread disease and surgical resection alone is not
sufficient. Historically, the treatment of metastatic NSCLC has relied heavily on
platinum-based doublet chemotherapies with a meager median overall survival of ~8
months and low response rates of approximately 20%.4
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Advances in the molecular profiling of lung tumors have led to the discovery of
many molecular abnormalities, which has led to a more personalized approach to lung
cancer treatment, especially for those patients whose tumors are of the adenocarcinoma
subtype. Molecular testing can identify patients whose tumors do not harbor clinical
actionable alterations and who are unlikely to respond to targeted drug therapies, sparing
these patients and payers the cost of non-efficacious therapy. For those patients whose
tumors do have clinically actionable molecular abnormalities, targeted drug therapies,
such as EGFR tyrosine kinase inhibitors (TKIs) and ALK inhibitors, are FDA approved
and are the preferred treatment. Patients with EGFR-mutated lung cancers who received
targeted therapies in clinical trials have experienced significant improvements in tumor
response rates (RR) and median progression-free survival (PFS) and have experienced
fewer side effects and an improved quality of life.5-9 While PFS has been favorable for
patients receiving targeted drugs, increased overall survival (OS) has not been observed
in patients participating in clinical trials10-12 possibly due to drug crossover in randomized
studies.10 Still, use of targeted therapies is considered by the National Comprehensive
Cancer Network (NCCN) as the best choice to treat patients with advanced NSCLC
whose tumors harbor molecular abnormalities.
Specific Aims
Study 1. Family Physician Perceptions and Experiences with Low-Dose Computed
Tomography Screening for Lung Cancer
Recently, new guidelines for lung cancer screening using low-dose computed
tomography (LDCT) have been published by the United States Preventative Services
Task Force (USPSTF) and supported by many professional cancer societies and advocacy
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groups, such as the American Cancer Society, American Society of Clinical Oncology,
American College of Radiology, and National Comprehensive Cancer Network (Table
1.1). As a result, the Centers for Medicare and Medicaid Services (CMS) approved
coverage for annual lung cancer screening using LDCT in select, high risk adults. Since
the announcement of the CMS coverage decision memo and publication of requirements
for reimbursement on February 5, 2015 (Table 1.2),13 qualitative literature published on
family physician perceptions and experiences towards LDCT has been sparse.14,15
Quantitative data previously collected and published was obtained through the
administration of an electronic and paper questionnaire from family physician members
of the South Carolina Chapter of the American Academy of Family Physicians16 and
primary care physician employees at Carolinas HealthCare System17 and was used to
inform the development of an interview guide for this study. Follow-up interviews were
conducted with a subset of physicians who completed the questionnaire and who agreed
to be contacted for future research to obtain qualitative data. The specific aims of this
qualitative study are to:
1. Assess family physician knowledge surrounding the current scientific evidence on
LDCT for lung cancer screening
2. Assess family physician knowledge with regards to current patient eligibility
criteria defining patients at “high risk” for lung cancer
3. Explore family physician attitudes on implementation of lung cancer screening
discussions, including shared decision-making processes
4. Explore barriers and facilitators to lung cancer screening
5. Explore current LDCT referral and follow-up practices
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Study 2. Factors Predicting Molecular Testing and Erlotinib Utilization and their Impact
on Survival in Patients with Advanced, Non-Small Cell Lung Cancer
State and national cancer registries do not collect data on the molecular
characteristics of lung tumors. Thus, it has been difficult to evaluate the public health
significance of molecular testing and targeted therapies at a population level.
Specifically, utilization of molecular testing, factors associated with receipt of testing,
and survival of patients with NSCLC undergoing molecular testing and treatment with
targeted therapies has not been previously evaluated at the population level across the
time period evaluated in this study. This study will use an administrative claims database
linked to a state cancer registry database to examine these topics. In this study, 20022014 data from South Carolina (SC) Central Cancer Registry NSCLC cases will be
linked to SC State Employee (SCSEHP) and SC Medicaid members to examine these
topics at the state level. Knowledge on utilization and factors associated with molecular
testing and erlotinib use can give us insight to the current landscape o across SC and can
allow us to identify factors associated with non-utilization.
Published research on the utilization of molecular testing and erlotinib in patients
with NSCLC at the population level across these years is extremely limited. Research
addressing lung cancer molecular testing and erlotinib utilization in the US and their
impact on survival has not previously been conducted using SC linked administrative
claims and cancer registry data. By combining administrative claims data with
population-based cancer registry data, we have the advantage of being able to capitalize
on the strengths of each dataset while minimizing their weaknesses when used alone. For
example, SCCCR does not collect data on whether or not a patient had molecular testing,
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but this information is available by searching for molecular testing Common Procedure
Terminology (CPT) codes in SCSEHP and Medicaid claims. The results of this study will
characterize the current landscape of molecular testing in NSCLC patients and identify
disparities in utilization among SC residents. Increasing the number of patients who
receive molecular testing (and when appropriate, targeted therapy) can lead to decreases
in the cost of supportive care that would result from treating chemotherapy toxicity and
may lead to increased quality of life for more patients. Additionally, it may also spare
chemotherapy in patients that are unlikely to benefit.
The specific aims of this study are to:
1. Identify factors that are associated with molecular testing and erlotinib utilization
2. Estimate propensity scores for each case to predict molecular testing and to
predict erlotinib utilization
3. Evaluate the relationship between molecular testing and survival
4. Evaluate the relationship between erlotinib utilization and survival
Significance
Lung cancer screening with low-dose computed tomography is underutilized and most
lung cancers are diagnosed late-stage.
Historically, lung cancer screening methods in the US have included chest x-ray,
computed tomography, and sputum cytology, however, no mortality benefit was observed
with any of these approaches. Recently, the National Lung Screening Trial reported a
20% reduction in lung cancer mortality and a 6.7% reduction in overall mortality with
annual screening using LDCT for three years.18 Because of these findings, the United
States Preventative Services Task Force recommended LDCT screening for high
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risk patients at the grade B level in 2014.19 A grade B level recommendation requires
lung cancer screening to be provided free of charge to patients covered under the
Affordable Care Act. Subsequently, the Centers for Medicare and Medicaid Services
(CMS) announced coverage for high risk adults defined as those aged 55–77 years who
are asymptomatic for lung cancer, have a tobacco smoking history of at least 30 packyears, are current or former smokers (quit within the past 15 years) and have
documentation of a counseling and shared decision-making visit prior to LDCT
screening.13
Currently, about 70% lung cancers are diagnosed late or advanced stage (III or
IV).20 Of these, roughly 40% have metastatic disease and despite surgery or combined
therapy are considered incurable, while about 40% have locally advanced disease and
will undergo multimodal therapy.21 Lung cancer screening with LDCT can identify
earlier stage lung cancer that is more likely to be treated with surgical resection alone.
Median overall survival in NSCLC patients is low with chemoradiation.
Multiple treatment modalities exist for lung cancer patients. Surgical resection,
systemic chemotherapy, and radiotherapy are the cornerstones of lung cancer therapy.
However, surgical resection is mostly limited to those presenting with early stage disease.
Most unresectable, advanced stage patients are treated initially with one of four platinum
doublet chemotherapy regimens (e.g., cisplatin plus paclitaxel or docetaxel, cisplatin plus
gemcitabine, or carboplatin plus paclitaxel)21 with concurrent radiation therapy (if
tolerable), as this combined approach has yielded the best overall survival.20,22 An
Eastern Cooperative Group (ECOG) evaluation of these four regimens was recently
conducted in 1,207 patients, of which 1,155 were eligible for analysis. The median
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overall survival was 7.9 months (95% CI: 7.3-8.5), with no meaningful difference in
survival by chemotherapy regimen. One and two-year survival rates were 33% and 11%,
respectively (95% CIs: 30-36% and 8-12%, respectively). More recently, the ECOG
evaluated overall survival of the drug pemetrexed (a folate antimetabolite) versus
carboplatin plus pemetrexed.23 In this randomized trial of 205 eligible patients, a small
increase in overall survival was observed in the carboplatin-pemetrexed group (median
OS = 9.3 months, 95% CI: 7.4-11.2 months) with a more favorable toxicity profile.23
Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, has also
emerged as a therapeutic drug in the treatment NSCLC. In a multicenter, phase II study,
patients treated with paclitaxel-carboplatin plus bevacizumab (PCB) combination therapy
had significantly better overall survival compared to those treated with paclitaxelcarboplatin (PC) alone, although an increase in treatment-related deaths was observed.
Median OS for those on the PCB arm was 12.3 months compared to 10.3 months on the
PC arm (HR=0.79; P=0.003).24 While chemotherapy does have its place in the treatment
of NSCLC patients, newer drug therapies, including targeted therapies and
immunotherapies, are quickly emerging as efficacious treatment modalities.
Clinically relevant molecular abnormalities have been identified in patients with NSCLC.
Within the past one to two decades, knowledge of molecular markers has
proliferated. The three most studied clinically relevant molecular abnormalities in
NSCLC include Kirsten rat sarcoma viral oncogene homolog (KRAS), epidermal growth
factor receptor (EGFR) and anaplastic lymphoma kinase (ALK), and these abnormalities
are typically mutually exclusive.20,25 However, other molecular abnormalities also exist
(i.e. MET, ROS-1).25-27 This dissertation focuses on molecular testing in general and
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focuses on the utilization of the EGFR TKI, erlotinib (Tarceva; Genentech). EGFR is a
cell surface receptor that is activated either by protein overexpression, increased gene
copy number or genetic mutation. EGFR is involved with cell proliferation, suppression
of apoptosis (cell death), cell motility, invasion and angiogenesis (formation of new
blood vessels).20,25 Prevalence of EGFR mutated lung cancers range from 15%-80%,
depending on racial and behavioral characteristics. Those most likely to have EGFR
mutated lung tumors include Asian ethnicity, females, never smokers, and those with
adenocarcinoma histology.25 The RAS family mutations (including KRAS) encode for
proteins on the cells surface and are involved with cell proliferation, survival, and
metastasis.20 In adenocarcinoma patients, prevalence of KRAS mutated lung cancers
ranges from 20%-30%, with higher prevalence among Caucasians and ever-smokers.20,25
The availability of molecular tests to predict response to targeted therapies is increasing.
Molecular testing can be conducted using both FDA-approved tests (“companion
diagnostics”) and other non-FDA approved laboratory developed tests. Some tests are
run individually, while some are run as a “panel” and may assess multiple biomarkers in
one test administration (e.g., Lung Cancer Panel, Solid Tumor Mutation Panel by Next
Generation Sequencing). Local Coverage Determinations published by Medicare
administrative contractors are used to establish Medicare coverage guidance for existing
and newly developed laboratory diagnostic tests. Historically, clinical laboratories have
billed payers, such as Medicare, using a technique call “code stacking”. This methodbased approach to billing uses combinations of CPT or Healthcare Common Procedure
Coding System (HCPCS) codes to bill for molecular tests. This approach can result in a
variety of code combinations, as well as costs, for one molecular test.

9

As the availability of molecular testing has increased, the need for distinct,
individualized, gene-specific codes emerged. Revisions to the coding systems were
drafted and a new set of CPT codes were published in 2013 that are more accommodating
to the modern molecular testing performed in laboratories. For example, Palmetto GBA,
the administrative servicer for South Carolina’s Medicare program, has approved the
code 81235-22 (EGFR, common variant) for EGFR testing of tumor and plasma
specimens.28
Molecular testing is used to assist providers in selecting targeted therapies based on
tumor characteristics and these therapies have yielded improved outcomes.
Several targeted therapies have been approved by the FDA to treat patients with
NSCLC whose tumors harbor EGFR mutations, including the EGFR TKIs erlotinib,
afatinib, and gefitinib. Improvements in progression-free survival and overall response
rates have been noted.6,29 Additionally, targeted drug therapies are less toxic than
systemic chemotherapy regimens and studies have reported low frequencies of both
adverse events (e.g. skin reactions, diarrhea, and appetite challenges) and serious adverse
events.6,29,30
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TABLES
Table 1.1 Professional societies that support the use of lung cancer screening with low-dose computed
tomography

Population
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USPSTF

ACS

55 to 80
years

55 to 74
years

ACCP/
ASCO
55 to 74
years

30 pack
year
smoking
history

30 pack
year
smoking
history

30 pack
year
smoking
history

30 pack
year history

Current or
have quit in
past 15
years

Current or
have quit in
past 15
years

Current or
have quit in
past 15
years

20 pack
years (with
additional
lung cancer
risk factors)

No
symptoms

No
symptoms
In good
health

AATS

ALA

NCCN

CMS

55 to 79
years

Should
follow that
of the
NLST,
USPSTF,
CMS

55 to 74
years

55 to 77
years

30 pack
year
smoking
history and
smoking
cessation
with 15
years

30 pack
year
smoking
history

OR

OR
Age ≥50
years with ≥
20 pack
year
smoking
history plus
one
additional

Current or
have quit in
past 15
years
No
symptoms
Written
order for
lung cancer
screening

risk factor
for lung
cancer
(other than
secondhand
smoke
exposure)
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Smoking
cessation

Yes

Yes

Not
discussed

Not
discussed

Yes

Yes

Yes

Shared
decision
making

Yes

Yes

Not
discussed

Not
discussed

Yes

Yes

Yes

Year
Updated

2013

2015

2012

2012

2015

2015

2015

Abbreviations: AACP-American College of Chest Physicians, AATS-American Association for Thoracic Surgery, ACR-American
College of Radiology, ACS-American Cancer Society, ALA-American Lung Association, ASCO-American Society of Clinical
Oncology, CMS-Centers for Medicare and Medicaid Services, NCCN-National Comprehensive Cancer Network, NLST-National Lung
Screening Trial, USPSTF-U.S. Preventive Services Task Force.
*Note: USPSTF is grade B recommendation. NCCN is a category 2B recommendation.

Table 1.2. Requirements for CMS Coverage of LDCT Screening for Lung Cancer
Initial Screening
• 55-77 years

Symptoms

• None; asymptomatic patients only

Tobacco smoking history

• ≥30 pack years

Current smoking status

• Current or former smokers; former smokes must have quit
within the last 15 years

Health Care Professional

• Physicians or qualified non-physician practioners
(physician assistants, nurse practioners, clinical nurse
specialist (as defined by Section 1851(r)(1) of the Social
Security Act))

Shared decision-making visit

• Determination and documentation of age, lack of
signs/symptoms of lung cancer, calculation of smoking
pack-years, and report of current smoking status
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Age

• Use of 1+ decision aids that describe the benefits and
harms of screening
• Counseling on the importance of adhering to LDCT
screening schedule (annual LDCT), impact of
comorbidities, and agreement to undergo diagnosis and

treatment if suspicious findings are present
• Written order for LDCT for lung cancer screening
• National Provider Identifier (NPI) for ordering practioners
Radiology imaging facility

• Performs LDCT with volumetric CT dose index of
≤3.0mGy for standard size patients and appropriate
reductions/increases for smaller/larger patients
• Uses standardized lung nodule identification,
classification, reporting system
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• Provides information and interventions for smoking
cessation in current smokers
Reading radiologist

• Board certified/eligible with American Board of
Radiology (ACR) or equivalent organization
• Documented diagnostic radiology and radiation safety
training and continuing medical education (according to
ACR standards)
• Involvement in supervision/interpretation of at least 300
chest CTs within past 3 years
• Conduct LDCT screening in a radiology facility that meets
CMS eligibility criteria

Lung cancer screening registry

• Radiology facility must collect/submit data to CMSapproved registry for each LDCT screening performed.
Minimum data submission includes: facility identifier,
NPI, patient identifier, CT manufacturer/model, indication
for screening, nodule identification system employed,
patient smoking history, radiation dose delivered,
screening date
• Establishment of steering committee/governance board to
oversee registry
• Registry management plan with identification of key
registry personnel
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• Operation plan describing plan for collecting and
submitting data to the registry and from registry to CMS,
including agreement to use CMS-approved data dictionary
• Registry catchment area and list of facilities participation
in the registry
• Description of methods to permit linkage of registry data
to external databases (e.g. Medicare claims)
• Description of data management, quality review and
validation
• Quality assurance plan

Subsequent Screenings
Health Care Professional

• Physicians or qualified non-physician practioners
(physician assistants, nurse practioners, clinical nurse
specialist (as defined by Section 1851(r)(1) of the Social
Security Act))

Shared decision-making visit

• Not required, however if practioners decides to conduct a
lung cancer screening shared decision-making visit, the
same requirements as the initial screening apply

*Adapted from Centers for Medicare and Medicaid Services Decision Memo (February 2, 2015).13
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CHAPTER II:
LITERATURE REVIEW
Low-Dose Computed Tomography for Lung Cancer Screening
Historical Summary of Lung Cancer Screening
For over 60 years, research has been conducted on the efficacy of various lung
cancer screening methods, including chest radiography, sputum cytology, and low-dose
computed tomography, but until recently, no recommendation was made as to which
method, if any, increased lung cancer survival. In the 1950s, the earliest clinical trials in
the United States and London evaluated chest x-ray, sputum cytology, or the combination
of both and were usually evaluated at six month intervals. These early trials had major
limitations including lack of randomization and control groups. In the 1970s, the
National Cancer Institute (NCI) sponsored three randomized controlled trials, specifically
aimed at examining mortality from lung cancer. These trials were conducted at Johns
Hopkins University (JHU), the Mayo Clinic, and Memorial Sloan-Kettering Cancer
Center (MSKCC). Each trial had a slightly different design and the goals was to evaluate
the efficacy of sputum cytology. At JHU and MSKCC, both the intervention and control
groups received annual chest x-rays and the intervention group received chest x-ray plus
sputum cytology screening every four months. At the Mayo Clinic, the intervention
group received chest x-ray and sputum cytology every four months and while the control
group received these services annually. This trial was designed to evaluate the effect of
the frequency of screenings. Overall, the results of these NCI-sponsored trials showed
17

that screening detects earlier stage lung cancers and that case-survival rates were
improved however, mortality rates did not differ. Additionally, these trials suffered from
length-time, lead and patient selection bias, common biases of screening studies.31 Other
studies conducted around the same time period in Czechoslovakia and Germany had
similar results.32,33 As a result of these studies, in 1989, neither the American Cancer
Society, the American College of Radiology, the National Cancer Institute, the United
States Preventive Services Task Force, or the Canadian Task Force recommended any
screening test at any frequency for lung cancer.34
Observational, Single Arm Studies Involving Low-Dose Computed Tomography
Advances in multidetector helical computed tomography resulted in better scan
images with decreased radiation exposure.35 Other advantages include increased scan
speed, improved spatial resolution, and a clearer detection of lung nodules due to the
cross-sectional data display.36 During the 1990s and early 2000s single arm,
observational studies demonstrated improved identification of lung nodules and earlystage lung cancers37 with low-dose helical computed tomography. Also during this time,
the Prostate, Lung, Colorectal, and Ovarian (PLCO) began and completed enrollment to
assess mortality benefit for lung cancer screening using chest x-ray compared to usual
care.38 Ultimately no mortality benefit was established,38 confirming the need for
research on other lung cancer screening methodologies.
Studies such as the Early Lung Cancer Action Project (ELCAP) and the
International Early Lung Cancer Action Project (I-ELCAP), both initiated in 1993, were
instrumental in reporting not only the benefits of LDCT in terms of increased nodule
detection, but also demonstrated that screening with LDCT detected smaller and more
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lung nodules compared to chest radiograph39 and that LDCT screening led to the
detection of cancers that could be cured.3 The I-ELCAP reported that 85% of cancers
detected by LDCT lung cancer screening were classified as clinical stage I and the
estimated 10-year survival was 88%.3 A similar trial was conducted in Japan among
1,611 asymptomatic patients ages 40-79 years. The Anti-Lung Cancer Association
(ALCA) study reported that 71% of cases at initial screening were Stage IA and 82% of
cases at diagnosed at repeat scan were stage IA.40 Many other single arm studies of
LDCT were conducted during this time period (Figure 2.1).40-50 Trials such as these
ultimately lead to the development of several large, randomized clinical trials of LDCT in
the United States and Europe.
Randomized Clinical Trials Involving Low-Dose Computed Tomography
The Lung Screening Study (LSS) was a feasibility study evaluating the use of
LDCT versus chest x-ray (CXR). A total of 3,318 subjects participated in the study.
Eligible subjects were between 55 and 74 years old, had at least a 30 pack-year history of
cigarette smoking, and were either a current smoker or a former smoker (if former, had to
have quit within last 10 years).51
Any non-calcified nodule ≥4mm found during screening was considered a
positive screen. A total of 25.8% of LDCT and 8.7% of CXR scans were positive at the
baseline scan and 48% and 40% of cases were diagnosed as stage I cancer, in the LDCT
arm and CXR arm, respectively. This study was the first to demonstrate that a
randomized clinical trial evaluating LDCT was feasible in the United Sates and
ultimately led to the development of the National Lung Screening Trial (NLST).51
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In 2002, the United States launched a larger, randomized trial comparing annual
LDCT to CXR.36 The NLST, sponsored by the National Cancer Institute (NCI), enrolled
53,454 “high risk” subjects ages 55-74 with a 30 pack-year history of cigarette smoking,
who were current or former smokers. Former smoker must have quit within the past 15
years.18 Subjects were randomized to either three annual LDCT scans or three annual
CXR scans. Across all three rounds of screening, there was a higher rate of positive
screening tests with LDCT compared to CXR (T0, 27.3% vs 9.2%; T1, 27.9% vs 6.2%;
T2, 16.8% vs 5%).18 A high proportion of positive screening tests were followed up with
further diagnostic evaluation (90%), such as additional diagnostic imaging and more
invasive procedures (thoracotomy, bronchoscopy, needle biopsy), at T0 compared to the
other time points. Across the three rounds, a high proportion of the positive screening
tests were false-positives (96.4% LDCT; 94.5% CXR). Despite a high number of falsepositives resulting in additional follow-up, the majority of patients had no complications
resulting from the additional procedures (99.6% LDCT; 99.7% CXR). Among those with
at least one complication, rates were similar or higher for the LDCT arm compared to the
CXR arm for all complications assessed. The most striking result from this trial was the
reduction in lung cancer mortality observed with LDCT, 20% (p=0.004). Additionally,
the rate of all-cause mortality was reduced by 6.7% with the use of annual LDCT
(p=0.02). For the first time, lung cancer screening, using LDCT, resulted in a mortality
benefit.
The Nederlands Leuvens Longkanker Screeningsonderzoek (NELSON) study is
the largest LDCT screening trial conducted in Europe. Starting in 2003, subjects aged
50-75 years old, who had smoked either ≥15 cigarettes a day for ≥25 years or ≥10
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cigarettes per day for ≥30 years, and who were current or former smokers were enrolled.
Former smokers must have quit within the past 10 years. The original study design called
for three screening rounds (baseline, 1 year later, 2 years later, 2.5 years later) included
15,822 subjects, mostly males. The goal was to demonstrate a 25% reduction in the risk
of lung cancer death with LDCT compared to no screening 10 years after
randomization.52,53 However, a fourth round was added in 2009 (5.5 years later) to
evaluate the inclusion of a 2.5-year screening interval (n=7,915).54 Over the first three
screening rounds, 493 positive LDCT scans were reported and of these 40.6% were
diagnosed with lung cancer. Of these lung cancer cases, 70.8% of lung cancers were
diagnosed as stage I and 8.1% were diagnosed as stage IIIB/IV.53 Most subjects were
diagnosed with adenocarcinoma (51.2%). In the fourth screening round, more patients
were diagnosed with late-stage lung cancer (17.3%, p=0.02) and squamous-cell (21.7%),
bronchoaveloar (8.7%), and small-cell carcinomas (6.5%) compared to the second round
of screening (p=0.001).54
A recent randomized trial conducted in the United Kingdom compared a single
screen LDCT to standard care in high risk patients.55 Individuals age 50-75 years old and
residing specific geographic areas were identified through population Primary Care Trust
records and were asked to complete a questionnaire to identify those at high risk of lung
cancer. High risk patients were defined as those who scored a 5-year lung cancer risk of
≥5% on the Liverpool Lung Project version 2 risk model.56 Those who were deemed
high risk were asked to participate in the United Kingdom Lung Screening (UKLS). Of
the 249,988 who were identified through Primary Care Trust records, 4,061 consented to
participate in the UKLS trial and were randomized to one of the two arms. Of the 1,994
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individuals who received a LDCT screen, 34 (1.7%) were diagnosed with lung cancer at
baseline. A total of 47.7% of participants underwent at least one additional screen due to
a nodule finding on the baseline scan, resulting in a total of 42 diagnosed lung cancers.
The majority of diagnosed lung cancers were adenocarcinomas (59.5%). A total of
85.7% of the diagnosed cancers were stage I or II and 83% had surgery as their primary
treatment. Mortality reports on this data are expected in coming years.55
The NLST and NELSON studies are the largest performed to date. Other
randomized clinical trials of LDCT include the Danish Lung Cancer Screening Trial
(DLCST),57 ITALUNG,58 Lung Cancer Screening Intervention (LUSI),59 and the
Multicentric Italian Lung Detection (MILD).60
Risks and Benefits of Lung Cancer Screening with Low-Dose Computed Tomography
Proponents of lung cancer screening with LDCT argue that the benefits of
screening justify its use, however, most agree that, as with many screening tests, there are
some inherent risks. False positive scans are one such risk61 and are perhaps the leading
concern for screening. False positive scans also contribute to the overall cost of
screening. The false-positive screening rate in most studies involving LDCT is high. For
example, in the NLST, the false-positive rate for LDCT was 96.4%, but this was only
slightly higher than the false-positive rate for CXR (94.5%).18 Inclusion of the LungRADS classification (introduced in May 2014) reduced the false positive rate but also
slightly reduced test sensitivity.62 The Lung-RADS classification changes the criteria for
a positive screen slightly. The definition of a positive screen using Lung-RADs includes a
6-mm transverse bidimensional average (20mm for nonsolid nodules) and requires
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growth for preexisting nodules as opposed to the NLST, which required only a 4-mm
greatest transverse diameter.62
Conversely, another harm of lung cancer screening is false negatives. There may
be instances where a lung cancer is not detected on a screening test and may give patients
a sense of “protection” from lung cancer and false reassurance.
Overdiagnosis is a common risk of any cancer screening program including lung
cancer screening with LDCT.61,63,64 Overdiagnosis can occur when a patient is diagnosed
with an indolent or slow growing cancer that would not otherwise have been detected
without screening. Persons may in fact die of other reasons without ever being
diagnosed. The USPSTF modeling study reported a 10-12% of screen-detected cancer
cases are overdiagnosed.19
Another risk of lung cancer screening is increased exposure to radiation.61,64,65
Persons undergoing LDCT screening may be exposure to additional radiation, not only at
the time of LDCT screening, but also at screening follow-up. For a LDCT the average
effective dose value is about 2 mSv for an average size patient compared to 7 mSv for a
standard CT.66 Brenner et al evaluated the estimated risk of lung cancer due to radiation
exposure from screening. If 50% of current or former smokers ages 50-74 residing in the
United States received annual LDCT screening, the estimated number of lung cancer
cases would increase by 1.8% (95% CI: 0.5 – 5.5%).65 Excess risk of radiation-induced
lung cancer is greatest for those around 55 years of age.65 Unfortunately, this
corresponds to the appropriate age range for lung cancer screening. Increased risk for
radiation-induced lung cancer depends on age at start of screening, how many scans a
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person has, and other sources of radiation exposure.19 One scan is not the concern; it is
the cumulative amount of radiation that is concerning.
Discovery of incidental findings on a lung cancer screening LDCT present
another potential harm of screening. A NELSON sub-study found a non-clinically
relevant incidental finding (e.g., emphysema, thyroid nodule) rate of 73% and a possibly
clinically relevant incidental finding (e.g., liver lesion, aortic aneurysm > 6 cm) rate of
8% (of which 79% were actually clinically relevant after further evaluation).67 A report
of 2,812 patients by Gareen et al reported a significant incidental finding (e.g. abdominal
aortic aneurysms and renal cysts) rate of 12.2%. While some studies report that
incidental findings are commonly picked up by LDCT screening, the USPSTF stated
there was insufficient evidence on harms of incidental findings identified through LDCT
screening.19
Lastly, complications resulting from diagnostic work up procedures68,69 may also
present a potential harm to persons undergoing screening with LDCT. Following a
positive screening, a person may need to undergo additional follow-up, such as additional
CT imaging or needle biopsy, which may present additional harm. Overall, the NLST
reported few and minor complications arising from diagnostic evaluations following a
positive screen (1.6% in the LDCT arm).18 In the NLST, risk of major complications
following surgical procedures for benign nodules was 4.5 per 10,000 for the LDCT arm
compared to 1.5 for the CXR arm.69
Benefits of lung cancer screening with LDCT include reduction in risk of lung
cancer and all-cause mortality, psychosocial benefits, such as reassurance of having a
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normal CT scan, and the opportunity to incorporate smoking cessation into lung cancer
screening decision making discussions.68
Cost of Lung Cancer Screening with Low-Dose Computed Tomography
A NLST cost-effectiveness analysis compared LDCT to no screening. Black et al
reported that lung cancer screening with LDCT cost an additional $1,631 per person
(95% CI: 1,557-1,709). LDCT provides an additional 0.0316 life-years per person (95%
CI: 0.0154-0.0478) and 0.0201 quality adjusted life years (QALYs) per person (95%CI:
0.0088 - 0.0314). Incremental cost-effectiveness ratios (ICERs) were $52,000 per lifeyear gained (95% CI: 34,000 – 106,000) and $81,000 per QALY gained (95%: 52,000 –
186,000).70 This amount is similar or less than other cancer screenings. The authors state
that the cost effectiveness of screening will depend on how screening programs are
implemented.70
Another study conducted by Mahadevia et al in 2003 simulated data to evaluate
mortality and cost-effectiveness of LDCT compared to no screening for hypothetical
cohorts of 100,000 current, quitting, and former heavy smokers aged 60 years while
incorporating known screening biases and assuming 50% stage shift. Their simulated
models revealed the cost-effectiveness of lung cancer screening with LDCT was
$116,300 for the current smoker cohort, $558,600 for cohort of quitting smokers, and
$2,322,700 for the former smoker cohort, respectively, per QALY gained.71 Sensitivity
analyses were also conducted to evaluate cost-effectiveness under a variety of efficacy
assumptions. Age at first screening, stage shift, and length of follow-up were also varied.
Under extremely ideal model conditions (e.g., lower probabilities for non-adherence,
estimates for length and overdiagnosis bias, lower cost of LDCT screening, and better
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QOL for localized stage), the cost-effectiveness of LDCT screening would drop to
$42,500 per QALY for current smokers. Important to note, the simulated models did not
include costs related to incidental findings.71
The UKLS trial described previously also included a cost effectiveness
component. The ICER for single-screen LDCT screening was ₤8466 per QALY.55 This
translates to approximately $11,071, which is substantially less the found in the NLST,
but differences in the frequency of screening in addition to resource expenses are likely to
explain this difference.55
Physician Attitudes, Perceptions, and Experiences with Low-Dose Computed
Tomography
Several studies have evaluated primary care physician attitudes, perceptions and
practices regarding lung cancer screening with LDCT, prior to and following the
publication of the NLST. The first quantitative study on primary care physician’s lung
cancer screening beliefs and recommendations was published in 2010.72 Klabunde et al
conducted a nationally representative survey of practicing PCPs from 2006-2007. A total
of 962 physicians responded (70.6% response rate; 76.8% cooperation rate). Physicians
were unsure of the USPSTF and American College of Radiology recommendations
(38.8% and 58.2%). Overall, LDCT was perceived as a somewhat or very effective
screening tool and was viewed as more effective than CXR or sputum cytology.
Approximately 31% of the physicians believed that LDCT was effective in reducing lung
cancer mortality.72
Physicians were also presented with clinical scenarios in which age, smoking
history, and secondhand smoke exposure were varied. In cases where screening was
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recommended, interestingly, physicians more frequently chose screening with CXR
compared to LDCT or sputum cytology. Most physicians would screen the current
smoker scenario (84.4%; CXR=40.1%, LDCT=17.2%). Few physicians reported that
they would screen the age 50, never smoker (17.4%; CXR=16.5%, LDCT=0.2%).72
The first qualitative study, published by Henderson et at in 2011, conducted five
telephone-based focus group with 28 primary care physicians (PCPs) in the United States
to evaluate the factors influencing a PCPs decision to screen patients for lung cancer.73
The focus groups were conducted in May and June 2009, prior to the publication of the
NLST results. Physicians reported CXR as outdated and not sensitive enough to detect
lung cancer. Some PCPs viewed CTs favorably stating that CT scans are efficacious and
can detect small nodules. Most physicians were aware of the recommendations published
by USPSTF and ACS. Some physicians reported using the recommendations to direct
practice while others did not. Physicians who had multiple patients undergo follow-up
for what turned out to be benign lesions had a negative view of lung cancer screening.
Most physicians based their decision on whether to order lung cancer screening based on
their perception of their patient’s risk of lung cancer, however, the physician’s perception
of risk varied. Smoking was cited as the most important risk factor, however, other risk
factors considered by physicians included family history, immunocompromised status,
personal cancer history, secondhand smoke exposure, and history of pulmonary disease.
Most physicians ordered a lung cancer screening test regardless of their knowledge of
screening efficacy, when a patient requested the test.73
Physician practice regarding ordering lung cancer screening was also assessed.
Just over two-thirds of physicians reported never ordering a lung cancer screening test,
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while 55% ordered chest radiography and 22% ordered LDCT.74 Almost 70% of
physicians had at least one patient ask about lung cancer screening in the previous year.
The authors noted that several factors influenced PCP ordering of LDCT. Time since
graduating from medical school, being in a practice with 6-15 physicians, believing that
at least one expert group recommended screening, recommending lung cancer screening
for asymptomatic patients regardless of smoking exposure, and having patients ask about
lung cancer screening all increased the odds of ordering LDCT.74
Approximately two years after the dissemination of the NLST results (2013),
Lewis et al surveyed 293 PCPs (response rate = 60%) via email at a large academic
medical center75 to assess use of lung cancer screening, perceived screening
effectiveness, knowledge of screening guidelines, perceived barriers to LDCT use and
interest in screening education.75 PCPs reported that the USPSTF, ACS, and ASCO
guidelines influenced their practice (88.4%, 71.8%, 46.0%, respectively). Only 42% of
PCPs viewed LDCT as very or moderately effective in reducing lung cancer mortality
and 30% did not know about the benefit in reducing lung cancer mortality. PCPs who
reported more than 15% of their practice consisting of current or former smokers and
those who knew at least three of the guideline components (e.g., age, annual screening,
start screening age of 50, end screening age of 75 or 80, 20 or 30 pack-year smoking
history, and not including individuals exposed to only secondhand smoke) were more
likely to perceive LDCT as very or moderately efficacious (OR=3.0, 95%CI: 1.1-8.4,
OR=5.1, 95%CI: 2.6-9.9, respectively). Interestingly, colonoscopy, pap smear, and
mammography had higher rates of perceived effectiveness (92.9%, 99%, 95.7%, all
p<0.0001, respectively), while PSA had a lower rate (27.4%, p=0.002) compared to
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LDCT.75 Almost one-quarter of physicians reported using CXR to screen for lung cancer
(21.3%, 95%CI: 16.0%-27.5%)75, despite the results of the NLST reporting no mortality
benefit with CXR by the time of this survey. Only 12.3% reported using LDCT (95%CI:
8.2%-17.5%). Knowing three or more guideline components significantly predicted
likelihood of LDCT ordering (OR=3.0, 95%CI: 1.1-8.6). Most physicians (79.8%) were
open to receiving further information and education on lung cancer screening.75
Perceived major barriers to lung cancer screening reported by PCPs in this cohort
included patient financial cost (86.9%), potential harm from false-positives (82.7%),
patient knowledge (81.3%), potential patient harm, incidental findings requiring further
workup (81.3.%), and insurance coverage/cost (80.1%).75 Geographic availability, was
also reported as a perceived barrier; approximately 25% of physicians reported
geographic availability as a major or minor barrier.75 A report by Eberth et al confirmed
this perceived barrier and reported that while most LDCT screening centers were located
in counties with the highest lung cancer incidence in the Northeast and East North
Central states, in four states (Oklahoma, Nevada, Mississippi, and Arkansas) geographic
availability of LDCT screening centers may be a concern.76 A second study published by
the Eberth team, surveyed members of the Society of Thoracic Oncology to determine
availability of LDCT lung cancer screening programs. Fourteen states, including those
where availability of LDCT screening centers was a concern, had no screening center
respond to their survey.77
A qualitative assessment of PCP attitudes and beliefs occurred just prior to the
Centers for Medicare and Medicaid services coverage determination announcement in
2015.13 Hoffman et al conducted in depth, semi structured interviews with PCPs in New
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Mexico clinics serving rural and urban minority patients from February-September
2014.78 The interviews (n=10) focused on a range of lung cancer related topics, including
tobacco cessation, perceptions of the NLST results, and perceptions and attitudes toward
informed decision making for cancer screening. Prior to the interviews, physicians were
given information on screening guidelines and results of the NLST. Some physicians
were not aware of changes to screening lung cancer screening guidelines. No physicians
reported ordering LDCT scans for lung cancer screening; however, some physicians
reported ordering CXR and believed that this was in alignment with screening guidelines.
No physicians reported a patient demand for LDCT services. Some providers were not
aware of the NLST results. When presented information on the NLST, physicians
perceived the absolute mortality risk to be small and were concerned about the high rate
of false-positives and the risks of screening. Physicians also reported concerns over long
term radiation exposure.78
PCPs reported being cautious to begin to offer LDCT screening in their clinics.
Some PCPs stated that they would feel more obligated to offer screening if it were
incorporated into performance measures. Additionally, some physicians reported
concerns over whether New Mexico radiology facilities had the ability to support high
quality screening programs and listed this a potential barrier. Other patient related
barriers reported by PCPs included, travel expenses to get to a screening facility, as well
as the costs of follow-up testing and potential treatment. Such costs would make
screening for lung cancer unreasonable for their patients. Physicians were also concerned
about the potential resource barriers they might face (e.g. time and effort), stating that
PCPs are already overloaded and lack adequate time for preventive patient education.78
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In addition to increased time required by physicians to conduct lung cancer
screening visits, PCPs were also concerned about the responsibility of explaining such a
complex screening test to their patients with limited appointment times and the low
literacy of most patients. Physicians also voiced concern about discussing follow-up of
abnormal findings with patients.78
A report by Volk and Foxhall published in August of 2015 surveyed 350 PCPs on
their current lung cancer screening practices and readiness to implement lung cancer
screening programs at two Continuing Medical Education events in late 2014 (following
the USPSTF recommendation and draft CMS coverage decision memo).79 Most PCPs
reported being somewhat or very familiar with the current guidelines, however, only
10.1% had a formal lung cancer screening program in their practice. Over half (56.0%)
planned to refer patients to high-quality screening programs, however, less than half were
currently doing so (25.0% in practices that do not train residents; 43.1% in practices that
offer residency programs). There were some concerns also reported. PCPs requested
clarity on screening coverage, information on screening centers that offered LDCT, and
decision aids and educational materials.79
A qualitative study by Kanodora et al assessed the perceptions and perspectives
on lung cancer screening among Veteran’s Affairs PCPs and patients.15 A total of 13
PCPs in South Carolina participated in focus groups in 2014. PCPs at this site had
participated in lung cancer screening programs since 2012. Their program consisted of
clinical reminders built into the electronic medical records to notify VA PCPs that a
patient was eligible, then the PCP made a referral to a lung cancer screening nurse
coordinator for a shared decision-making visit. Posters, streaming videos, decision aids
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in the clinic all facilitated conversations about screening. More than half aware of the
PCPs were aware of USPSTF recommendations for screening, however there was
variation in commitment and enthusiasm for LDCT. Additionally, some PCPs continued
to believe CXR is effective.15
PCPs interviewed preferred that the lung screening nurse coordinator to review
details with patients, like continued surveillance and the features of the scan (low-dose).
The providers reported that a majority of patients willing to have screening, but some
feared cancer diagnosis or other illness. Lung cancer screening discussions were met
with little resistance and that resulted in shortened discussions, however, PCPs still
reported not having enough time to have sufficient depth screening discussions. Only
23% of PCPs made referrals to local smoking cessation clinic and admitted to not
devoting enough time to smoking cessation counseling.15
PCPs reported that patients with recent cancer deaths in the family or heavy
smokers were more likely to request screening, but that they most often requested CXR.
Some patients were concerned about exposure while in the military that may increase
their risk for lung cancers.15
Another recent study, published in 2017 by Simmons et al, used focus groups
consisting of Florida PCPs (e.g., physicians, nurse practioners, and physician assistants)
to assess knowledge and attitudes towards lung cancer screening.14 Prior to the focus
group, PCPs were provided a summary of the current evidence for lung cancer screening,
patient eligibility criteria, risks and benefits of screening, and reimbursement
requirements in a webinar format. The majority PCPs stated that patients did not inquire
about lung cancer screening and they were not recommending screening to patients. A

32

few reported still requesting CXR for screening purposes. The majority said they
currently had limited information about screening, although most said they would
recommend it if they had more information. Some providers also mentioned lack of
understanding of the testing process and follow-up of abnormal results. After viewing
the webinar on lung cancer screening, a few PCPs reported screening to be more
complicated than they initially thought.14
Early detection was reported as the main benefit. PCPs also discussed that lung
cancer screening discussions can motivate smoking cessation and overall outcomes.
Others benefits included coverage for patients with insurance/Medicare, low-dose of
radiation with the scan, and patient reassurance that they do not have cancer.14
The most common barriers to lung cancer screening were cost, time, and potential
for false positives. The time barrier includes a simple lack of time to discuss, as well as
concerns over the complexity of discussion required for the SDM reimbursement. Again,
EMR pop-up reminders to indicated patient eligibility were viewed as facilitators to lung
cancer screening.14
In the past couple years, several other quantitative assessments of primary care
physician knowledge, perceptions, and utilization have been reported.80-83 Earlier this
year, Jemal et al reported extremely low rates of patient self-reported LDCT for lung
cancer screening (<4%) between 2010 and 2015.84 Despite these prior studies, research,
education, and promotion of lung cancer screening is still of importance. Since the
finalized CMS coverage decision memo was released in February 2015 and the use of
CMS reimbursement codes for the shared decision-making counseling visit were
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published, no mixed methods studies evaluating family physician perception and
practices surrounding LDCT have been reported.
Molecular Testing in Non-Small Cell Lung Cancer
Over the last two decades, knowledge of the biology of cancer and the molecular
pathways involved in cancer has flourished and a variety of treatments have been become
standard, including targeted therapies and immunotherapies (Table 2.1). Identification of
genetic anomalies, including mutations, gene rearrangements, and copy number changes,
identified within cancer initiation and progression pathways have led to the development
of personalized medicine and targeted therapeutics. Many lung cancer biomarkers have
been researched and published however, only a few biomarkers for lung cancer have use
in the clinic and directly impact patient treatment. Despite the clinical benefit of
molecular testing and clinical guidelines for its use, molecular testing is likely still
underutilized by thoracic oncologists, especially in the community-based setting85.
Clinically Actionable Biomarkers for NSCLC
Several clinically actionable biomarkers have been identified in tumors of patients
with NSCLC. For example, 15-25% of patients harbor KRAS mutations,25,27 3-7%
harbor ALK fusions/translocations,27,86,87 2-5% harbor MET amplifications,25,27 and 1-2%
of patients have tumors that are ROS-1 rearranged.25,27
Among the most prevalent is the epidermal growth factor receptor (EGFR; also
referred to as ErbB1). EGFR is a member of the ErbB family of receptors.88,89 The
EGFR signaling pathway is visualized in Figure 2.2. The most common EGFR
abnormalities are point mutations and in-frame deletions.90 Other abnormalities in EGFR
include increases in gene copy number, EGFR single nucleotide polymorphisms (SNPs),
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and EGFR protein expression.91 EGFR is most frequently mutated in either exon 19 and
21 (L858R, L861Q) (Figure 2.3).88 In exon 19, four amino acids are deleted. In exon 21,
most commonly, a T to G mutation at nucleotide 2,573 leads to a substitution of arginine
for leucine at position 585.92 EGFR resistance mutations can also occur (exon 20
insertions and T790M).93
The EGFR mutation was first discovered in 2004 and is present in 10-35% of
patients; it more frequently occurs in females and never smokers.27,88,92,94,95 Incidence is
higher in the Asian population; approximately 22-62% of East Asians with lung
adenocarcinoma harbor EGFR mutations.27,96,97
EGFR testing is important for both predictive and prognostic implications.
Presence of activating EGFR mutation indicates potential response to an EGFR TKI,
such as gefitinib or erlotinib. Progostically, patients with EGFR mutations have better
outcomes compared to patients whose tumors are EGFR wild-type.
Currently in the clinical setting, EGFR, ALK, and ROS-1 are the most frequently
used biomarkers to direct therapy and resistance mutations have emerged (e.g. EGFR
T790M). A number of other mutations in lung adenocarcinomas exist, including BRAF,
KRAS, HER2, PTEN, MEK1, AKT, FGFR, c-MET and PIK3CA,22,26,95,98 however these
mutations are not clinically actionable and are still under clinical investigation. Methods
to molecularly profile tumors vary and include polymerase chain reaction (PCR),
immunohistochemistry (IHC), and fluorescence in situ hybridization (FISH), and
chromatic in situ hybridization (CISH). Next generation sequencing (NGS) allows for
assessment of multiple biomarker simultaneously and is the preferred approach to broad,
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panel-based molecular profiling. Whole genome NGS provides the most comprehensive
assessment of the tumor.99
FDA Approved Diagnostic Tests for EGFR Mutations
Several clinical assays are FDA approved for the detection of EGFR mutations,
including the EGFR pharmDx, Therascreen EGFR RGQ PCR, and cobas EGFR Mutation
Test.26 These tests are performed using tumor tissue resected from the patient via biopsy
or surgical resection. A blood-based EGFR test was also approved in 2016, cobas EGFR
Mutation Test v2.100 NGS, a broad molecular profiling approach, also has the ability to
detect EGFR abnormalities.
Disparities in ordering molecular testing for lung cancer are likely to exist. A
recent abstract presented at the ASCO Annual Meeting in 2014 revealed that academic
oncologists were more likely than community oncologists to order a NGS molecular test
(59.4% vs 33.4%, p=0.01).101 Community oncologists are likely to be less knowledgeable
and have less experience with NGS compared to their academic counterparts.101
Historically, billing for these tests was complex. There were no unique Current
Procedural Codes (CPT) to test individual genes. Thus, laboratory billing managers
billed by method of analysis (e.g. lysis of cells, extraction of highly purified nucleic acid)
used to perform for the test in a technique called “code stacking”. Code stacking results
in different total costs depending on how each laboratory performs molecular testing and
stacks the CPT codes. An example of three different KRAS testing code stacks is
presented by Carlson and demonstrates a $35.98 difference in price depending on code
stacking approach.91
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To address this problem, the American Medical Association organized a
workgroup to construct a new section of the CPT Pathology and Laboratory manual. The
workgroup recommended a two-tiered, volume based coding format. Tests (including
non-oncology) that are performed most frequently are assigned a Tier 1 level. Each tier
has its own CPT code. At the time of publication of an article authored by Klein, 120
analytes and procedures were assigned to Tier 1 and 599 tests were placed into Tier 2 (9
levels). Each level had a CPT code used for that level. Test level is assigned based on
the resources required to carry out the test. These new codes were published on January
1, 2013. The 2015 CPT edition now also includes sections for Multianalyte Assays with
Algorithmic Analyses (MAAAs), Genomic Sequencing Procedures (GSPs), and Other
Molecular Multianalyte Assays (for coding NGS).102
Clinical Practice Guidelines for EGFR Testing in Lung Cancer
Clinicians often rely on clinical practice guidelines (CPG) to direct and justify
therapy. CPGs are systematically produced statements that guide practioners in decisionmaking throughout the healthcare spectrum, from preventive medicine to disease
treatment and follow-up. Good CPGs present validity, reliability, reproducibility, clinical
applicability, clinical flexibility, and clarity.103 They consist of a multidisciplinary
review process and document evidence for a particular procedure or treatment, as well as
suggest areas for future research.103,104 CPGs provide decision support tools that
incorporate references and consider healthcare costs and coverage.103
By 2011, the National Comprehensive Cancer Network recommended the use of
molecular testing in patients with brain, breast, colon, lung, and prostate cancers and
acute myeloid leukemia105. The American Society of Clinical Oncology (ASCO) also
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published a provisional clinical opinion (PCO) regarding the use of EGFR mutation
testing for patients with advanced, NSCLC considering first-line treatment with an EGFR
TKI, such as erlotinib or gefitinib.104 The 2011 ASCO PCO reports that patients with
EGFR-mutated NSCLC treated with EGFR TKIs have significantly higher rates of
response and progression-free survival, however, no overall survival benefit from the
selection of patients for EGFR testing had been observed at that point. They based their
opinion on the results of five clinical trials of gefitinib and erlotinib. At the time of
publication and currently, the clinical opinion is that patients with non-squamous NSCLC
who are being considered for first-line therapy with an EGFR TKI should have their
tumor evaluated for EGFR mutations to guide therapy decisions.104
Around the same time, a consensus meeting of Asian and Canadian medical
oncologists, pulmonologists, and molecular pathologists also produced a standardized
EGFR mutation testing protocol.91 They recommended that Asian patients with nonsquamous, NSCLC, particularly adenocarcinoma, be routinely tested for EGFR
mutations. Testing in patients with squamous histology may be considered, except for
males and heavy smokers, but is not recommended. Their report also included detailed
laboratory considerations and methodologies and asks the pathology community to
consider the emergence and growth of multiple biomarker tests, as done in the
Biomarker-integrated Approaches of Targeted Therapy for Lung Cancer Elimination
Trial (BATTLE).91,106,107
In 2013, a joint guideline was released by the College of American Pathologies
(CAP), International Association for the Study of Lung Cancer (IASLC), and Association
for Molecular Pathology (AMP).103 The purpose of this guideline was to describe the
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evidence-based recommendation for lung cancer molecular testing required to guide
treatment with both EGFR and ALK-targeted therapies. A total of 37 guideline
recommendations were made. Major recommendations included the emphasis on testing
for EGFR mutations and ALK fusions in all patients with advanced, lung
adenocarcinoma (including those with mixed subtypes), regardless of sex, race, smoking
history, or other clinical risk factors. EGFR testing was not recommended in squamous
or large cell carcinomas. The consensus group also prioritized EGFR and ALK testing
over other molecular tests. The group recommended that EGFR testing be conducted at
the time of diagnosis for patients who present with advanced stage disease and at time of
recurrence or progression for those who initially presented with earlier stage disease and
were not previously treated. The guideline also included information on specimen
sample quality, processing, testing validation, and result reporting.103 The European
Society of Medical Oncology (ESMO) largely agrees with the previously described
guidelines for EGFR-mutated NSCLCS in its metastatic NSCLC guideline.108 The
ASCO officially endorsed the guideline issued by the CAP/IASLC/AMP team in
2014.109,110
Epidemiologic Studies Evaluating EGFR Testing in Lung Cancer Patients
Few studies evaluating the utilization of molecular diagnostic testing, specifically
EGFR testing, in a population-based setting currently exist. In a retrospective,
observational study published in 2013, several proprietary and publicly available datasets
were merged to evaluate hospital use of the EGFR assay among lung cancer patients.85
Multivariate logistic regression was performed to identify factors associated with a
hospital’s use of the assay. A total of 7,958 EGFR tests were ordered from 743
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institutions. Non-federal acute care hospitals ordered the largest proportion of EGFR
tests (76%). Geographically, California, Florida, Illinois, New York, and Pennsylvania
hospitals ordered the highest number of tests. Interestingly, North Dakota (a state with
no National Cancer Institute (NCI) Cancer Center or hospital with cytogenetic testing
accreditation) had the highest percentage of lung cancer cases tested (17.6%). However,
these hospitals had academic medical school affiliations, participated in NCI cooperative
group studies, were located in urban areas, and had above average education and
income.85
In the multivariate models, affiliation with an academic medical center (OR=1.48;
95% CI:1.20-1.83), participation in NCI cooperative group studies (OR: 2.06; 95% CI:
1.66-2.55), ability to perform PET scans (OR: 1.44; 95% CI: 1.07-1.94), located in a
metropolitan county (OR: 2.08; 95% CI: 1.48-2.91) and above average education and
income (OR: 1.46; 95% CI: 1.09-1.96 and OR: 1.46; 95% CI: 1.04-2.05, respectively)
were significantly associated with ordering molecular tests.85 Annual number of lung
cancer cases, inpatient chemotherapy, and race were not related to assay ordering.
Pan et al assessed EGFR biomarker testing using US Oncology data from the
iKnowMed™ database, billing claims, and chart reviews.111 Of 26,381 patients with
existing or newly diagnosed non-squamous NSCLC, 1,168 met the additional eligibility
criteria, which included, but was not limited to, only those patients diagnosed with stage
IIIB/IV disease and who initiated second-line therapy between January 1, 2007 and June
30, 2011. Few patients received testing for EGFR (11.0%) prior to date of initiation of
second-line therapy. When the analysis was restricted to only those whose index date
was prior to 2010, the rate of patients was only 2.3%. In 2010, the EGFR testing rate
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significantly increased to 15.2% in 2010 (p<0.0001) and increased again to 32.0% in the
first six months of 2011 (p<0.0001). Half of patients with EGFR-mutated NSCLC were
treated with erlotinib-containing regimens.
Another US study assessed the real-world patterns of EGFR testing in the
population-based setting.112 Enewold and Thomas used Surveillance, Epidemiology, and
End Results (SEER) database to identify a random sample of patients diagnosed with
NSCLC and conducted a National Cancer Center Patterns of Care (POC) study. Eligible
patients included those diagnosed in 2010 with invasive, histologically confirmed,
primary NSCLC. Patients with a history of cancer, diagnosed with a second cancer
(within 60 days), diagnosed at autopsy or death certificate, those with neuroendocrine
carcinomas, those with unknown stage, and those younger than 20 years old were
excluded. The medical records of sampled patients were reviewed and the physicians of
sampled patients were queried using POC survey instruments.112
A total of 1,358 patients diagnosed with NSCLC were included in the analyses.
The majority of patients were stage III (18.2%) or stage IV (55.3%). Overall, 16.8% of
patients with NSCLC had EGFR testing performed. More adenocarcinomas were tested
than other histologies (20.8%). EGFR testing was also more frequently performed in
patients with stage IV disease (19.9% for all histologies; 22.6% for adenocarcinoma),
however, no statistically significant differences were found by stage. Of all patients with
an EGFR mutation, 33.6% received erlotinib, while 48.3% of stage IV patients with an
EGFR mutation did. Factors significantly associated with EGFR testing in stage IV
patients included Hispanic and Asian Pacific Islander heritages (p<0.01), married status
(p=0.05), having private, military, or other insurance (p<0.01), non-smoker status
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(p=0.04), adenocarcinoma or other non-specified carcinoma histology (p<0.01), having
no comorbidities(p<0.01), and living at least two months post-cancer diagnosis (p<0.01).
In 2017, two epidemiologic studies of EGFR testing in NSCLC patients were
published. One study, conducted by Shen et al, used data from Truven Health
MarketScan (commercial health plans and Medicare supplemental plans) from patients
diagnosed between January 2013 and June 2014,113 while the study by Lynch et al used
Veterans data from patients diagnosed between 2011 and 2013.114 Both of these studies
assessed EGFR testing only, not broad molecular testing.
In the study by Shen et al, 18% of included all NSCLC patients (overall cohort)
had a claim for EGFR testing within 6 months of diagnosis. Increasing rates of EGFR
testing were observed over time, 16%-21% over the study period. When limited to
adenocarcinoma histology, this increased to 37%. When limited to patients who received
the drug erlotinib, the testing rate was 42%. Mean time from diagnosis to EGFR testing
was 40 days. In the overall cohort, patients who were younger, female, residing in the
western region of US, and had lower comorbidity scores were more likely to receive
EGFR testing.113 This population-based assessment of EGFR testing indicates that EGFR
testing rates in the US are still low, despite recommendations by oncology groups
supporting its use.
Lynch et al also reported subpar rates of EGFR mutation testing in their
population of Veterans.114 Approximately 34% of patients who were eligible for EGFR
testing had testing performed. The majority of patients tested had adenocarcinoma
histology. In 7% of the tested cases, EGFR sensitizing mutations were detected, which is
much lower than the reported average in the US (10-15%). As EGFR mutation tends to
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develop in non-smokers, this finding is expected. Veterans have a higher smoking rate
compared to the general US population.
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
Overview of FDA Approved Targeted Therapies for EGFR-mutated NSCLC
EGFR mutations can be treated with both monoclonal antibodies (e.g., cetuximab)
and tyrosine kinase inhibitors (TKIs).27 Three EGFR TKIs are FDA approved for use in
EGFR-mutated NSCLC, gefitinib, erlotinib, and afatinib (Figure 2.4). One EGFR TKI,
osimertinib, is only approved for patients whose tumors were EGFR+ (exon 19 and 21
L858R) and developed resistance.
Gefitinib (IRESSA) was the first to receive FDA approval (accelerated) for lung
cancer treatment in unselected populations in 2003,92 however, its approval was later
withdrawn from the market due to failure to reach clinical efficacy endpoints in
confirmatory trials.115 The drug’s manufacturer later designed and executed clinical trials
of gefitinib in selected (EGFR-mutant) patient populations with greater success and
gefitinib was approved for use in patients whose tumors harbor EGFR+ (exon 19 and 21
L858R) mutations in the US in 2015. The administration of gefitinib in patients is
contingent upon use of a companion diagnostic to identify the required mutations
(therascreen EGFR RGQ PCR Kit).116
Afatinib was approved in the US in 2013.117 Afatinib (Gilotrif) is indicated for
use as first-line therapy in patients whose tumors harbor EGFR (exon 19 and 21 L858R)
mutations. Afatinib was approved for use with the companion diagnostic test therascreen
EGFR RGQ PCR Kit.117
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Erlotinib (Tarceva), some would say, has dominated the US EGFR TKI market in
recent years, first gaining approval in 2004 for the treatment of unselected patients with
locally advanced or metastatic NSCLC after failure of one prior chemotherapy
regimen.118 Erlotinib also received approvals in 2010 and 2013, for maintenance therapy
and for first line treatment in the selected, EGFR-positive (exon 19 and 21 L858R),
respectively. Patients must undergo EGFR testing with erlotinib’s companion diagnostic
test, the cobas EGFR Mutation Test.119
Randomized Phase 3 Clinical Trials Involving Erlotinib
Multiple preclinical and early phase (I and II) trials of erlotinib have been
conducted globally.120-125 Randomized phase III trials evaluating response rate (RR),
progression-free survival (PFS), and overall survival (OS) have also been conducted
internationally, in various settings and patient populations (Table 2.2). In selected patient
subgroups, RR and PFS have mostly been increased with erlotinib, however, trials
assessing OS have reported mixed results.
Second line and beyond
The first FDA approval for the use of erlotinib in the second-line setting and
beyond was based on data from the BR.21 study published by Shepherd et al.11 The
randomized, placebo-controlled, double blind trial evaluated erlotinib (150 mg) versus
placebo following failure of first-line or second-line chemotherapy. OS, PFS, overall
response rate (ORR), duration of response, toxicity, and quality of life were assessed.
Eligible patients included those who met the following criteria: Eastern Cooperative
Oncology Group (ECOG) performance status (PS) of 0-3, pathological evidence of
NSCLC, recovered from chemotherapy side effects, no prior breast cancer, melanoma, or
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hypernephroma, no symptomatic brain metastases, no clinically significant cardiac
disease within past 12 months, no ventricular arrhythmias and no clinically significant
ophthalmologic or gastro-intestinal abnormalities. Patients were not required to have
EGFR-mutated NSCLC. A total of 731 patients were randomized to erlotinib (n=488) or
placebo (n=243).11
Overall response rate (partial and complete responses) was better in the erlotinib
arm (8.9%) compared to the placebo arm (<1%; p<0.001). Response rate (RR) for
patients with EGFR-positive tumors was 11.3% compared to 3.8% for patients with
EGFR-negative tumors (p=0.10). Duration of response was also better for the erlotinib
arm compared to placebo (7.9 vs 3.7 months (mos), p<0.001, respectively). Additionally,
PFS and OS was improved for the erlotinib arm compared to placebo. Progression-free
survival was 2.2 vs 1.8 months (Hazard ratio (HR): 0.61, p<0.001). Overall survival was
6.7 vs 4.7 months (HR: 0.70, p<0.001).11 After adjustment for treatment and other
significant factors, adenocarcinoma subtype (HR: 0.8, 95%CI: 0.6-0.9, p=0.004), Asian
origin (HR: 0.7, 95% CI: 0.5-0.9, p=0.01) and never-smoking status (HR: 0.8, 95% CI:
0.6-1.0, p=0.048) were significant predictors of survival. Toxicities (rash and diarrhea)
and quality of life were acceptable with erlotinib therapy.11
Subset analyses of patients from the BR.21 study assessed the role of EGFR
protein, copy number and mutation status in response and survival outcomes126. Female
sex (p=0.007), Asian origin (p=0.02), never smoker status (p<0.001), adenocarcinoma
subtype (p<0.001), and polysomy or amplification of EGFR (p=0.03) were associated
with response. Increased response to erlotinib for patients with EGFR- mutated tumors
compared to patients with EGFR wild-type tumors was observed, however the difference
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in response between the groups was not significant (16% vs 7%, p=0.37). OS was not
influenced by EGFR expression, copy number or mutation status.126
Another study that evaluated erlotinib in the second line setting was published by
Garassino et al in 2013.127 The TArceva Italian Lung Optimization tRial (TAILOR) trial
assessed the efficacy of erlotinib compared to the standard second-line chemotherapy,
docetaxel, in patients with EGFR wild-type NSCLC tumors. The primary endpoint was
overall survival and secondary endpoints included PFS, RR, and QOL. Patients included
in the trial were those who failed previous chemotherapy (pemetrexed, vinorelbine,
gemcitabine), were not previously treated with taxanes or anti-EGFR drugs, and had
ECOG PS of 2 or less.127
A total of 222 patients were randomly assigned to received either erlotinib
(n=122) or docetaxel (n=110). Tumor response in the erlotinib group was not longer than
the docetaxel group (3.0 vs 15.5 months (mos), p=0.003). Median PFS was 2.4 months
in the erlotinib group compared to 2.9 months in the docetaxel group HR:0.71, 95% CI:
0.53-0.95, p=0.02). Median OS was shorter in the erlotinib arm compared to the
docetaxel arm (5.4 vs 8.2 mos, HR=0.73, 95% CI: 0.53-1.00, p=0.05). The results of this
study demonstrate that treatment with docetaxel is preferred to erlotinib in the secondline, EGFR wild type setting.127
The Tarceva in Treatment of Advanced NSCLC (TITAN) study was conducted
concurrently with the SATURN maintenance therapy study.98 However, unlike
SATURN (which included patients without disease progression), the TITAN study
enrolled patients who rapidly progressed on standard chemotherapy (within four cycles).
Eligibility criteria were similar to that of the SATURN study, with the exception that

46

TITAN also included ECOG PS 2 patients. The primary endpoint of this randomized,
international trial was OS. RR and OS were also assessed. There were no statistically
significant differences in RR, PFS, or OS. The results of the TITAN study were not
impressive, however, the study suffered from multiple limitations (e.g., underpowered,
unbalanced baseline factors progostically benefiting the chemotherapy arm).98
A Greek randomized study by Karampeazis et al evaluated erlotinib compared to
pemetrexed in the second line and beyond setting.9 The primary endpoint of this trial was
time to progression (TTP), and RR, PFS, and OS were evaluated as secondary endpoints.
Biomarker status was also assessed. Eligible patients included those who were diagnosed
with stage IIIB/IV NSCLC with a ECOG PS of 0-2, were pemetrexed and TKI-naïve, and
progressed after one or two lines of chemotherapy. Those patients with second primary
tumors, active infections, severe heart disease and uncontrolled diabetes were excluded.9
A total of 179 patients were randomized to the erlotinib arm; 178 were randomized
to receive pemetrexed. RR was better for the pemetrexed arm compared to the erlotinib
arm (11.4% vs 9%, p=0.469). PFS and OS did not differ significantly between the
pemetrexed and erlotinib groups (2.9 vs 3.6 mos, p=0.136 and 10.1 vs 8.2 mos, p=0.986,
respectively). There were no differences in RR or OS by EGFR mutation status.9
First line combination therapy
A phase III trial of erlotinib evaluated the drug in combination with standard
chemotherapy (carboplatin and paclitaxel) in the first-line setting.128 The primary
objective of the TRIBUTE trial was OS. Other objectives included time to progression
(TTP), ORR, and safety. PFS was not assessed. Eligible patients include those with
histologically confirmed stage IIIB or IV NSCLC with ECOG PS of 0-1. Patients with
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prior systemic chemotherapy, symptomatic or untreated brain metastases, unstable
disease that would preclude use of chemotherapy, and inadequate laboratory values were
excluded. EGFR protein expression was not an eligibility requirement. Patients were
randomly assigned to receive daily erlotinib plus chemotherapy concurrently (n=539) or
placebo plus chemotherapy concurrently (n=540).
There was no significant difference in objective RR, TTP, or OS in the TRIBUTE
trial. Objective RR for the erlotinib plus chemotherapy arm was slightly higher
compared to the placebo plus chemotherapy arm (21.5% vs 19.3%, p=0.36). Median OS
was similar between the arms (HR:0.995, 95% CI: 0.86-1.16, p=0.95). In a subgroup
analysis, the only group to demonstrate a survival advantage with the addition of erlotinib
to standard chemotherapy was in never smokers. Never smokers who received erlotinib
plus chemotherapy survived longer compared to those who received placebo plus
chemotherapy (22.5 vs 10.1 mos, HR=0.49, 95% CI:0.28-0.85). Never smokers who
received erlotinib also had an increased TTP compared to the placebo group (6.0 vs 4.3
mos, HR=0.50, 95% CI: 0.31-0.80). Rash, diarrhea, and nausea were higher in the
erlotinib arm.128
Erlotinib was also evaluated in combination with chemotherapy (cisplatin and
gemcitabine) in the first line setting in the Tarceva Lung Cancer Investigation Trial
(TALENT).129 TALENT was an international study designed to evaluate OS, TTP, RR,
duration of response, and QOL. Eligible patients included those with histologically
confirmed, unresectable, locally advanced, recurrent, or metastatic NSCLC (stage
IIIB/IV) with EGOG PS of 0-1, and adequate laboratory values. Patient with previous
exposure to chemotherapy/systemic antitumor therapy or EGFR directed agents were
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excluded. Patients with unstable systemic disease, other prior malignancies (within 5
years), and significant ophthalmologic abnormalities were also excluded.129
Of the eligible patients, 1,159 were randomly assigned and started study therapy.
Patients received either erlotinib plus chemotherapy (cisplatin and gemcitabine) or
placebo plus chemotherapy for six cycles. RR was similar between the two arms; 31.5%
of patients responded to treatment with erlotinib plus chemotherapy and 29.9% responded
to treatment with placebo plus chemotherapy. There was no difference in OS survival
between the arms (43 vs 44.1 weeks (wks); HR=1.06,95% CI: 0.90-1.23, p=0.49). EGFR
expression (by IHC) was not correlated with response or survival outcomes.129
First line monotherapy
Following positive RR, PFS, and OS results with erlotinib in the second-line and
beyond setting,11 several studies evaluated the drug as monotherapy in the first-line
setting.7,12,130 The first trial to evaluate erlotinib in the first-line monotherapy setting was
conducted by Zhou et al in China.7 The purpose of the OPTIMAL trial was to evaluate
the efficacy (RR, PFS) and tolerability of erlotinib versus standard chemotherapy
(carboplatin/gemcitabine). The open-label, randomized trial included patients with
histologically confirmed stage advanced or recurrent IIIB/IV NSCLC with activating
EGFR exon 19 deletion or exon 21 L858R point mutation. Other eligibility criteria
included presence of measurable disease, EGOG PS of 0-2, and adequate laboratory
values. Patients with uncontrolled brain metastases and those who had received previous
systemic therapy for advanced cancer were excluded.7
A total of 165 patients were randomized (83 to erlotinib arm; 82 to standard
chemotherapy arm). 83% of patients on the erlotinib arm achieved a complete or partial
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response compared to 36% for the standard chemotherapy arm (p<0.0001). Median PFS
was significantly better for patients treated with erlotinib compared to patients treated
with standard chemotherapy (13.1 vs 4.6 mos, HR=0.16, 95% CI: 0.10-0.26, p<0.0001).
OS data were not mature at time of publication. Erlotinib administration was associated
with a higher incidence of skin rash and diarrhea, but were low in severity (73% vs 19%,
p<0.0001 and 25% vs 6%, p=0.00085, respectively).7
Also in the first line, monotherapy setting, the EURTAC trial, conducted in
France, Italy, and Spain by Rosell et al, evaluated the safety and efficacy of erlotinib
compared to standard platinum-based chemotherapy (cisplatin/docetaxel or
cisplatin/gemcitabine; carboplatin was allowed for patients unable to tolerate cisplatin).12
Inclusion criteria included histologic confirmation of stage IIIB/IV NSCLC,
measurable/evaluable disease, and no history of chemotherapy for metastatic disease.
Only patients with activating EGFR mutations (either exon 19 deletion or exon 21 L858R
mutation) were enrolled. Additionally, patients with asymptomatic, stable brain
metastases were allowed. Patients were randomized in a 1:1 fashion to receive either
erlotinib (n=86) or standard chemotherapy (n=87). Trial endpoints included RR, PFS,
OS and safety. 64% of patients treated with erlotinib achieved a response compared to
only 18% in the standard chemotherapy group. Median PFS was significantly longer in
the erlotinib arm compared to the standard chemotherapy arm (9.4 vs 5.2 mos, HR=0.42,
95% CI: 0.27-0.64, P<0.0001). OS did not differ significantly between the two arms
(19.3 mos for erlotinib vs 19.5 mos for standard chemotherapy, HR=1.04, 95% CI: 0.651.67, p=0.87). Common side effects included anemia and neutropenia.12
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Following the positive interim analysis, the trial was halted and full data analysis
was conducted. A slight increase in PFS was observed in the erlotinib arm compared to
the standard chemotherapy arm (9.7 vs 5.2 mos, HR=0.37, 95%CI: 0.25-0.54, p<0.0001).
FDA approval for use of erlotinib monotherapy in the first line setting was based on the
results of the EURTAC trial. Updated RR, PFS and OS data are included in the erlotinib
package insert. RR continued to be better for the erlotinib group compared to the
standard chemotherapy group. PFS remained better for the erlotinib group compared to
the standard chemotherapy group (10.4 vs 5.2 mos, HR=0.34, 95% CI: 0.23-0.49,
p<0.001), however, there also remained no significant difference in OS (22.9 vs 19.5
mos, HR=0.93, 95% CI: 0.64-0.35).131
Lee et al evaluated erlotinib as first line monotherapy therapy in the TOPICAL
trial.130 Conducted in the UK, this randomized, placebo-controlled trial evaluated
efficacy (RR, PFS, OS), toxicities and quality of life. Patients included in the trial were
those with stage IIIB/IV newly diagnosed, pathologically confirmed NSCLC who were
chemotherapy naïve, and deemed unsuitable for chemotherapy due to performance status
≥2. Patients were not required to have EGFR mutations. The treatment arms were
slightly imbalanced with 350 patients treated with erlotinib and 320 patients receiving
placebo.130
Response rate was better in the erlotinib group compared to the placebo group
(4% vs 2%). A small, but significant improvement is PFS was observed with first line
erlotinib monotherapy compared to placebo (2.8 vs 2.6 mos, HR=0.80, 95% CI: 0.680.93, p=0.0054). No difference in OS was observed (3.7 vs 3.6 mos, HR=0.92, 95% CI:
0.78-1.07, p=0.31). Cognitive and physical functioning was better in the erlotinib arm.
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Interestingly, a subgroup analyses of first-cycle rash revealed improved PFS and OS for
those in the erlotinib arm who had rash compared to those who did not have rash
(HR=0.24, 95% CI: 0.16-0.35, p<0.0001).130
Maintenance therapy
Erlotinib has also been evaluated as maintenance therapy. The Sequential
Tarceva in Unresectable NSCLC (SATURN) trial evaluated the administration of
erlotinib as switch maintenance therapy in an international study.132 The objectives of
this study were to evaluate PFS in patients with both wild-type and EGFR-mutated
tumors. Patients with histologically confirmed, measurable unresectable or metastatic
NSCLC with EGOG PS of 0-1 were included. Other eligibility criteria included lack of
previous exposure to anti-EGFR agents, uncontrolled, symptomatic brain metastases, or
other malignancies within past 5 years. Finally, patients were only eligible if they had
participated in the run-in phase of the study and had not progressed following first-line
platinum based doublet chemotherapy (investigators choice of seven regimens).132
Tumor response rate was better with erlotinib compared to placebo (11.9% vs
5.4%, p=0.0006). Median PFS was longer in the erlotinib group compared to placebo
(12.3 vs 11.1 weeks, HR=0.71,95% CI: 0.62-0.82, p<0.0001) in the overall population
and was also prolonged in the EGFR-mutant population (12.3 vs 11.1, HR=0.69, 0.580.82, p<0.0001). OS was significantly longer in the erlotinib arm compared to the
placebo arm in the overall population (12.0 vs 11.0 mos, HR=0.81, 95% CI:0.70-0.95,
p=0.0088).132 FDA approval for erlotinib in the maintenance setting was based on the
results of the SATURN trial.118

52

Another trial evaluated the sequential administration of chemotherapy plus
erlotinib vs chemotherapy plus placebo (switch maintenance) among 451 unselected
patients. Wu et al published the results of the FASTACT2 trial, conducted in China, in
2013.133. The primary endpoint was PFS and other endpoints included RR and OS.
Eligible patients were those diagnosed with stage IIIB/IV NSCLC, had a ECOG PS of 01 and had measurable disease. Excluded patients included those with brain metastases,
spinal cord compression, or HIV, those previously treated with agents targeting the HER
axis, and those with recent surgery or radiation therapy.133
Patients were randomized in a 1:1 fashion to receive cisplatin or carboplatin plus
gemcitabine followed by erlotinib or placebo (n=226 and n=225, respectively). In the
overall population, RR was better in the erlotinib group compared to the placebo group
(44% vs 16%, p<0.0001). Median PFS was longer in the erlotinib group compared to the
placebo group, as was OS (7.6 vs 6.0 mos, HR=0.57, 95% CI: 0.47-0.69, p<0.0001 and
18.3 vs 15.2 mos, HR=0.79, 95%CI: 0.64-0.99, p=0.04200).
In the EGFR-positive population, increases in both response and survival
endpoints were observed. In this population, 84% of patients in the erlotinib group
achieved response compared to only 15% in the placebo group (p<0.0001). Median PFS
and OS were also significantly improved for erlotinib group compared to placebo group
(16.8 vs 6.9, HR=0.25, 95% CI: 0.16-0.39, p<0.0001 and 31.4 vs 20.6 mos, HR=0.48,
95% CI: p=0.0092).133
Epidemiologic Studies of Erlotinib
Several epidemiologic studies, described previously, that assessed EGFR testing
in NSCLC patients also evaluated erlotinib utilization.112-114 In the Shen et al study,
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EGFR testing was significantly associated with erlotinib use. Approximately 5% of
patients received erlotinib treatment.113
Enewold and Thomas reported that 6.3% of all NSCLC patients received erlotinib
in their study. Of patients with an EGFR mutation, 33.6% of all patients and 48.3% of
stage IV patients received erlotinib. Erlotinib was less likely to be prescribed to in
smokers (OR=0.27, 95% CI: 0.12-0.59) and patients with non-adenocarcinoma
histologies (OR=0.14, 95% CI: 0.04-0.54). Erlotinib was not associated with increased
survival.112
Approximately half (56%, n=36) of patients whose tumors were EGFR-positive
received erlotinib in a study of Veterans.114 Erlotinib was also prescribed to patients that
were EGFR-negative (10%), had non-sensitizing EGFR mutations (11%), or whose
EGFR status was unknown (17%). Erlotinib utilization was in agreement with the EGFR
test results in 87% of the cohort cases. Patients who had an EGFR mutation and were
treated with erlotinib had the best survival outcome (median=921 days, range=56-3730
days).114
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Tables and Figures
Table 2.1. Selected FDA Approved Systemic, Targeted and Immune Therapies for Non-Small Cell Lung Cancer
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Patient Population

First Line

Second Line and beyond

No EGFR mutation

Carboplatin/pemextrexed/pembrolizumab
Pembrolizumab*
Carboplatin/pemextrexed/bevacizumab
Carboplatin/paclitaxel/bevacizumab
Carboplatin/pemextrexed
Carboplatin/paclitaxel
Carboplatin/gemcitabine
Carboplatin/docetaxel

Nivolumab
Docetaxel
Ramucirumab/docetaxel
Pembrolizumab**
Atezolizumab
Pemetrexed
Gemcitabine

EGFR mutation

Afatinib
Erlotinib
Gefinitib
Osimertinib

Nivolumab
Pembrolizumab**
Ramucirumab/docetaxel
Docetaxel
Osimertinib
Atezolizumab
Pemetrexed
Gemcitabine

Abbreviations: FDA, Food and Drug Administration
*For use in patients with high (≥50%) PD-L1.
**For use in patients with microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR)

Table 2.2. Randomized, phase 3 clinical studies of erlotinib
Author /
Study /
Year

Country

Arms

Therapy

Garassino
et al

Italy

Erlotinib vs
chemo

Second

TAILOR
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2013
Wu
et al

RR (%)

Median
PFS
(months)

Median OS
(months)

3.0 vs 15.5*

2.4 vs
2.9

5.4 vs
8.2*

UNS: 43.0
vs 18.0*

UNS: 7.6
vs 6.0*

UNS: 18.3
vs 15.2

EGFR+:
84.0
vs 15.0*

EGFR+:
16.8
vs 6.9*

EGFR+:
31.4
vs 20.6

UNS: 9
vs 11.4

UNS: 3.6
vs 2.9

UNS: 8.2
vs 10.1

Erlotinib/
EGFR+ vs
EGFR wild:
33.3 vs 7.3*

Erlotinib/
EGFR+ vs
EGFR wild:
NA

Erlotinib/
EGFR+ vs
EGFR wild:
23.0 vs 9.7

7.9 vs 6.3

6.3 vs 8.6
weeks

5.3 vs 5.5

SEQ

Asia

FAST-ACT2
2013
Karampeazis
et al

Patient
N
Population
/ EGFR
Testing
Method
EGFR wild 222
type only

Greece

Chemo plus
erlotinib vs
chemo plus
placebo
(sequential)

Switch
UNS
maintenance
SEQ

Erlotinib vs
chemo

Second and
beyond

UNS

451

357

SEQ
HORG
2013

Ciuleanu
et al

INT

Erlotinib
monotherapy

Second

UNS

424

vs chemo

IHC and
SEQ

TITAN
2012

Rosell
et al

France,
Italy,
Spain

Erlotinib
monotherapy
vs chemo

First

EURTAC
57

2012
Lee
et al

UK

Erlotinib vs
placebo

First

EGFR
mutation
positive
only
SEQ
UNS

EGFR+
IHC: NR

EGFR+
IHC: 5.6 vs
5.5

EGFR+
SEQ:
NI

EGFR+
SEQ: NI

9.7 vs 5.2*

19.3 vs 19.5
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Figure 2.1. Timeline of Single Arm and Randomized Studies of Low-Dose Computed Tomography

Reprinted with permission from My Cancer Genome,
https://www.mycancergenome.org/media/content-images/mapk-pk13.png), Copyright
2016 by Vanderbilt University.

Figure 2.2. EGFR Signaling Pathway
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Reprinted with permission from My Cancer Genome,
https://www.mycancergenome.org/media/content-images/EGFR-nsclc-revised2.png,
Copyright 2016 by Vanderbilt University.
Figure 2.3. EGFR in Non-Small Cell Lung Cell
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Figure 2.4. Timeline of EGFR TKI and companion diagnostic approvals
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CHAPTER III:
OBJECTIVES AND METHODS
Study 1: Family Physician Perceptions and Experiences with Low-Dose Computed
Tomography Screening for Lung Cancer
Objectives
The main objective of this study was to quantitatively and qualitatively evaluate
current family physician perceptions and experiences towards lung cancer screening with
LDCT. Specifically, we assessed FPs’ knowledge of the evidence supporting lung cancer
screening and patient eligibility criteria. Additionally, we explored attitudes and
experiences related to patient selection, shared decision-making visits, LDCT referrals,
and LDCT follow-up practices.
Methodology
This sequential explanatory mixed-methods134 research approach consisted of
quantitative electronic questionnaire data followed by the collection of qualitative guided
audio interview data. First, a quantitative questionnaire was administered to two primary
care physician cohorts using Qualtrics software (Appendix A). In January 2015,
members of the South Carolina chapter of the American Academy of Family Physicians
(SCAFP) were sent an email containing a link to the survey (n=1,330). A follow-up
email reminder was sent on January 22, 2015. The questionnaire consisted of a total of 32
questions (22 multiple-choice, 7 fill in the blank, 3 Likert scale) and took approximately
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20 minutes to complete. A total of 85 SCAFP physicians started the electronic survey,
with 65 completing the survey. To increase sample size, additional paper questionnaires
were distributed to physicians attending the SCAFP Summer Breakaway and Annual
Assembly (June 7-12, 2015). Paper questionnaires were placed in registration bags
(n=135) and physicians were directed to submit the completed questionnaires at the
University of South Carolina exhibitor booth. A total of 16 physicians completed the
paper questionnaire (total sample size = 101). The last question in the questionnaire
asked physicians if they agreed to be contacted for future research. A total of 19
physicians provided contact information. Additionally, primary care physician
employees of the Carolinas HealthCare System (CHS) were surveyed. These physicians,
located in North and South Carolina, were emailed a link to the survey in May 2015,
several months after the CMS coverage announcement decision was made. A total of 57
physicians responded to the email survey. Results of this quantitative assessment were
published in 2016.16,17 Importantly, the results of the survey were used to develop the
qualitative interview guide.
Qualitative data was obtained through convenience sampling to better and more
deeply understand both urban and rural family physician perceptions towards and
practices surrounding lung cancer screening. Participants in the qualitative phase of this
study included a subset of those who participated in the quantitative survey.
Additionally, we mailed personalized invitations to a sample of family physicians from
North and South Carolina identified from the American Medical Association (AMA)
Physician Masterfile. FPs were asked to return the invitation, using a provided RSVP
card, to indicate their interest in participating. FPs were also recruited by referral from a
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non-profit cancer advocacy group in North Carolina. The interviewer followed a semistructured interview guide (Appendix A). Questions were developed based on responses
to the survey, as well as Cabana’s framework.135
Data Collection
The interviews took place until thematic saturation was reached and took
approximately 30-40 minutes to complete. Due to the geographic spread of physicians in
the SCAFP and CHS cohorts, the interviews were conducted via Skype and were limited
to audio recordings only. No video recordings were made. Interviews were audio
recorded using Call Recorder for Skype, transcribed verbatim, and reviewed for accuracy
to ensure data quality.
Analysis Plan
Following quality review, the interview transcripts were assessed to develop a
theme dictionary. Transcripts were then uploaded to NVivo qualitative data analysis
software (QSR International Pty Ltd. Version 10, 2012) for thematic coding. Using a
constant comparison technique, transcribed interviews were reviewed throughout data
collection and the interview guide was adapted along the way to further explore relevant
concepts identified during the initial interviews. The interview transcripts were then
critically assessed to identify themes and subthemes by two separate persons. Any
discrepancies in coding were discussed until consensus was met. Data was assigned to
multiple themes.
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Study 2: Molecular Testing Utilization and Targeted Therapy (Erlotinib)
Administration and Survival Among Patients with Late Stage Non-Small Cell Lung
Cancer
Objectives
The main objective of this study was to identify factors associated with receipt of
molecular testing and erlotinib in patients diagnosed with late stage NSCLC residing in
South Carolina. Additionally, we evaluated overall survival among molecular testing
(yes/no) and erlotinib (yes/no) groups.
Methodology
This study involved the use of state-level data obtained from the South Carolina
Central Cancer Registry (SCCCR) and the SC Revenue and Fiscal Affairs Office (RFA).
The SCCCR is a population-based system that collects data on newly diagnosed cancer
cases in South Carolina. Data in the SCCCR includes information on demographics,
diagnosis date, cancer location and histology, treatment, and overall survival. The
majority of information on cancer cases in the SCCCR is reported electronically from
hospitals with existing cancer registries. However, some information is collected by
SCCCR staff (i.e., independent pathology labs, free-standing treatment centers and
physician offices, and non-registry hospitals). The quality of data from the SCCCR is
good and undergoes quality control audits. The SCCCR has received Gold or Silver
certification from the North American Association of Central Cancer Registries every
year since 1997.
The SC Revenue and Fiscal Affairs Office (RFA) is an independent agency that
houses administrative claims data from both the SC State Employee Health Plan
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(SCSEHP) and SC Medicaid plan members. The RFA developed a series of algorithms
using various combinations of personal identifiers to create its own unique identifier,
enabling statistical staff to “link across” multiple providers and settings. Hence, it allows
for linkages while protecting confidentiality of the client. The SC RFA and SC Central
Cancer Registry frequently work together to complete data linkage requests for
researchers in SC.
A cohort of patients from the SCCCR with a diagnosis of stage IIIB/IV non-small
cell lung cancer from January 1, 2002 through December 31, 2012 was assembled. The
cohort was linked to the same patients in the SCSEHP and Medicaid datasets. The
resulting combined dataset was used to conduct all analyses.
In this project, we evaluated utilization of molecular testing and the EGFR TKI,
erlotinib, using CPT codes and National Drug Codes (NDC), respectively, to identify
patients who received molecular testing or erlotinib after diagnosis of lung cancer. CPT
and NDC codes to be used in this analysis are listed in Appendix C. Additionally, we
identified factors associated with molecular testing and erlotinib use. Lastly, we
evaluated the impact of molecular testing and erlotinib on survival.
Analysis Plan
Descriptive statistics for patient and provider characteristics were summarized for
the overall cohort and by 1) molecular testing status and 2) erlotinib status. Comparisons
between molecular testing and erlotinib groups were performed using chi-square tests for
categorical variables and a two-sample t-test for age. Univariable and multivariable
logistic regression were used to identify factors that significantly predicted molecular
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testing or erlotinib utilization. Odds ratios (OR) and corresponding 95% confidence
intervals (CI) will be estimated. Covariates included in the final multivariable model will
be determined using backwards elimination procedures.
Kaplan–Meier techniques will be used to estimate survival distributions and logrank tests compared the survival distributions for the 1) molecular testing and 2) erlotinib
groups. Univariable Cox proportional hazards regression was used to identify individual
prognostic factors predictive of overall survival and multivariable Cox proportional
hazards regression was used to evaluate the independent impact of the covariates and
molecular testing status on overall survival. Unadjusted and adjusted hazard ratios (HR)
and corresponding 95% CIs were estimated. Cox proportional hazards models were also
estimated using propensity scores as covariates in parsimonious and non-parsimonious
models.
All statistical analyses were performed using Statistical Analysis Systems
software, version 9.2 (SAS Inc., Cary, NC). All hypothesis testing was 2-sided with a
p<0.05 level of statistical significance.
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CHAPTER IV:
A QUALITATIVE STUDY OF NORTH AND SOUTH CAROLINA
FAMILY PHYSICIANS’ PERCEPTIONS AND EXPERIENCES
WITH LOW-DOSE CT SCREENING FOR LUNG CANCER1

1

Ersek JL, Turner G, Cartmell K, Sercy E, Adams SA, Hébert JR, Kim ES, Symanowski JT, Jan
Eberth JM. To be submitted to Lung Cancer.
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Abstract
Objectives: The United States Preventive Services Task Force recommends lung cancer
screening (LCS) in high risk patients using low-dose computed tomography (LDCT). In
2015, the Centers for Medicare and Medicaid Services announced coverage of LCS
shared decision-making counseling visits and LDCT. Despite this, LDCT utilization
remains extremely low. This study assessed family physician (FP) knowledge of the
evidence supporting LCS and patient eligibility criteria, as well as explore attitudes and
experiences related to patient selection, shared decision-making visits, LDCT referrals,
and LDCT follow-up.
Methods: We conducted a qualitative interview study using thematic content analysis. A
convenience sample of 15 FPs in the Carolinas completed semi-structured Skype audio
interviews. No information about LCS was provided prior to the interview. Interviews
were transcribed verbatim and analyzed using NVivo software.
Results: Most FPs reported making a LDCT referral, however, the majority of FPs
reported suboptimal awareness of the scientific evidence for LCS, patient eligibility
criteria, and documentation and billing procedures. Smoking history was the primary
driver of a FP’s decision to discuss LCS. FPs were less likely to discuss LCS in patients
with short life expectancies, comorbid conditions, or without insurance. While FPs knew
they should limit discussions about LCS to high risk patients, they expressed willingness
to screen outside of established criteria in certain circumstances. FPs preferred to
conduct LCS discussions during annual visits, but acknowledged that many eligible
patients do not visit the clinic unless there is an acute need. Barriers to LCS included
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cost and administrative complexities, including lack of support resources and difficulties
with documentation and billing.
Conclusions: FPs have varying degrees of knowledge about and experiences with LDCT.
FPs are open to using LDCT as a LCS tool, with additional education and support.
Introduction
Despite advances in lung cancer treatment, lung cancer remains a major cause of
cancer-related death in the United States, due in part to the fact that the majority of
patients are diagnosed with advanced disease. Early lung cancer screening approaches
(e.g., sputum cytology, chest x-ray) were largely unsuccessful and no improvement in
lung cancer mortality was reported. In 2011, the National Lung Screening Trial (NLST)
concluded that annual screening for lung cancer using low-dose computed tomography
(LDCT) resulted in a 20% reduction in lung cancer mortality and a 6.7% reduction in
overall mortality compared to chest x-ray.18 Subsequently, the United States Preventive
Services Task Force (USPSTF) published an updated guideline recommending annual
LDCT screening in high risk patients at the Grade B evidence level in December 2013.19
As a result, high risk patients with private insurance were allowed the option to have
LDCT screening at no cost under the Affordable Care Act. High risk was defined as a
patient aged 55 to 80 years who had at least a 30 pack-year smoking history, who
currently smokes or has quit smoking within the past 15 years. Shortly thereafter, in
February 2015, the Centers for Medicare and Medicaid Services (CMS) released a
decision memo announcing coverage of LDCT screening for high risk adults. CMS
defines high risk individuals similarly to USPSTF criteria; however, the age range was
reduced to a maximum age of 77 years and CMS notes that patients should be
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asymptomatic. CMS requires documentation of smoking history and a counseling visit
with the use of decision aids to review the risks and benefits of lung cancer screening
(i.e., a shared decision-making visit; SDM). The SDM counseling visit should include
discussions of the importance of annual screening, patient comorbidities, and patient
willingness to undergo further evaluation and treatment if a suspicious lung nodule is
identified, as well as undertake smoking cessation.13 Thus, specific patient eligibility
criteria must be met and documented for Medicare reimbursement. Professional
organizations, in general, describe the implementation of SDM visit, smoking cessation
counseling, and promote standardized follow-up for abnormal LDCT results as
components of successful lung cancer screening programs.13,19,136
While LDCT screening in now approved in high risk patients, current research
indicates that uptake of lung cancer screening guideline adoption has been slow in the
primary care setting. A recent study by Jemal et al reported low rates (<4%) of selfreported LDCT utilization from 2010-2015.84 Several quantitative studies have assessed
family physician’s knowledge and attitudes following USPSTF recommendations and
CMS coverage announcements.16,80-82 However, only one qualitative study, to our
knowledge, has assessed family physician (FP) knowledge, attitudes, and practices since
the CMS decision memo announcement that FPs could obtain Medicare reimbursement
for LCS counseling visits.14 To enhance the existing literature, we conducted a
qualitative study to assess North and South Carolina FPs’ knowledge of the evidence
supporting LCS and patient eligibility criteria. Additionally, we explored attitudes and
experiences related to patient selection, SDM visits, LDCT referrals, and LDCT followup practices.
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Methods
A qualitative interview study was conducted using thematic content analysis. We
selected this approach because of the highly structured nature of the research questions
we had, which were broad. We wanted to capture a holistic understanding of LCS in the
Carolinas, from physicians’ knowledge-base of lung cancer screening to following up
with patients after LDCT screening was performed.
A convenience sample of physicians were asked to participate in a 30-45-minute
telephone interview between March 2016 and August 2017. Physicians were recruited
via multiple methods including postal mail, email, and telephone. First, physicians that
provided contact information upon completion of a questionnaire on LCS that we
administered in 201516,17 were contacted via email and/or phone and invited to participate
in this follow-up study. Additionally, we mailed personalized invitations to a sample of
FPs from North and South Carolina identified from the American Medical Association
(AMA) Physician Masterfile. FPs were asked to return the invitation, using a provided
RSVP card, to indicate their interest in participating. FPs were also recruited by referral
from a non-profit cancer advocacy group in North Carolina. The sample size goal was 12
interviews, based on the recommendation of Guest, Bruce, and Johnson,137 however, we
continued recruitment until we felt that thematic saturation was achieved. All physicians
gave verbal consent to participate as part of the audio recorded interview. The University
of South Carolina Institutional Review Board approved the study.
Data Collection
One interviewer (JLE) conducted all the FP interviews using a semi-structured
interview guide. Topics addressed in the interview guide included current evidence and
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guidelines for lung cancer screening, who to approach for lung cancer screening
discussions, how the conversation about lung cancer screening was performed, making a
referral for screening, and following up after a LDCT. The interview guide was
developed in an iterative fashion, with input from epidemiologists, medical oncologists,
and nurses. Prior to finalization, the guide was tested with a FP and lung cancer
screening thought leader. We did not provide any structured education to FPs prior to the
interviews. Additionally, we emailed participating FPs educational materials published
by the Agency for Healthcare Research and Quality (ARHQ) upon completion of the
interview.
Interviews were executed via Skype with the Call Recorder for Skype [Ecamm,
North Andover, MA].138 All interviews were recorded in their entirety and transcribed
verbatim by individuals trained in dictation. Transcribed interviews were then reviewed
for quality by the interviewer (JLE) and revisions to the transcribed interviews were
made if required. Quality-checked interviews were then imported into NVivo®
Qualitative Data Analysis Software version 11.4.139 While interviews were reviewed for
quality, an initial codebook was drafted (JLE) using a directed approach to content
analysis.140,141 The codebook was continuously reviewed and revised using the constant
comparison technique142 with input from two reviewers (JLE, GT).
Data Analysis and Interpretation
Reviewers independently coded each interview using NVivo® and codes
documented by each reviewer were compared. A Cohen’s Kappa coefficient was
calculated for each node for each interview. An overall interview Kappa was calculated
by averaging the Kappa values obtained for each node. The interview Kappa was used to
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measure inter-rater reliability while accounting for the amount of agreement that could
result by chance.143 Interviews with overall Kappa coefficients approximately ≤ 0.75 (or
excellent agreement)144 were further compared and discussed among the reviewers until
consensus was reached. We then queried the NVivo® database to build a report for each
individual code and reviewed all the content within that code. Codes were refined and
combined to identify key themes. A key theme was defined as a theme that occurred in
the majority of FP interviews. The coding reports were then reviewed a final time and
representative quotes were selected.
Results
Interviews ranged from 27-52 minutes. Overall interview kappa statistics ranged
from 0.75-0.88. A total of 15 physicians completed the interview (NC=7, SC=8).
Physician and practice characteristics
Table 4.1 reports physician characteristics. About half were male. Almost all
were non-Hispanic White and were at least 40 years old. Most were in a group practice.
FPs practicing in 12 different counties in North or South Carolina participated.
About half of the FPs worked in clinics with at least 5 other employees and most
worked full-time. There was a mixture of rural and urban clinics, as well as a mixture of
hospital-based, academic, and community-based single or group practices. All but two
FPs reported accepting Medicare/Medicaid patients and most saw a high proportion of
these patients. The two FPs that did not accept Medicare/Medicaid worked at free clinics
and submitted no claims for billing. A few FPs described having LCS programs in place
at their practices.
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All FPs saw middle age and senior patients and the majority described seeing
patients with a “grab bag” of chronic diseases (e.g., heart disease, chronic obstructive
pulmonary disease, diabetes, hypertension, arthritis, pain). FPs mentioned that in patients
with comorbidities, the focus was compliance with therapies for their chronic disease and
less importance was placed on preventive services and screening. Additionally, a few
FPs described other cancer screenings as taking priority. All FPs described having
patients with either active or remissive lung cancer and the majority reported seeing
many smokers or heavy smokers.
Evidence and guideline knowledge
Table 4.2 includes a list of key themes and supporting quotes from participating
FPs. The majority of FPs interviewed had suboptimal awareness of the scientific evidence
for LDCT screening. Most physicians were aware of some of the evidence in support of
LDCT screening (including the NLST and/or the PLCO studies), but few could recite
specific details. A few were completely unaware of the scientific evidence supporting
LDCT screening in high risk patients. Most physicians were able list at least some the
organizations that supported LDCT screening, but a couple noted that these organizations
have made “mistakes” or have changed their recommendations in the past. A few FPs
reported inaccuracies about gender, stating that reductions in mortality observed from
LCS in the scientific literature were not applicable in women.
Most FPs also had suboptimal awareness of patient eligibility criteria for LDCT
screening. The majority of physicians incorrectly recited at least one of the main criteria
(e.g., age, smoking pack-years, or current/quit smoking status). Only a few physicians
reported not knowing any of the criteria and described looking up the criteria at the point
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of care. A few FPs reported screening patients with symptoms (e.g., cough, weight loss),
even though current recommendations pertain to asymptomatic patients.
Deciding on which patients to discuss lung cancer screening
A patient’s smoking history (e.g., length of time, volume smoked) was cited as the
primary driver of a FP’s decision to counsel patients on LDCT screening. Patient age
also was frequently reported as a driver of whether counseling should be initiated. A few
FPs discussed various other patient exposures (e.g., cotton dust, secondhand smoke, coal
dust, asbestos, silicon dust) that would motivate them to initiate counseling, and a few
described targeting individuals with known lung disease as candidates for screening, even
though these patient groups are not listed in the current criteria defining high risk
patients. A few FPs incorrectly reported that gender should also be considered and that
screening “doesn't apply to women”.
The majority of FPs felt that screening should be limited to those who fit the
criteria for high risk, although there was sometimes uncertainty about the specific criteria.
Some FPs reported not approaching patients with short life expectancies or comorbid
conditions, in alignment with current recommendations. Some FPs also reported
choosing not to engage in counseling about LDCT screening with uninsured patients due
to concerns over the patient’s ability to pay for the LDCT and follow-up diagnostics.
Some FPs also described that it “wasn’t fair” to discuss screening with a patient that
would likely not be able to afford screening. Other FPs felt that counseling about LDCT
should be done with all high risk patients, regardless of insurance status and that
“judgements” about a patient’s ability to pay for screening should not dictate the decision
to initiate counseling.
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Most FPs indicated that they know that they should initiate discussion in high risk
patients only, but are willing to engage in counseling and make LDCT screening referrals
for patients who do not fit the criteria for high risk if the patient requested screening or if
“anything strikes them…that they should undergo screening”, indicating that they felt
other factors would influence their decision to initiate a screening discussion. Henderson
et al reported that physicians were more likely to order screening when a patient
requested it.73 Importantly, when discussing lung cancer screening in lower-risk
patients, FPs frequently described explaining to their patients that they may have out-ofpocket radiology costs and that “they [the patient] will have to see if their insurance
would cover it”. However, FPs reported that they felt most patients were not interested
or “do not want to know [if they have lung cancer]” and rarely initiated screening
discussions themselves. Of the few patients who do ask, FPs described patients to be
former or current smokers, more education or health conscious or to have a family
member recently diagnosed with cancer. A few providers stated that their patients asked
for chest x-ray, not LDCT. Only a few FPs described dissuading lower risk patients from
having screening and steering the conversation more towards smoking cessation.
Lung cancer screening discussion and low-dose CT referral
Most FPs felt that the screening discussion and referral is their responsibility
because FPs knew the patient's values and social issues (e.g., transportation needs).
When asked if pulmonologists could or should discuss lung cancer screening with
patients, FPs felt that pulmonologists were certainly qualified to have these discussions.
However, concern that not all patients would have access to a pulmonologist deters FPs
from the idea of large scale implementation of lung cancer screening programs at
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pulmonology clinics. Additionally, one FP expressed concern that pulmonologists and/or
radiologists may not truly be able to give an unbiased explanation of the pros and cons of
lung cancer screening because they stand to profit from low-dose CTs. While most
physicians felt comfortable conducting shared decision-making (SDM) counseling visits
with their patients, some FPs reported the need for additional education on the risks and
benefits of lung cancer screening to truly implement SDM properly. One FP stated, “I
would be comfortable. I probably need to review the specifics of the risks and benefits of
the procedure first, but yeah, I would be comfortable doing it.” Many described scenarios
where they present screening pros and cons and then let the patient make the decision.
One FP described SDM as an “arm twist” where he explains to the patient that he
“doesn’t have to do this” and states that usually patients will agree to it if you’re
recommending it. Only a couple of FPs reported that they took a more paternalistic
approach. One felt that the decision to engage in SDM or paternalism is really patientdriven. The FP said, “I guess the way I described it sounds more like benign paternalism,
or benevolent paternalism…but umm, I do try to engage my patients in that shared
decision-making, and then the ones who I feel like would be willing to cooperate, I will
bring things out…tell me what your values are, and…I’ll tell you the kind of things I
recommend. I try to bring that stuff out, but it doesn’t really work for everybody. So, I
can’t say that I always take that approach.” No FPs mentioned the use of decision aids as
a tool to conducting SDM.
Most FPs prefer to conduct lung cancer screening discussions during annual or
wellness visits. While this was the preferred setting, some FPs were concerned that the
patients most appropriate for screening were more likely to be seen in the clinic only for
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acute health issues and often missed annual wellness visits. One FP stated, “I can’t really
get them to come to the office dependably once a year…usually [they schedule a visit]
for some acute need and we just wouldn’t get around to that [lung cancer screening].”
Most FPs reported challenges to conducting SDM during acute or sick visits and stated
that they were less likely to have adequate time (if any). Some of these challenges
included addressing other health concerns (i.e. ongoing chronic conditions, such as
hypertension and diabetes, or acute needs, such as flu or infections) or the need to discuss
“higher priority” cancer screenings (e.g. breast, cervical, or colon).
Most providers felt they could adequately conduct shared decision-making for lung
cancer screening in 10 minutes or less during planned annual or wellness visits, however,
some FPs reported the length of the discussion is dependent on the patient's questions and
whether they were on schedule that day. One FP stated that they would consider
initiating SDM “...if I’m not behind…” but quickly added “I’m so frequently not ahead”.
Scheduling the patient for a separate visit was an option discussed by FPs when time is
limited, but FPs stated multiple reasons as to why they would prefer not to make a
follow-up appointment solely for lung cancer screening purposes. These included
additional cost of patient co-pays and patient compliance. One FP simply said that “it’s
hard for me to make appointments for just that [lung cancer screening]” and explained
that the patient was unlikely to show up.
FPs reported that education on smoking cessation is a key component to counseling
patients on LDCT screening. Some FPs also described conversations where they
presented the patients with details on the risks and benefits of screening. Several FPs
specifically mentioned telling their patients that a risk of screening is increased radiation
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exposure. Less emphasis was placed on educating patients on the need to complete
screening annually, with only a few FPs mentioning this topic.
Overall, FPs agreed that counseling for LDCT screening was feasible in their clinic,
but that adjustments and processes to do this type of visit had either already been
implemented or needed to establish. Many FPs reported making at least one referral for
LDCT screening, however, a couple FPs confused screening with diagnostic testing and
upon additional questioning, it was determined that they really made a diagnostic CT
referral for a symptomatic patient. Only one physician reported making no LDCT
referrals. Most FPs reported no major challenges making the referral, even in clinics
without organized lung cancer screening programs. A few FPs described having minor
challenges (e.g., radiologists had a question or there was pushback from the billing
processor) before a lung cancer screening program was implemented in their practice.
Low-dose CT follow-up
The majority of FPs described feeling responsible for informing their patients of
their LDCT screening results, however, some agreed that pulmonologists or radiologists
could conduct SDM adequately. One FP had an opposing view and described one way to
administer a lung cancer screening program would be through radiology clinics. She
went on to describe how she could refer the patient to that department where, in the same
day, the radiologist they could handle the SDM discussion, perform the LDCT scan, and
give feedback on the results. She also suggested that the radiology clinic be responsible
for following up with the patient if additional scans or procedures are needed. She
basically felt that her role was to identify patients appropriate for screening.
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Most FPs did not report any challenges in getting the result from LDCT scans.
Many reported the scan being immediately available in their electronic medical record
(EMR). Many FPs reported using phone calls to give good news or reports of “negative”
scans and asking patients to come back to clinic to receive bad news about a “suspicious”
finding. There were varying approaches to the management of suspicious findings. One
FP reported making an immediate referral to a general oncologist and some FPs reported
that their local oncologists would not see the patient until after an official diagnosis was
made by tissue biopsy or bronchoscopy. One FP admitted not knowing what she was
supposed to do regarding further follow-up and replied “I think I may have to beg
ignorance. I’m not exactly sure what kind of result I’d get. Do I get something like a
mammogram, where I’d see something suspicious on their CT and they’d need a biopsy
next? I don’t know enough about what the next step would be. If that would be a referral
to a general surgeon or cardiothoracic, biopsy, bronchoscopy, I don’t know.”
Pulmonary nodule clinics could play a role in lung cancer screening, but FPs had
varying levels of knowledge as to whether pulmonary clinics existed in their geographic
area. Only a couple FPs reported with certainty that they had a pulmonary nodule clinic
in their area dedicated to evaluating suspicious lung nodules. A couple of FPs described
patients having to travel too far to receive that type of specialty care or not having access
to specialty care at all.
Barrier and facilitators to implementing lung cancer screening in the clinic
Not surprisingly, a majority of FPs reported cost (e.g., patient visit co-pay or
radiology fee) as a barrier to LDCT screening, even for insured patients. Most FPs
reported that the cost was either unknown or was too high. Specifically, one FP said “So,

82

we don’t know the prices, we don’t know the costs, and many, many, many folks ask
questions about what this is going to cost.” For most FPs, there were no LDCT financial
assistance programs in their area for asymptomatic patients, although some financial
assistance programs were available for symptomatic patients to get diagnostic scans.
While most FPs reported getting LDCTs paid for as a barrier, most FPs described no
issues with getting a patient treated if a lung cancer was diagnosed. In fact, one FP stated
“yeah, it’s a done deal after the diagnosis is made, that’s not even a problem.”
Emergency Medicaid and indigent care programs were reported as approaches for getting
lung cancer treated in uninsured patients. One FP described “fabricating symptoms” to
move a patient into the “diagnostic” category so that the scan would be covered or using
different, more historical approaches, such as calcium scoring exams to get an image of
the lungs. This particular FP thought ordering calcium score exams were a “2-for-1”
approach to disease detection. He stated that this exam captured information most of the
lungs (85%) as well as the heart. Using this approach, he felt, provided information on
detecting both lung cancer and coronary artery disease, two diseases in which smoking is
a risk factor.
Some FPs mentioned administrative barriers to LDCT screening that included
lack of support staff to assist with preparation or execution of SDM counseling visit (e.g.,
nurses, other ancillary staff) and no established practice quality metrics requiring lung
cancer screening to be performed (as is the case with other cancer screenings). A
majority of FPs had suboptimal knowledge on the complex documentation and billing
procedures for LDCT screening. Many either did not know that they could submit claims
for a lung cancer screening counseling visit or did not understand all the documentation
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requirements for a Medicare claim to be processed (e.g., LDCT written order with
documentation of age and smoking history, evidence of SDM visit with use of a decision
aid, and smoking cession counseling).
All FPs reported some type of time constraint as a barrier to lung cancer
screening discussions. Some FPs reported time constraints that resulted from overbooked
schedules and reported often “running behind” and others discussed time barriers in
reference to competing health issues being prioritized over lung cancer screening during
already short office visits. Of the entire group of FPs interviewed, only one FP felt so
strongly about lung cancer screening that she reported “always” making time for it,
despite her overloaded schedule and time constraints.
FPs had some ideas that would facilitate lung cancer screening discussions with
their patients. Patient education (e.g., take-home materials, print and video media
campaigns) and systematic approaches to identifying guideline appropriate patients in the
clinic were suggested. EMR pop-up reminders, paper chart notifications, and patient
completed screening tools (used in the waiting room) addressing multiple screening
topics were systematic approaches described by FPs as facilitators. “…one of the
answers would be a good EMR. What do they call them, kiosks? You know or patient
check in module things? Well, yeah, it’s interactive too…and keep going down menus
based on their answers. Just like a human interview would do. So that will be helpful.”
Few providers mentioned patient financial assistance programs as potential facilitators.
Discussion
This qualitative assessment aimed to provide an in-depth look at family physician
knowledge and perceptions towards LCS, as well as their experiences implementing (or
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not implementing) screening in their practice. In comparison to other recently published
qualitative studies on this topic,14,15,78 we did not provide any structured education on
lung cancer screening prior to our interviews, allowing us to gain insight into what
practicing FPs may know and practice without any direct influence. While the FPs we
interviewed described many challenges, the majority felt that LCS was feasible in their
clinics, with some additional education, planning, and assistance.
FPs had suboptimal knowledge of the scientific evidence and patient eligibility
criteria for LDCT screening, but welcomed education on these topics. Uncertainty about
who is eligible for screening and the scientific evidence that underlies screening
guidelines has been reported across both quantitative and qualitative research studies,
rural and urban geographic areas, physicians and advanced care providers, and
community-based, Veteran, and academic-based practices.14,15,73,75,78,80,82,83 Raz et al
reported that less than half (47%) of primary care physicians surveyed in Los Angeles
county were aware of the USPSTF recommendations for lung cancer screening and many
could not identify when LDCT was recommended and not recommended. Another
survey study, conducted by Duong et al found that only 31% of PCP providers answered
age and smoking criteria correctly.83 Simmons et al conducted telephone focus groups
with physicians, nurse practitioners, and physician assistant and reported that the majority
of the providers had limited knowledge on LCS.14 Despite limitations in knowledge,
providers across studies were open to receiving additional education about lung cancer
screening and incorporating it into their practice,14,83 similar to the providers in our study.
The FPs interviewed in this study also were uncertain about the requirements for
documenting and submitting claims for reimbursement, an education gap not previously
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highlighted. Interestingly, despite the CMS requirement that a shared decision-making
counseling visit incorporated the use of a decision aid, not one FP we interviewed
described using a decision aid in their LCS discussions. This lack of emphasis on the
importance of using a decision aid is in contrast to a recent electronic survey study by
Triplette et al where 51% of PCP and pulmonary providers reported decision aids as an
important facilitator to LCS discussions.82 When asked about billing for lung cancer in
general, many physicians reported not being aware that they could bill for SDM
counseling visits and/or LDCT.
We found that smoking history, one of the criteria for defining high risk patients,
was the primary driver of a FP’s decision to initiation LCS. Smoking history and
secondhand smoke exposure were also reported as drivers of the decision to initiate lung
cancer screening discussions by Henderson et al in 2011.73 However, we also found that
FPs were willing to screen patients outside the established criteria for a high risk patient
if the patient was requesting screening or if the FP was motivated by factors not
addressed in the recommendations, such as family history, secondhand smoke exposure,
or occupational exposures. Henderson (2011) described confliction over ordering LDCT
in lower risk patients as something they coined the “physician struggle”, meaning that
FPs may make decisions about screening that are contrary to their beliefs about screening
as they contemplate other factors, such as patient requests or presence of other risk
factors. Propensity to screen patients outside of guidelines (over screening) has been
reported previously,73 is a concern across cancer screening programs, and results in
increased financial burden at the population level. Other qualitative studies reported
provider concerns over litigation resulting from failure to suggest screening prior to a
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lung cancer being diagnosed;73,78 however, this concern was not described in any of our
FP interviews.
Some of the FPs in our study also reported using other approaches to get some
form of screening for patients, such as use of other scanning modalities, or ordering
diagnostic tests for truly asymptomatic patients. Prior research has documented
continued use of CXR or other less preferred computed tomography scans,14,15,73,78,81,82
however, the use of CXR was not commonly reported amongst our FPs. Hoffman et al
reported in 2015 that no primary care providers had ordered a LDCT78 and other studies
have reported subpar rates of LDCT utilization.74,75 More recently, Duong et al reported
that 58% of providers surveyed reported ordering LDCT83 and in our qualitative
assessment, most FPs reported making at least one LDCT referral, perhaps suggesting a
shift away from the use of CXR.
Several studies on LCS report financial concerns as a barrier to lung cancer
screening.14,75,78,80,81 Some FPs in our study also exhibited concern over discussing
screening in underserved or uninsured patients, while some FPs felt that this was not a
concern. This contradictory viewpoint appeared to be related to the availability of free or
affordable screening for uninsured/underserved patients in their geographic area. FPs
also expressed concern over difficulty discussing the patient’s portion of the cost of
screening, regardless of insurance coverage or type. With the variety of insurance plans
available, FPs felt they could not provide accurate estimates of what the patient out-ofpocket cost for screening would be and must “speculate”. A tool that could help
providers determine the cost of a patient’s copay would be useful and would promote
more discussion. Another possible approach to addressing this barrier could be a phone
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“hotline” for FPs to call for assistance. In addition to concerns about speculating on the
cost of LDCT screening, FPs also had concerns about patient’s out-of-pocket costs for
follow-up diagnostics (e.g., biopsies, bronchoscopies).
Both quantitative and qualitative studies have reported that providers expressed
the need for guidance (e.g., medical education)78,83 and assistance advising patients about
screening and follow-up care (e.g., point-of-care materials, additional staffing,
multidisciplinary input).15,78,82 A qualitative study by Kanodra et al described a LCS
program administered in the Veteran’s Administration (VA) in South Carolina, where
primary care providers were notified of LCS eligibility via electronic medical record
(EMR) notification and could then refer their patient to a nurse navigator who engaged in
SDM with the patients.15 VA providers viewed this LCS program structure as effective
and efficient. While the FPs in our study largely felt comfortable conducting SDM
counseling visits for LCS on their own, many reported time as a barrier and nurse
navigator programs could potentially be an approach to handling time constraints. FPs
had several other suggestions to facilitate LCS in their practices. EMR notifications were
suggested by many FPs in this study as the best way to systematically identify patients,
similar to other studies,14,15 however they noted that the EMR must include a way to
capture detailed information, including volume of cigarettes and length of time smoked
(pack year history) and type of exposure (e.g., personal or second-hand), information that
is less likely to be captured in existing EMR systems.
Several limitations should be considered when interpreting the results of this
study. Our interview focused mainly on evidence and guideline knowledge, making
decisions about who to approach for screening, and the LCS discussions. While we did
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incorporate a broad range of topics, less emphasis was placed on documentation and
billing for shared decision-making visits and LDCT follow-up. For example, we did not
specifically ask about what FPs did when a patient had a borderline nodule and only one
FP described his approach (referral to pulmonary for long term follow-up). Also, in our
study, many FPs reported not knowing that they could bill for SDM counseling visits,
limiting the questions we could ask about their billing processes. Lastly, our study
interviewed only family physicians, leaving out an important population of individuals
(e.g. nurses, advanced care practioners) that can participate in SDM visits and LDCT
referrals in the primary care setting. These limitations highlight areas for further
research. We had a diverse group of FPs from different geographic areas and practice
settings and reached thematic saturation across our interviews, despite our smaller sample
size.
Conclusions
Even though LCS with LDCT is a recommended cancer screening that is now
covered by most private insurers and Medicare, FPs still have varying degrees of
knowledge and experiences with LCS counseling visits, and while LDCT referral seem to
be increasing, LDCT remains underutilized. This study suggests that FPs are open to
using LDCT as an early diagnosis tool and consider SDM feasible in their clinics. If
given appropriate education and tools, they would be more likely to utilize low-dose
computed tomography for lung cancer screening.
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Tables and Figures
Table 4.1. Descriptive characteristics of family physician participants by
recruitment cohort
SC AFP CHS
AMA
Referral Total
Gender
Female
3
1
3
0
7
Male
5
1
1
1
8
Race / ethnicity
Non-Hispanic White 7
2
4
1
14
Non-Hispanic Black 1
0
0
0
1
Age range
20-29
1
0
0
0
1
30-39
1
0
0
0
1
40-49
2
2
3
0
7
50-59
1
0
0
1
2
60-69
3
1
0
0
4
State
NC
0
2
4
1
7
SC
8
0
0
0
8
Practice Setting
Group practice
3
2
4
1
10
Private practice
1
0
0
0
1
Hospital
1
0
0
0
1
Academic
2
0
0
0
2
Other
1
0
0
0
1
Specialty
Family medicine
8
1
4
1
14
Internal medicine
0
1
0
0
1
Abbreviations: AMA, American Medical Association; CHS, Carolinas HealthCare
System; NC, North Carolina; SC, South Carolina; SC AFP, South Carolina Academy of
Family Physicians
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Table 4.2. Key themes and supporting quotes
Topic

Key Theme(s)

Evidence and
guideline
knowledge

Suboptimal
awareness of
scientific evidence
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Making the
decision to
discuss LCS

Supporting Quote

“I’m aware that there is research and that it is
favorable, but I don’t know the details, and it's
because I haven't really been able to apply it very
well at my current practice.”
Suboptimal
"Umm, as far as who to screen, that’s what I’m not
awareness of patient
as confident about. I know that older people and
eligibility criteria
people who have a long smoking history, umm,
would be certainly would be greater candidates
than younger people or people who didn’t smoke,
but I don’t know exactly what the age is or how
much, how many cigarettes or any of that. That’s
the part that I would have to look it up."
Smoking history is
“Yeah, when they come in to the clinic, they fill out
the primary driver of a, uh, intake form that that describes smoking
FP decision to initiate history and so based on that form, we'd, you can
lung cancer screening sometimes, you can make the decision at that point
counseling visit
if they need to have screening..."
FPs are less to likely
to discuss lung cancer
screening in patients
with short life
expectancies and/or
comorbid conditions

"Well, [I wouldn't bring up screening in] people
that are sick from other things, perhaps. Um, you
know that you don't anticipate them getting benefits
based on how ill they already are."

Supporting Quote
“I don’t know about the scientific
evidence behind it.”

"I’ll have to be honest, as far as
the specific patients or past
history or patient age, I don’t. I
am aware that CT exists as an
option but as far as
recommendations as to who
should have that, I don’t really
know. "
"So I, yeah so all, all my smokers
get a talking to..."

"...unlikely to survive long enough
to benefit from, uh, having lung
cancer diagnosed and an
intervention."

"Hmmm, that's a tough situation. Uh…I don’t even
know that I would even bring it up for fear that it's
going to be unaffordable. They're going to feel like
they don't get wat everybody else gets because they
don't have insurance. I don't think I would probably
mention it."

PCPs are aware that
they should focus
lung cancer screening
discussions to high
risk patient

"…wouldn’t recommend anything outside the
guidelines."
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FPs are less to likely
to discuss lung cancer
screening in
uninsured patients

"I don't think we have any
programs in this community that
pays for that. We have free
mammograms but we don’t' have
any free stuff like that, so I'm not
sure if I would mention it. It
almost seems kind of cruel to
mention it and know that they have
no means to get it, but saying
maybe when you're able or you
know if your insurance goes
through then and most people will
get Medicare when they are 65, so
if they're still appropriate then,
then they can revisit it. So, I may
or may not discuss it, sorry."
"…you have to be the right age, 30
pack year history, not be a 15-year
non-smoker, and willing to follow
through with, if they have positive
screenings, willing to follow
through and willing to sustain and
survive surgical recommendations
if they have them. It's a very
narrow population."

Patient
driven LCS
requests
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Patients rarely initiate "I think that there’s, they know lung cancer is
lung cancer screening always there in the background, and umm they
discussions
don’t ask for screens because they don’t want to
know. That, that’s kind of my feeling based on my
patients. You know they’re not, they’re not asking,
and even the ones that are savvy and have heard of
it, uh they’re not. Mentally, they don’t want to
know. I mean, they know every time they smoke,
you know."

"It’s rare, to be honest, but most of
the ones that ask are usually
moderate risk smokers tell me
someone in their family was just
diagnosed with lung cancer."

Physicians are willing
to refer out of
guideline patients for
screening if a patient
requests screening

"I would approach that with
education. I would let them know
that testing that they read about in
Newsweek is only known to be
helpful in these folks. For
whatever reason, they don’t fall
into that category and we don’t
know if this test would be helpful
for you and it may be
harmful…because what they’re
requesting is help. I’ve had some
folks who insist on a screening test
even though I don’t recommend it.
I handle that like I would with any
informed consent. I tend to lean on
the side of getting the test for them
and informed consent that the risk
benefits may be more towards the
risk and we are obligated to follow
up with results and eyes wide open
going in."

"So I mean if someone [who was not at high risk for
lung cancer] asked me for something specific I try
to either explain why I think it’s a good idea, or if I,
or not a good idea and if they don’t, if they still
don’t agree with me and they still want that thing,
then we explore, you know, what the outcomes
might be. You know, uh for instance, if you get a
screening and you find something you weren’t
expecting maybe it wasn’t along these lines and
then they need to be worked up further, you know
we talk about risk and benefits. But, if people,
people really want the screening and they are
willing to pay for it even if their insurance doesn’t,
I certainly would be fine with ordering it."

LCS
discussion
and LDCT
referral

"I mean, I see it like I do any other kind of
screening. I think it’s my responsibility. Umm, we
screen for colorectal cancer and cervical cancer
and breast cancer, so why should we not also be
screening for lung cancer?"

Annual/wellness
visits are the best
time to conduct lung
cancer screening
discussions

"If it’s an annual checkup, I feel obligated to make
sure they are caught up on all of their screenings
because they are coming in for that specific
purpose, the way I look at it. If they are coming in
for chronic disease management or an acute visit,
then I still feel the responsibility to make sure that
we have done the appropriate screening processing
with them and if time allows we will try and do it,
but if not we make sure before they leave they have
a follow up appointment with me to get that done."

Shared decisionmaking discussions
can be completed in
10 minutes or less

"Well, it depends on how many questions the
patient has. I if, if they just say, “well, ok sure,”
then, I mean I think it could be a five-minute
discussion, and, and they would know enough and
we’d be done."
"Yes, [I am comfortable with it]. I do it [shared
decision-making] all the time. I tell the patients the
risks and benefits of lung cancer screening, and it’s
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Providers feel that the
screening discussion
and referral is their
responsibility

Providers are
comfortable with
shared decision-

"Yeah, I think we need to do it
because we are the front line and
most folks see us first and they
have that great relationship and
trust with us so I think we need to
be doing it absolutely."
“Certainly, screening tests are a
huge part of discussion when you
have someone in for that wellness
visit, annual checkup, when we are
already going through
mammograms, bone density
testing, colonoscopy, other
immunizations, adult
immunizations up to date. Um to
add in, ‘this is your history, you’re
at risk of lung cancer maybe we
should consider this CT test’, I
think it would feel natural. I would
be willing, I guess that is my
answer, willing to add that to the
discussion.”
“Let’s be honest, that’s a good 510 minutes to really do what we’re
supposed to be doing."

"I mean I would say that I’m
moderately at least moderately
comfortable with that. I mean, I’m

making approach to
lung cancer screening
discussions
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Education on
smoking cessation is
a key component to
lung cancer shared
decision-making
discussions
Majority of primary
care providers have
made at least one
referral for low-dose
computed
tomography
Challenges making
referrals has resolved
with time

their decision, not mine.”

accustomed to, umm like, the
concept of ‘shared decisionmaking,’ and when I have
sufficient time and when I feel like
my patients are willing to engage
me on it, then I do that already,
and I have discussed umm you
know the guidelines as far as
what’s recommended for lung
cancer screenings."
"Nowadays our conversations typically go like,
"It’s supposed to be done in
‘you’re not on any inhalers, your lungs sound
conjunction with the smoking
clear, I would certainly encourage you to quit while cessation counseling as well."
you’re ahead before any damage has been done to
your lungs’."
"I am doing it. I do make those recommendations.
Again, at the time of the office visit, with time being
limited, do I do it as often as I should be? The
answer is no but do I do it, yes... I’m not sure what
it was, but something made me change my practice
to where I do recommend more lung cancer
screenings now than I did a year ago."
"I didn’t start making the referrals until I knew that
there was a program in place. The place that I’ve
been referring them to get the low-dose CT is not
the usual place I refer for other radiologist studies.
So, it’s kind of a special scenario. So, I guess some
difficulty because it wasn't a facility I usually use.
But almost everybody I attempted to schedule, the
test has been performed."

"Yes, I have, but it’s umm I mean I
could count the number of people
who allow me to refer them on
one, maybe two hands."

" I would say that prior to three or
four months ago, yes it was very
difficult because we had to order
the CT scans ourselves and there
was no option available for lowdose CT for the purpose of lung
cancer screening. Prior to the
comprehensive cancer center

stepping in February or March it
was really difficult to get the
referral in Epic. Now it is much
easier, we just type referral for a
lung cancer screening and it will
pop up and it is pretty nice."
LDCT
follow-up

FPs believe it is their
responsibility to
inform patients of
low-dose computed
tomography results
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No challenges
obtaining scan results

Pulmonary nodule
clinics could play a
role in lung cancer
screening discussions

"Well…it, uh, us…me the primary doctor. That, we " I like to be more hands on with
do that, the positive screening and then we talked to our patients and the local gals
them about making a formal diagnosis."
who do the mammogram know
that. I’m always going to beat
them to the punch before they call
them back. There’s your answer, I
would rather be the one to tell,
you know share that with the
patient. Walk them through it and
make the plan."
"No [problems], the, the reports are readily
"Mhmm, yeah [scans are in EMR]
available on the computer."
and a lot of times they’ll
[radiologists] call if something
shows up."-Sum
"We work pretty closely with the pulmonology
“Um, usually if nodules that are
clinic for our COPD patients and asthma patients
kinda iffy, I refer to pulmonology
and then they usually follow them
and that kind of thing and I’m not aware of them
for a couple of years and if they
ever recommending screening for high risk
patients. So now that we talked about it I’m curious are stable, they just hand them
to know if they ever recommend it, and how we
back to me.”
could complement each other in that way...I, I
absolutely would consider that, um, but it would
only cover a small part of the patients that would

potentially be eligible I would think."

Barriers and Patients have
facilitators to financial concerns
implementing
LCS in the
clinic
97
Lack of support staff
and practice or
quality metrics are a
challenge

"Specifically, you know, how well
is this covered and what’s the outof-pocket costs associated with
having the screening completed.
Folks have, nowadays they can opt
maybe to have higher co-pay or
deductible insurances and
sometimes the benefit is available
but there are still associated costs
out of pocket. So, we don’t know
the prices, we don’t know the costs
and many, many, many folks ask
questions about what this is going
to cost."
"I mean, we have these elaborate electronic
“I just don’t know how something
medical records but it still proves to be a challenge like this [is doable], without
to keep track of all the little, um, quality
having some kind of protocolized
parameters and I'm not aware of lung cancer
system where there is some other
screening being a quality parameter in our system." ancillary health person who can
really do the documentation that
Medicare requires.”
"We have a strict policy of $80 copay [for
counseling visits] just to see me if you don't have
insurance and then I can talk about them [the
recommendations for screening]. I can make
recommendations and I can even give referrals but
often times those referrals will get denied or not
even scheduled because their insurance data,
especially if their clean [asymptomatic]. Now if
you are symptomatic, I am able to make a couple of
phone calls and get the copay waived but general
screening, that is a very difficult thing to do."

“You know, for a long time, we were still waiting
on those codes, so even if we did it, how would we
even get it done, and again a heavily weighted
Medicare practice."

Busy schedule often
leads to "running
behind"

“I feel l maybe 25% of the time, if someone is
coming in, feasibly I could do it, umm, because I
mean the issue with that, if I get really far behind
because I’ve had that conversation with one
person, then I won’t be able to have it with the next
one.”
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Suboptimal
knowledge regarding
complex
documentation and
billing procedures

"Uh, my colleagues who are trying
to see two or three times as many
patients as I do in a day, um, are
just not going uh to generate the,
the volume of documentation
sufficient to satisfy these kinds of,
uh, of audits and wind up, uh,
frustrated with the amount of time
that’s, uh, generated in the audit,
and the negative impression that
their patients get if they realize
that their doctor/patient visit was
not covered and they’re, uh, being,
uh, charged that they [their
doctor] didn’t document this
discussion and so forth...just a few
of those kinds of, uh, frustrations
dissuade a lot of physicians from
doing the right thing."
"…if I’m not behind and umm the
patient has fits the criteria and I
haven’t spoken with it before, then
it certainly would be a chance to
grab them. Umm, I would I’m so
frequently not ahead that I don’t
frequently, don't want, to add
those things to visits that uh umm
are not, not screening type visits."

Patients have other
competing health
issues that are
prioritized over lung
cancer

99

Patient education
materials facilitate
lung cancer screening
discussions

"I tend to prioritize, I do try and do it, but lung
cancer screening really hasn’t gotten to the top of
my radar quite yet, whereas breast cancer, cervical
cancer, colon cancer screening are kind of already
part of my problem visits, meaning that I’ll check
and see if they are up to date and if they are not,
then I will usually mention those.”

"Make it streamlined for the very,
very busy primary care providers
in and you know under-resourced
Medicare-heavy population
because I’m very, even though I
know who I should be talking to,
I’m very challenged. Once I’m in a
room with a patient and I’ve
handled you know the five
healthcare maintenance and the
diabetes follow-up things and
whatever, and then they hit me
with three things they need you to
do, I honestly don’t have time to
talk about it."
"I think also something that would help us would be "I get in the situation where I say
just more patient education. You know I’ve had so
you know this is what I
many people ask about, like, shingles vaccine when recommend, but think about it for
they see the commercial and you know it's like oh
a minute, talk to your family about
yeah, that's a great idea you know, um, so but just
it. Let me know if you change your
public information helps them to help us
mind. I may ask you next time but I
remember...yeah I mean people watch TV, that's
won’t fuss at ya. That kind of
how a lot of stuff, messages and things like that,
patient...it might be kind of helpful
maybe some flyers or something in the office would to have a little bit of a brochure. I
be helpful, but yeah people, really notice the
might just hand ya a little
commercials."
brochure or pamphlet to say
here’s a little bit more
information, look at it and we’ll
talk next time."

Systematic
approaches to patient
identification
facilitate lung cancer
screening

"This is a good place where electronic records and
electronic checking systems could be helpful. We’ve
played with some of those but never really found
one that played well with our EMR. Those little
kiosks that check-in and ask the basic screening
questions and if they’re positive they keep going
down to the menu so they can do a full screening.
They can do all the screening tests. What’s your
age range, pack year history? All of that. So... one
of the answers would be a good EMR...patient
check in module things...so that will be helpful."

"Um, actually kinda like a lot of
the other triggers we’ve built in
for other stuff now, just sorta build
the guidelines in so it’s easier to
identify the patients um and that's
probably the biggest thing, is just
identifying the people that qualify
and then just making a check, so
saying has it been done or not,
what interval and we decide to
follow up from there."

Abbreviations: CT, computed tomography; LCS, lung cancer screening; LDCT, low-dose computed tomography
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CHAPTER V:
FACTORS PREDICTING MOLECULAR TESTING AND ITS
IMPACT ON SURVIVAL IN PATIENTS WITH ADVANCED, NONSMALL CELL LUNG CANCER: A RETROSPECTIVE,
POPULATION-BASED ANALYSIS USING ADMINISTRATIVE
CLAIMS2

Ersek JL, Symanowski JS, Kim ES, Adams SA, Hébert JR, Eberth JM. Submitted to
Journal of Thoracic Oncology, 11/17/17.
2

101

Abstract
Introduction: Lung cancer is the leading cause of cancer-related death in South Carolina
(SC). Tumor molecular testing (MT) advances led to the development of precision
medicine treatments, improving outcomes. However, disparities in MT utilization may
exist. We evaluated factors related to MT utilization and the impact of MT on overall
survival (OS).
Methods: Cases diagnosed with stage IIIB/IV non-small cell lung cancer (NSCLC)
between January 1, 2002 and December 31, 2012 and available through the SC Central
Cancer Registry were linked to SC State Employee Health Plan and Medicaid
administrative claims data. Logistic regression (LR) was used to identify predictors of
MT utilization. Kaplan-Meier methods were used to estimate survival distributions and
log-rank tests compared the survival distributions between MT and no MT groups. Cox
proportional hazards modeling was used to assess the impact of patient demographic and
clinical characteristics (including MT) on survival, while adjusting for other prognostic
covariates. Propensity scores were calculated and included as covariate in propensityscore adjusted Cox models.
Results: A total of 2,266 cases were eligible. In the multivariable LR model, predictors
of having at least one procedure claim for MT included younger age (p=.008), in-state
providers (p=.003), low tumor grade (p=.008), adenocarcinoma histology (p=.015), and
diagnosis year of 2010 or later (p<.001). OS was longer in patients who received MT
(median OS=13.0 vs. 6.0 months, p<.001). When adjusting for significant prognostic
factors, patients with MT had a 43% lower risk of death compared to patients without MT
(HR=0.57, 95% CI: 0.40-0.81, p=.002).
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Conclusions: Several characteristics are associated with MT utilization. In patients with
advanced NSCLC, MT may positively impact OS in the population-based setting.
Introduction
Lung cancer is the leading cause of cancer-related death in the United States and
in South Carolina.1,145 In 2017, approximately 4,320 new lung cancer cases and 2,920
lung cancer deaths are expected in South Carolina (SC) alone.1 Over half of patients with
lung cancer are diagnosed with advanced disease, contributing to the dismal 5-year
survival rate of approximately 4%.1 Historically, patients with advanced lung cancer
have been treated with one of several platinum-based doublet chemotherapy regimens
(e.g., cisplatin + paclitaxel or gemcitabine or docetaxel)or pemetrexed, none of which
provided much hope for long-term response and improved survival.4,146 Precision
medicine, including targeted and immunotherapy drugs, may offer improvements in
outcomes.
Within the last decade, advances in the genomic profiling of lung tumors have
identified multiple alterations in lung tumor cells, especially non-small cell lung cancer
(NSCLC), that can be targets for treatment. Various laboratory procedures are used to
identify alterations in tumors including immunohistochemistry (IHC) to evaluate protein
expression, in situ hybridization (ISH) to evaluate abnormalities in a specific region of
nucleic acid on a chromosome, polymerase chain reaction to identify gene mutations, and
sequencing to evaluate alterations in deoxyribonucleic acid (DNA) and ribonucleic acid
(RNA).147,148 For example, epidermal growth factor receptor (EGFR) is a cell surface
receptor that can be evaluated using different laboratory approaches. EGFR is altered
either by protein overexpression, increased gene copy number or genetic mutation.
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EGFR is involved with cell proliferation, suppression of apoptosis, cell motility, invasion
and angiogenesis.20,25 Other targetable alterations found in lung tumors include ALK,
ROS1, BRAF, and MET.26,27
Genomic, or molecular testing, has led to progress in treating advanced, NSCLCs
and has allowed oncologists to use targeted approaches to treating selected patients,
sparing many the systemic effects of cytotoxic therapies. However, little is known about
the factors influencing molecular testing utilization in population-based settings. The
purpose of this study was two-fold. We determined factors associated with molecular
testing utilization among patients with advanced stage, NSCLC residing in SC. We also
assessed the impact of molecular testing on overall survival.
Methods
Study Design, Data Source, and Cohort Selection
We conducted a retrospective cohort study using data from the South Carolina
Central Cancer Registry (SCCCR) linked to administrative claims data obtained from the
South Carolina Revenue and Fiscal Affairs (RFA) office. Eligible patients were those
diagnosed with first primary stage IIIB/IV lung cancer between January 1, 2002 and
December 31, 2012 who enrolled in the SC State Employee Health Plan (SCSEHP) or SC
Medicaid during the study period. Patients with secondary malignancies and those
insured concurrently by an HMO plan or who had Medicare as the primary payer were
excluded.
Outcomes
Two outcomes were examined among patients in this study: 1) use of any
molecular test, and 2) overall survival time in months. Prior to 2013, molecular tests were
104

coded using a billing method called “code stacking”.147,149 This method utilized a
combination of Common Procedure Terminology (CPT) codes, consisting of laboratory
procedure codes and reporting codes, to bill for molecular tests. Thus, different facilities
could code for the same test in multiple combinations of stacked codes. In this study,
patients with at least one procedure claim submitted with a CPT code indicative of
molecular testing, codes 83890-83914, were categorized as having any molecular test
(“yes”) and patients without any claims utilizing codes were categorized as not having
any molecular test (“no”).
Overall survival was measured from date of first primary cancer diagnosis to date
of death from any cause. Surviving patients were censored at the date of last SCCCR
follow-up or December 31, 2014.
Covariates
Patient demographics
Age at diagnosis was evaluated as both continuous and categorical variables (<52,
52-57, 58-62, 63+ years). Race was categorized as White, Black, Other and Hispanic
ethnicity as Hispanic, non-Hispanic, or unknown. Marital status was categorized as
married, not married, or unknown. Insurance status was categorized as SCSEHP or
Medicaid. Of note, all patients in this study had some form of insurance coverage, but
did not have Medicare. Patient metropolitan status was derived using rural-urban
continuum codes assigned to each patient’s county of residence at diagnosis and were
ultimately dichotomized as non-metropolitan (including rural) versus metropolitan
counties.
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Patient disease
Histology was categorized using ICD-0-3 codes: adenocarcinoma (8140, 8250, 8252,
8253, 8255, 8260, 8480, 8481), large cell (8012), squamous (8070, 8071), and mixed or
other NSCLC (8000, 8010, 8046, 8560). Stage was limited to advanced stage and was
categorized according to American Joint Committee on Cancer (AJCC) staging criteria
(IIIB or IV). Grade was categorized as low (grade I or II), high (grade III or IV) or
unknown. Primary site was defined as main bronchus (including carina, hilum, bronchus
intermedius; C340), lobe (including upper lobe, lingual, apex, and pancoast tumors,
C341; middle lobe, C342; lower lobe and base, C343), overlapping lesion of lung (C348),
and lung or bronchus, not otherwise specified (NOS; C349). We choose to dichotomize
year of diagnosis (prior to 2010 or 2010 and later) and selected a cutoff year prior to the
drafting and publication of clinical opinion papers and clinical practice guidelines for
molecular testing,103-105,108,150 assuming some physicians were ordering molecular testing
prior to 2010 for research and drug authorization purposes.
Provider characteristics
For each procedure claim, the submitting provider’s county of service was
documented. Each individual claim was categorized as “in-state” or “out-of-state”.
Claims billed by providers in SC counties were classified as “in-state” and those
submitted by providers not in a SC county were classified as “out-of-state”. A patient
with at least one claim submitted by an out-of-state provider was classified as out-ofstate.
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Statistical Analysis
Descriptive statistics for patient and provider characteristics were summarized for
the overall cohort and by molecular testing status. Comparisons between molecular
testing groups were performed using chi-square tests for categorical variables and a twosample t-test for age.
Univariate and multivariable logistic regression was used to evaluate the impact
of patient and provider characteristics on receipt of molecular testing. Factors included in
the final model were identified using backwards elimination followed by forward
selection modeling procedures (p<.05). Unadjusted and adjusted odds ratios (OR) and
corresponding 95% confidence intervals (CI) were estimated.
Kaplan–Meier techniques were used to estimate survival distributions and logrank tests compared the survival distributions between the molecular testing groups.
Univariable Cox proportional hazards regression was used to identify individual
prognostic factors predictive of overall survival and multivariable Cox proportional
hazards regression was used to evaluate the independent impact of the covariates and
molecular testing status on overall survival. Unadjusted and adjusted hazard ratios (HR)
and corresponding 95% CIs were estimated.
To reduce potential biases associated with molecular testing on survival, Cox
proportional hazards models were estimated using propensity scores. Individual
propensity scores were calculated using logistic regression using two separate approaches
(non-parsimonious model and parsimonious model). The non-parsimonious model
consisted of a logistic regression model using all available covariates, while the
parsimonious model contained only variables we found to be significant in our final

107

multivariable logistic regression model. Next, individual patient propensity scores were
calculated based on predicted probabilities from the logistic regression models. Patients
who had molecular testing were weighted by the inverse of the probability for getting
molecular tested, while patients who did not have molecular testing were weighted by the
inverse of the probability for not getting molecular tested. The propensity scores were
then used as a covariate to estimate the adjusted effect of molecular testing on survival in
the Cox proportional hazards regression models. We then compared the propensity
score-adjusted Cox proportional hazards regression models to the model based on
independent patient and provider prognostic factors.
All p-values were from two-sided tests and p-values <.05 were considered
statistically significant. All analyses were performed with SAS® version 9.4 (SAS Inc.,
Cary, NC).
Results
A total of 3,842 stage IIIB/IV first primary lung cancer cases were identified
during the study period (State Health Plan=341, Medicaid= 3,501). During the same
period, 467,832 medical procedure claims from the patients in our cohort were submitted
to State Health Plan (115,087) and Medicaid (352,745). Figure 5.1 shows the criteria for
patient and claim exclusion. After patient exclusions, 2,266 cases remained eligible for
analysis. Of these, 44 cases (1.9%) received molecular testing.
Patient and physician demographics
Table 5.1 details the patient and physician demographic characteristics for the
entire study population and by molecular testing subgroup. Mean age at diagnosis was
57.4 years (range: 23-90 years). Males comprised 60.6% of the study population. Over
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half of the study population was White (56.9%) and the majority were non-Hispanic
(98.0%). The majority of included patients were covered by SC Medicaid (86.0%) and
lived in metropolitan counties at the time of diagnosis (75.8%). Similarly, most
procedure claims submitted were from in state providers (75.7%). There were no
significant differences between those who received molecularly testing and those that did
not receive molecularly testing by most demographic characteristics, except for age at
diagnosis (p=.002), insurance (p=.007) and provider state (p=.004). Approximately 4%
of patients enrolled in SCSEHP received molecular testing, compared to only 1.6% of
Medicaid patients. Approximately 2%of patients with in-state only claims received
molecular testing, compared to only 0.5% of patients with at least one out of state claim.
Patient disease characteristics
Over 77% of the lung cancer patients in the cohort were diagnosed with stage IV
disease. In over half the cases, grade was unknown (60.5%). Adenocarcinoma was the
most common histology (37.2%), followed by mixed or other NSCLC (31.0%) and
squamous cell carcinoma (23.1%). Lung lobe was the most common disease site
(69.5%). Significant differences between molecularly tested and not molecularly tested
groups were observed for grade (p=.025) and histology (p<.001). Low-grade patients
were more likely to receive molecular testing compared high-grade patients (3.6% vs.
0.9%, respectively). Patients with adenocarcinoma had the highest rate of molecular
testing (3.8%) compared to other histologies.
Predictors of molecular testing
Univariable logistic regression identified six individual prognostic factors of
having at least one CPT claim for molecular testing. These factors were age at diagnosis,
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insurance, provider state, histology, grade, and year of diagnosis (Table 5.2). Most
variables that were significant in the univariable models remained independent prognostic
factors in the adjusted logistic regression model, except for insurance status (p=0.131,
Table 5.3). Similar to the unadjusted models, the adjusted odds of having a molecular
test were reduced by 50% for each decade increase in age (OR=0.95, 95% CI: 0.91-0.99,
p=.008). Patients with claims submitted by out-of-state providers were about 84% less
likely to have molecular testing, after adjustment (OR=0.16, 95% CI: 0.05-0.53, p=.003).
Patients with high and unknown grade tumors had reduced odds of having a molecular
test compared to patients with low grade tumors (high grade: OR=0.17, 95% CI: 0.060.53; unknown grade: OR=0.37, 95% CI: 0.16-0.86; p=.008) after adjustment. Patients
with squamous, mixed or other NSCLC, and large cell histologies were all less likely to
have molecular testing compared to patients with adenocarcinoma histologies (squamous:
OR=0.06, 95% CI: 0.01-0.47; mixed or other NSCLC: OR=0.46, 95% CI: 0.21-1.05;
large cell: OR=0.53, 95% CI: 0.15-1.84; p=.015). Patients diagnosed in 2010 or later
were over 15 times more likely to having molecular testing compared to patients
diagnosed prior to 2010 (OR=15.60, 95% CI: 6.48-37.53, p=<.001).
Molecular testing and overall survival
Median overall survival varied significantly by molecular testing status (log-rank:
p<.001; Figure 5.2). Overall survival was longer for patients with molecular testing
compared to patients without molecular testing (median=13 vs. 6 months, CI: 8-25 vs. 56, respectively). The censoring rate was higher in the molecular testing group compared
to the no molecular testing group (27.27% vs 7.83%).
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Factors that were individually associated with overall survival included age at
diagnosis, insurance, provider state, stage, grade, histology, primary site, year of
diagnosis, and molecular testing status. All variables, except grade, remained significant
in the multivariable model (Table 5.3). There remained an increased risk of death for
each additional decade of age (10%; HR=1.01, 95% CI: 1.00-1.01, p=.004) after
adjustment. Patients enrolled in SC Medicaid had an increased risk of death compared to
patients enrolled in SCSEHP, once adjusted (HR=1.37, 95% CI: 1.21-1.56, p<.001).
Patients who had at least one procedure claim for molecular testing submitted by an outof-state provider had a 36% reduced risk of death compared to patients whose claims
were submitted by an in-state provider (HR=0.64, 95% CI: 0.57-0.71, p<0.001). Stage
IV patients had an 83% increased risk of death compared to stage IIIB patients (HR=1.83,
95%CI: 1.64-2.04, p<.001). Patients with mixed or other NSCLC (HR=1.17, 95% CI:
1.05-1.30), large cell carcinoma (HR=1.09, 95% CI: 0.92-1.28), or squamous cell
carcinoma (HR=1.12, 95% CI: 1.00-1.26) had increased risk of death compared to those
with adenocarcinoma, after adjustment (p=.034). Patients with tumors in the lung and
bronchus, not otherwise specified (HR=1.25, 95% CI: 1.11-1.39), overlapping lesions
(HR=1.30, 95% CI: 1.00-1.68), or tumors in the main bronchus (HR=1.21, 95% CI: 1.011.45) had increased risk of death compared to patients with tumors located in a lung lobe
(p<0.001). Patients diagnosed in 2010 or after had a 11% reduced risk of death compared
to those diagnosed prior to 2010 (HR=0.89, 95% CI: 0.81-0.99, p=.027).
Once adjusted for age at diagnosis, insurance, provider state, stage, histology,
primary site, and year of diagnosis, patients who had molecular testing continued to have
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a reduced risk of death compared to patients without molecular testing, although this
association was slightly attenuated (HR=0.57, 95% CI: 0.40-0.81, p=.002).
The relationship between molecular testing and overall survival also was adjusted
for using propensity scores calculated by both parsimonious and non-parsimonious
logistic regression models. Neither model differed greatly from the model based on
independent patient and provider prognostic factors. Patients who had molecular testing
had a 46% reduced risk of death compared to patients who did not have molecular
testing, in both the parsimonious and non-parsimonious models (HR=0.54, 95% CI: 0.380.78, p=.001 and HR=0.54, 95% CI: 0.38-0.78, p=.001, respectively; Table 5.4).
Discussion
Overall, this study found a very low rate of molecular testing for patients with
advanced NSCLC in SC compared to other studies of EGFR-specific testing that reported
EGFR testing rates between approximately 15-32%.111-113 Overall, ≈2% of patients in
this study received any molecular testing with a higher proportion of patients diagnosed
in 2010 or later having molecular testing (5.9%) compared to those diagnosed prior to
2010 (0.37%). This may indicate physician adoption of molecular testing in this
population over time, likely as a result of the publication and dissemination of multiple
molecular testing guidelines,103,104,108-110,151 increased integration and ease of molecular
testing results in the clinic, and the approval of multiple effective targeted therapies (e.g.,
gefitinib, erlotinib, and crizotinib) since 2010.30,116,118
Several patient and provider factors were predictive of having at least one CPT
code for molecular testing. These factors were age at diagnosis, provider state, grade,
histology, and year of diagnosis. Our results pertaining to factors associated with having
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molecular tests were similar to several other studies.112,113 A recent study published in
2016 by Enewold and Thomas112 examined EGFR testing only, as opposed to any
molecular testing (e.g., KRAS, BRAF, ALK, ROS1).112 Their study found that patients
with stage IV lung cancer who were younger, covered by Medicaid, uncovered or had
unknown coverage, and diagnosed with large cell and squamous tumors were less likely
to have molecular testing, similar to our study results. Shen et al also reported younger,
as well as female, patients more likely to have molecular testing, similar to our study.113
Enewold and Thomas also found that EGFR testing was also associated with
Hispanic/Asian Pacific Islander (API) heritages, marital status, smoking status, having no
comorbidities, and living at least two months after cancer diagnosis.112 We found no
relationship between molecular testing and Hispanic ethnicity or marital status and had
insufficient information on the other factors. However, our study included few Hispanic
and API patients, and thus these results should be interpreted with caution. Patient
disease factors that were found to be associated with molecular testing, such as younger
age and adenocarcinoma histology, in this study are reported in metastatic NSCLC
molecular testing guidelines,103 suggesting that the early adopters of molecular testing
were likely selecting appropriate patients for testing.
We found that molecular testing status was predictive of overall survival. Patients
who received molecular testing had a 43% reduced risk of death compared to patients
who did not receive molecular testing. Patients with molecular testing also had a longer
median survival compared to patients with no molecular testing (13 vs. 6 months,
p<0.001). Many clinical trials have assessed collectively the impact of molecular testing,
presence of a molecular abnormality, and corresponding treatment on overall survival,

113

but no population-based studies, to our knowledge, have evaluated the impact of broad
molecular testing alone on overall survival. Our results suggest that molecular testing
alone, may benefit advanced NSCLC patients, presumably due to downstream effects,
such as treatment with the best available agent for the patient’s tumor molecular profile.
Alternately, our finding may indicate that patients who have molecular testing are cared
for by providers with greater knowledge about precision medicine, resulting in higher
quality care and ultimately longer survival.
Strengths and limitations
Perhaps the biggest limitation to this study is the inability specifically identify the
genes analyzed by the ordered molecular tests. This study evaluated patients diagnosed
between 2002 and 2012, at which time the practice of code stacking was the only way for
physicians to code and bill for molecular testing and EGFR testing was predominant.
Code stacking is based on method performed, not gene assessed, thus it is impossible for
us to know which genes were assessed. Because the patients in this study were diagnosed
between 2002 and 2012, however, we acknowledge that most patients were likely tested
for abnormalities in the KRAS and EGFR gene pathways. Additionally, there is the
potential for misclassification of molecular testing status. MT status may have been
misclassified due to 1) incorrect claim coding, 2) lack of insurance coverage at the time
of molecular testing, resulting in the claim not being included in our administrative
claims dataset, 3) molecular testing that was covered as part of a clinical trial, 4)
molecular testing that was paid by the patient out-of-pocket.
Our cohort consisted of patients with some form of insurance coverage and thus
no conclusions can be made for patients with no insurance coverage. Additionally,

114

patients with Medicare were excluded from this analysis. We may observe fewer patients
with molecular testing in cohorts of patients that have no insurance coverage or
Medicare, although the latter is likely to be changing as companies that provide
multigene molecular testing panels obtain local coverage determinations for their
products. As these data were obtained from SCCCR and RFA administrative claims, we
also did not have information on several important variables that may impact molecular
testing utilization and overall survival, including patient (e.g., socioeconomic status,
smoking status, performance status and comorbidities) and provider variables (e.g.,
specialty, years since medical school graduation, practice setting).
Our assessment of both patient and provider geographic location was limited at
the county level. Each provider-submitted claim included information on the county in
which the claim originated. Only one county in SC is designated as completely rural by
the rural-urban continuum codes and only two counties were designated as
nonmetropolitan counties not adjacent to a metropolitan area per United States
Department of Agriculture rural-urban continuum codes152 (used to define rurality in the
National Association of Central Cancer Registries). Thus, no molecular testing claims in
this dataset were submitted in the rural setting. As such, we assessed the provider
geographic location variable as “in state” versus “out of state”. Only 3 molecular tests
were performed out of state, thus conclusions on the impact of provider geographic
location must be interpreted with caution.
While our analyses had some limitations, a strength of the study was the ability to
provide an early assessment of the factors impacting molecular testing utilization based
on the only CPT codes available to track molecular testing at the time. Another strength
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of this study is its ability to assess the impact of molecular testing alone on overall
survival, an evaluation typically performed in clinical trials and in conjunction with
molecular test results. Finally, use of SCCCR and RFA administrative claims data
allowed us to assess these outcomes across a wide geographic area and with a large
number of cases. Approximately one-third of SC’s population is rural. Few academic
medical centers and only one National Cancer Institute designated cancer center is
located in SC, making this assessment of particular importance. Prior research indicates
disparities between academic and community-based provider knowledge and
understanding of molecular testing.101
Conclusions
Several disease characteristics were found to be associated with increased
molecular testing utilization in patients with advanced NSCLC, and molecular testing had
a positive impact on overall survival. Future research could evaluate more recent data
using the 2013 revised Tier 1 (gene specific; 81200-81383) and Tier 2 (molecular
pathology; 81400-81408) codes and could consider various methods of molecular testing
(e.g., tumor versus liquid biopsies). Assessment of provider-level variables affecting
these outcomes, such as geographic location, should be further investigated in national
datasets, such as the Surveillance, Epidemiology, and End Results-Medicare data.
Larger, more geographically diverse national datasets will provide more detailed data on
both providers and patients.
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Tables and Figures
Table 5.1. Patient, physician, and disease characteristics for the overall population and molecular testing subgroups
All Patients
(N, %)

Patient/Provider Characteristics

Molecular Test Yes
(N, %)

Molecular Test - No

P value

(N, %)

2266

100

44

1.94

2222

98.06

-

N

%

N

%

N

%

0.002*

Age at Diagnosis (years)
117

Mean (SD)

57.4

53.0

57.5

Median

57.4

54.5

57.0

Range

23.0-90.0

32.0-71.0

23.0-90.0
0.066

Age at Diagnosis (years)
<52

608

26.8

17

38.6

591

26.6

52-57

571

25.2

14

31.8

557

25.1

58-62

523

23.1

8

18.2

515

23.2

63+

564

24.9

5

11.4

559

25.1

0.438

Sex
Male

1372

60.6

24

54.6

1348

60.7

Female

894

39.5

20

45.5

874

39.3
0.181

Race
White

1289

56.9

29

65.9

1260

56.7

Black

953

42.1

14

31.8

939

42.3

Other

24

1.0

1

2.3

23

1.0
0.590

Hispanic
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Non-Hispanic

2221

98.0

43

97.7

2178

98.0

Hispanic

23

1.0

1

2.3

22

1.0

Unknown

22

1.0

0

0.0

22

1.0
0.120

Marital Status
Not married

1203

53.1

23

52.3

1180

53.1

Married

690

30.5

18

40.9

672

30.2

Unknown

373

16.4

3

6.8

370

16.7

Insurance

0.007*

State health plan

318

14.0

13

29.6

305

13.7

Medicaid

1948

86.0

31

70.4

1917

86.3
>0.999

Patient Metropolitan Status
Non-metropolitan/rural

549

24.2

10

22.7

539

24.3

Metropolitan

1717

75.8

34

77.3

1683

75.7
0.004*

Provider State
Out of state

551

24.3

3

6.8

548

24.7

In state

1715

75.7

41

93.2

1674

75.3

119

Disease Characteristics
0.587

AJCC Stage
IIIB

517

22.8

8

18.1

509

22.9

IV

1749

77.2

36

81.82

1713

77.1
0.025*

Grade
Low

250

11.0

9

20.45

241

10.8

High

646

28.5

6

13.64

640

28.8

Unknown

1370

60.5

29

65.91

1341

60.4

<.001*

Histology
Adenocarcinoma

842

37.2

32

72.73

810

36.5

Large cell

196

8.7

3

6.82

193

8.7

Squamous

524

23.1

1

2.27

523

23.5

Mixed or other NSCLC

704

31.0

8

18.18

696

31.3
0.385

Primary Site

120

Main bronchus

140

6.2

1

2.27

139

6.3

Lobe

1575

69.5

36

81.82

1539

69.3

Overlapping lesion

62

2.7

1

2.27

61

2.8

Lung and bronchus, NOS

489

21.6

6

13.64

483

21.7
<.0001*

Year of Diagnosis
Prior to 2010

1619

71.5

6

13.6

1613

72.6

2010 or later

647

28.5

38

86.4

609

27.4

Abbreviations: N, number; NOS, not otherwise specified; NSCLC, non-small cell lung cancer; SD, standard deviation
*Significant at the p≤0.05 level.

Table 5.2. Univariable and multivariable logistic regression results for molecular testing
Univariable Logistic Regression

Multivariable Logistic Regression

Unadjusted OR

95% CI

P value

Adjusted OR

95% CI

P value

0.95

0.92-0.98

0.002*

0.95

0.91-0.99

0.008*

Patient/Provider Characteristics
Age at Diagnosis (years)

0.412

Sex
Male
Female

Reference
1.29

0.71-2.34

121

0.314

Race
White

Reference

Black

0.65

0.34-1.23

Other

1.89

0.25-14.47
0.722

Hispanic
Non-Hispanic

Reference

Hispanic

2.30

0.30-17.47

Unknown

<0.001

<0.01->999.99

0.146

Marital Status
Not married

Reference

Married

1.37

0.74-2.57

Unknown

0.416

0.12-1.39
0.004*

Insurance
State health plan
Medicaid

Reference
0.38

0.20-0.73
0.82

Patient Metropolitan Status
122

Non-metropolitan/rural

0.92

Metropolitan

0.45-1.87
Reference
0.013*

Provider State
Out of state
In state

0.22

0.07-0.73

0.16

Reference

IIIB

0.461
Reference

0.05-0.53
Reference

Disease Characteristics
AJCC Stage

0.003*

IV

1.34

0.62-2.89
0.034*

Grade
Low

0.008*

Reference

Reference

High

0.25

0.09-0.71

0.17

0.06-0.53

Unknown

0.58

0.27-1.24

0.37

0.16-0.86

<0.001*

Histology
Adenocarcinoma

0.015*

Reference

Reference
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Large cell

0.39

0.12-1.30

0.53

0.15-1.84

Squamous

0.05

0.01-0.36

0.06

0.01-0.47

Mixed or other NSCLC

0.29

0.13-0.64

0.46

0.21-1.05

0.357

Primary Site
Main bronchus

0.31

Lobe

0.04-2.26
Reference

Overlapping lesion

0.70

0.10-5.20

Lung and bronchus, NOS

0.53

0.22-1.27

Year of Diagnosis

<0.001*

<.001*

Prior to 2010
2010 or later

Reference
16.77

Reference

7.06-39.88

15.60

6.48-37.53

Abbreviations: CI, confidence interval; N, number; NOS, not otherwise specified; NSCLC, non-small cell lung cancer; OR, odds ratio
Note: Only significant variables were included in the final model.
*Significant at the p≤0.05 level.
Table 5.3. Univariable and multivariable Cox proportional hazards regression for overall survival
Univariable Cox Proportional
Hazards Regression
Unadjusted HR
95% CI
P value

Multivariable Cox Proportional
Hazards Regression
Adjusted HR 95% CI P value

Patient/Provider Characteristics
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Age at Diagnosis (years)

1.01

1.01-1.01

1.01

1.01-1.01

0.091

Sex
Male
Female

<0.001*

Reference
0.93

Reference

0.85-1.01
0.548

Race
White

Reference

Black

0.96

0.88-1.04

Other

0.91

0.59-1.38

Reference

0.004*

0.167

Hispanic
Non-Hispanic

Reference

Hispanic

0.73

0.46-1.16

Unknown

1.34

0.87-2.06
0.124

Marital Status
Not married

Reference

Married

0.90

0.82-1.00

Unknown

0.96

0.85-1.09
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0.003*

Insurance
State health plan
Medicaid

1.21

Reference

1.07-1.37

1.37

1.21-1.56

0.922
1.01

Metropolitan

0.91-1.11
Reference
<0.001*

Physician State
Out of state

<0.001*

Reference

Patient Metropolitan Status
Non-metropolitan/rural

Reference

0.68

0.61-0.75

<0.001*
0.64

0.57-0.71

In state

Reference

Reference

Disease and Molecular Testing
Characteristics
<0.001*

AJCC Stage
IIIB
IV

<0.001*

Reference
1.76

Reference

1.58-1.95

1.83

1.64-2.04

0.002*

Grade
Low

Reference
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High

1.29

1.10-1.51

Unknown

1.29

1.12-1.49
0.001*

Histology
Adenocarcinoma

0.034*

Reference

Reference

Large cell

1.16

0.99-1.36

1.09

0.92-1.28

Squamous

1.08

0.97-1.21

1.12

1.00-1.26

Mixed or other NSCLC

1.23

1.11-1.36

1.17

1.05-1.30

Primary Site

<0.001*

<0.001*

Main bronchus

1.20

Lobe

1.01-1.44

1.21

Reference

1.01-1.45
Reference

Overlapping lesion

1.30

1.00-1.68

1.30

1.00-1.68

Lung and bronchus, NOS

1.33

1.20-1.48

1.25

1.12-1.39

0.005*

Year of Diagnosis
Prior to 2010
2010 or later

Reference
0.87
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No

Reference

0.79-0.96

0.89

0.81-0.99

<0.001*

Molecular Testing
Yes

0.027*

0.53

0.37-0.75
Reference

0.002*
0.57

0.40-0.81
Reference

Abbreviations: CI, confidence interval; HR, hazards ratio; N, number; NOS, not otherwise specified; NSCLC, non-small cell lung
cancer
*Only significant variables (p≤0.05) were included in the final model.

Table 5.4. Comparison of adjustment methods estimating the impact of molecular testing on overall survival

Method

Comparison of Adjusted Cox Proportional
Hazards Regression Methods
Adjusted HR
95% CI
P value

Cox PH model

0.57

0.40-0.81

0.002*

Propensity score, parsimonious

0.54

0.38-0.78

0.001*

Propensity score, nonparsimonious

0.54

0.38-0.78

0.001*

Abbreviations: CI, confidence interval; HR, hazards ratio; PH, proportional hazards
*Significant at the p≤0.05 level.
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SCCCR cases with SHP or Medicaid coverage
(SHP=341, Medicaid=3,501)

Medical procedure claims for SCCCR cases
(SHP=115,087, Medicaid=352,745)

Excluded cases with dual insurance
coverage
(SHP=13, Medicaid=13)

Excluded claims of cases with dual
insurance coverage
(SHP=2,607, Medicaid=1,369)

Excluded cases without NSCLC
diagnosis
(n=72)

Remaining procedure claims
(n=463,856)

Excluded procedure claims missing
physician metropolitan status
(n=16,559)

Remaining procedure claims
(n=447,297)

Remaining SCCCR cases
(n=3,744)

Linked

Reduced to one procedure claim per case
(n=2,317)

Excluded cases not included in both SCCCR
and procedure claims datasets
(n=1,478)

Final cases eligible for analyses
(n=2,266)

Abbreviations: NSCLC, non-small cell lung cancer; SCCCR, South Carolina Central
Cancer Registry; SHP, State Health Plan
Figure 5.1. Lung cancer registry case and corresponding claim(s) inclusion and
exclusion
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Figure 5.2. Overall survival for lung cancer patients, stratified by molecular testing
status
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CHAPTER VI:
PREDICTORS OF ERLOTINIB UTILIZATION AND THE IMPACT
OF ERLOTINIB USE ON OVERALL SURVIVAL IN ADVANCED,
NON-SMALL CELL LUNG CANCER: A RETROSPECTIVE
COHORT STUDY3

3

Ersek JL, Symanowski J, Kim ES, Adams SA, Eberth JM. To be submitted to Journal of
Thoracic Oncology.
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Abstract
Introduction: Epidermal growth factor receptor (EGFR)-directed therapies are approved
for selected patients with non-small cell lung cancer (NSCLC); however, little
information on predictors of utilization and efficacy in the population-based setting has
been reported. We aimed to identify predictors of early erlotinib prescribing and evaluate
the impact of erlotinib on survival in patients diagnosed with stage IIIB/IV NSCLC
residing in South Carolina (SC).
Methods: SC Central Cancer Registry cases diagnosed between January 1, 2002 and
December 31, 2012 were linked to SC State Employee Health Plan (SCSEHP) and
Medicaid administrative claims data. Logistic regression (LR) was used to identify
predictors of erlotinib utilization. Kaplan-Meier methods were used to estimate survival
distributions and log-rank tests compared the survival distributions between erlotinib
groups. Cox proportional hazards (PH) modeling was used to assess the impact of patient
demographic, disease, and treatment characteristics on survival, while adjusting for other
prognostic covariates. Multivariable LR models were used to estimate propensity scores,
which were then used as covariates in adjusted Cox PH models.
Results: A total of 1,623 patients were eligible. Independent predictive factors for having
at least one erlotinib claim, included younger age at diagnosis (p=.004), female sex
(p=.048), SCSEHP (p<.001), out-of-state providers (p<.001), adenocarcinoma histology
(p<.001), and having molecular testing (p=.018). Overall survival (OS) was longer for
patients who received erlotinib (median OS=14 versus 7 months, p<0.001). After
adjustment for significant prognostic factors, patients who received erlotinib had a 35%
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reduced risk of death compared to patients with no erlotinib (HR=0.65, 95% CI: 0.560.75, p<.001).
Conclusions: Several factors were associated with erlotinib utilization and disparities in
access may exist. Erlotinib utilization was associated with a reduced risk of death in
patients with NSCLC in SC.
Introduction
Lung cancer is the leading cause of cancer-related death in the United States and
in South Carolina.1,145 In 2017, approximately 4,320 new lung cancer cases will be
diagnosed and 2,920 lung cancer deaths will occur.1 Most lung cancer patients are
diagnosed with advanced disease and the overall 5-year survival rate is 18%.1 Until
recently, patients with advanced, non-small cell lung cancer have mostly been treated
with platinum-based chemotherapy doublets or pemetrexed. None of these systemic
regimens have demonstrated significant improvement in long-term response or
survival.4,146
Recently, advances in the genomic profiling (or molecular testing) of tumors have
identified multiple alterations in lung tumors that can be targets for treatment, providing
personalized targeted and immunotherapy options for patients with specific molecular
abnormalities. For example, epidermal growth factor receptor (EGFR) is a cell surface
receptor that is activated either by protein overexpression, increased gene copy number or
genetic mutation. EGFR is involved with cell proliferation, suppression of apoptosis (cell
death), cell motility, invasion and angiogenesis (formation of new blood vessels).20,25
Patients whose tumors harbor EGFR mutations can be treated with one of several EGFR
tyrosine kinase inhibitors (TKIs), including gefitinib, erlotinib, and afatinib,116-118 which

133

have demonstrated increased tumor response rates and median progression-free survival
and decreased toxicity in clinical trial patients.6,7,9,10,121,153 Prior to Food and Drug
Administration (FDA) approval, clinical investigators and treating physicians identified
several patient characteristics that appeared to be associated with response and therefore
would benefit patients receiving EGFR TKI therapy. As reported at annual oncology
meetings and in early publications, these characteristics included female sex, Asian race,
adenocarcinoma histology, and never-smoking history.92,94,122,154-156
In 2003, gefitinib was the first EGFR TKI to gain FDA accelerated approval for
use as monotherapy in patients with advanced non-small cell lung cancer after failure of
platinum-based and docetaxel regimens.157 Just two years later, in 2005, gefitinib was
restricted to use in patients currently or previously benefiting from gefitinib and/or
patients participating in clinical trials on the basis of failure to show improvement in
outcomes.158,159
Around the same time (2004), the FDA approved erlotinib for use in patients in
the similar, unselected patient population and erlotinib eventually gained approval in the
maintenance setting (i.e., following stable or response after 4-6 cycles of first-line
platinum-based chemotherapy) in 2010. ‘Unselected’ means the use of the drug is not
informed by a patient’s EGFR mutation status. In 2013, the FDA revised the indication
to restrict erlotinib use to a selected patient population, making it available in the firstline setting for patients with metastatic NSCLC whose tumors harbored selected EGFR
mutations (exon 19 deletion or exon 21 L858R mutated). Erlotinib remained an option
for second-line therapy and beyond in the unselected population. While progression-free
survival and toxicity outcomes across phase III clinical trials of erlotinib have been
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positive with regards to response, only small increases in overall survival (1-2 months)
have been observed in the unselected population.11,29,132 Additionally, in a recent study
by Enewold and Thomas using population-based data, no association between erlotinib
and survival was reported.112
Treatment of metastatic NSCLC continues to evolve at a rapid pace. Little
research has evaluated erlotinib in patients with NSCLC outside of the clinical trial
setting.112,114 The purpose of this study was to determine factors associated with whether
or not a patient received the EGFR TKI targeted therapy, erlotinib, among patients with
advanced NSCLC residing in South Carolina and to determine if erlotinib use improved
overall survival in the population-based setting.
Methods
Study Design, Data Source, and Cohort Selection
We linked outpatient drug and procedure claims data from the South Carolina
(SC) Revenue and Fiscal Affairs (RFA) administrative claims to eligible cases in the
South Carolina Central Cancer Registry (SCCCR) to retrospectively evaluate erlotinib
utilization and overall survival. Eligible cases were those included in the SCCCR
diagnosed with stage IIIB/IV lung cancer between January 1, 2002 and December 31,
2012, were enrolled in South Carolina State Employee Health Plan (SCSEHP) or SC
Medicaid during the study period, and had at least one procedure and one drug claim.
Patients with dual insurance coverage, HMO coverage, Medicare as the primary payer,
and patients with no insurance were not included in this study.
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Outcomes
Erlotinib utilization was determined using National Drug Codes (NDC) from drug
administrative claims. Patients with at least one claim for erlotinib, using one of the
following NDC codes, were classified as “yes”: '54868-5447-0’, ‘54868-5474-0', '691890063-1', ‘50242-062-01’, ‘50242-063-01’, ‘50242-064-01’, or ‘54868-5290-0’. Erlotinib
claims were for any line of therapy. Patients with all other NDC codes were classified as
not utilizing erlotinib. We assume that having at least one claim for erlotinib resulted in
utilization of the drug. Overall survival was calculated from the date of primary lung
cancer diagnosis to the date of death for deceased cases. Surviving cases were censored
at the date of last follow-up or December 31, 2014.
Covariates
Patient and provider demographics
Sex was categorized as male or female. Age at diagnosis was evaluated as both a
continuous and as a categorical variable (<52, 52-57, 58-62, 63+ years). Race was
categorized as White, Black, or other. Hispanic ethnicity was categorized as Hispanic,
non-Hispanic, or unknown. Marital status was categorized as married, not married, or
unknown. Patient metropolitan status was derived using rural-urban continuum codes
assigned to each patient’s county and were ultimately dichotomized as non-metropolitan
versus metropolitan.152 Non-metropolitan included rural counties.
Data on provider geographic location was not available for the drug claims, thus
we used provider geographic location for molecular testing (obtained through procedure
claims) as a proxy for drug claim provider geographic location. Procedure claims
contained information on provider geographic location, specifically county, for each
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claim submitted. All providers with procedure claims submitted in a SC county were
categorized as ‘in state’, while providers with procedure claims submitted outside of SC
were categorized as ‘out of state’.
Patient disease
Cases with the following ICD-0-3 codes were included in this study:
adenocarcinoma (8140, 8250, 8252, 8253, 8255, 8260, 8480, 8481), large cell (8012),
squamous (8070, 8071), and mixed or other NSCLC (8000, 8010, 8046, 8560). Small
cell lung cancer cases were excluded. Stage was limited to advanced stage and was
categorized according to American Joint Committee on Cancer (AJCC) staging criteria as
stage IIIB or IV. Grade was categorized as low (grade 1 or 2), high (grade 3 or 4) or
unknown. Primary site was defined as main bronchus (including carina, hilum, bronchus
intermedius; C340), lobe (including upper lobe, lingual, apex, and pancoast tumors,
C341; middle lobe, C342; lower lobe and base, C343), overlapping lesion of lung (C348),
and lung or bronchus, not otherwise specified (NOS; C349). Year of diagnosis was
defined as prior to 2010 and 2010 or later. 2010 was selected as the cutoff year as this
was the first year that erlotinib was approved as maintenance treatment for patients with
locally advanced or metastatic NSCLC whose disease had not progressed after four
cycles of first-line platinum-based chemotherapy regimen (or in other words, available in
the first line setting). Additionally, 2010 was just prior to the publication of many lung
cancer guidelines supporting the use of molecular testing and targeted therapy
approaches.103-105,108,150 Molecular testing was determined using Common Procedure
Terminology codes and included any molecular tests performed. Cases with molecular
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testing method codes (83890-83914) were categorized as ‘yes’. These include both
EGFR specific and multigene testing.
Statistical Analysis
Patient demographic and disease characteristics were summarized for the overall
cohort and by erlotinib use. Age was summarized as a continuous and a categorical
variable. Frequencies and percentages were reported for all other variables. Comparisons
between erlotinib groups were performed using chi-square tests for categorical variables
and a two-sample t-tests for age.
Univariable and multivariable logistic regression was used to evaluate the impact
of patient and provider characteristics on erlotinib utilization. Factors included in the
final multivariable model were identified using backwards elimination followed by
forward selection modeling procedures to confirm variables identified using backward
elimination. All variables significant at the p<.05 level were retained in the final model.
Odds ratios (OR), corresponding 95% confidence intervals (CI) and p-values were
estimated.
Kaplan–Meier techniques were used to estimate survival distributions and logrank tests compared the distributions between the erlotinib groups. Univariable Cox
proportional hazards regression was used to identify individual prognostic factors
predictive of overall survival. Multivariable Cox proportional hazards regression was
used to evaluate the independent impact of the covariates and erlotinib use on overall
survival. Hazard ratios (HR) and corresponding 95% CIs were estimated.
Propensity scores were estimated to reduce potential biases associated with
erlotinib use on overall survival and were included in separate Cox proportional hazards
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models. Two logistic regression models were estimated to calculate the predicted
probability of erlotinib use (non-parsimonious and parsimonious). The non-parsimonious
model included all 13 available covariates and the parsimonious model included only
covariates found to be significant in our final multivariable logistic regression model.
Individual propensity scores (weighted probabilities) were calculated based on predicted
probabilities from the logistic regression models. Patients who received erlotinib were
weighted by the inverse of the probability for getting erlotinib, while patients who did not
have molecular testing were weighted by the inverse of the probability for not getting
erlotinib. The propensity score was then used as a covariate in the Cox proportional
hazards regression models to estimate the adjusted effect of erlotinib utilization on
survival. We then compared the propensity score-adjusted Cox proportional hazards
regression models to traditional multivariable models. The results of the two propensity
score-adjusted models were then compared to the model based on independent patient
and provider prognostic factors.
All hypothesis testing was 2-sided with a p<0.05 level of statistical significance.
The SAS statistical package V9.4 was used for data analyses (SAS Inc., Cary NC).
Results
A total of 1,623 cases met eligibility criteria and had at least one claim in both the
procedures and drug claims datasets. 54,897 Medicaid and 19,533 SHP drug claims were
used to categorize erlotinib use. 18.4% of patients were members of the SCCEHP, while
81.6% were enrolled in SC Medicaid. Of all eligible cases, 14.0% had at least one claim
for erlotinib and 1,396 (86.0%) had no erlotinib claims (Table 6.1). Figure 6.1 outlines
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lung cancer registry case and corresponding procedure and drug claims inclusion and
exclusion criteria.
Patient and provider demographics
For the overall cohort, mean age at diagnosis was 56.8 years (Median=57, Range:
23-90). A higher proportion of patients were male, White, and non-Hispanic (58.9%,
58.1%, and 98.3%, respectively). About half of the patients were not married (51.0%)
and the majority had Medicaid insurance (81.6%). Most patients lived in metropolitan
areas at the time of diagnosis (75.4%). Provider state was most often in-state (70.0%).
Marital status, insurance, and provider state differed significantly by erlotinib status
(p=0.004, p<0.001, and p=0.0345, respectively). The rate of erlotinib utilization was
higher for patients who were married, had SCSEHP coverage, and had at least one
encounter with an out-of-state provider.
Patient disease characteristics
Most patients were stage IV at the time of diagnosis (75.9%). Adenocarcinoma
histology was most frequent (37.4%) followed by mixed or other NSCLC (29.8%),
squamous (24.0%) and large cell (8.8%). The majority of tumors were located in a lung
lobe (71.2%). Only 2.5% of patients received any molecular testing. Histology (p<.001)
and molecular testing (p=.002) varied significantly by erlotinib status, with a higher
proportion of adenocarcinomas and patients with a molecular testing claim received
erlotinib (55.1% and 5.7%, respectively).
Predictors of erlotinib utilization
Results from univariable analyses are presented in Table 6.2. Individual
significant predictors of erlotinib use were age of diagnosis (p=.001), sex (p=.010),
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marital status (p=.004), insurance (p<.001), provider state (p=.031), histology (p<.001),
and molecular testing (p=.001).
In the adjusted logistic regression models, most variables remained significant
predictors of erlotinib use, with the exception of marital status (p=0.322; Table 6.2). For
each increasing decade, the odds of erlotinib utilization were reduced by 30%, (OR=0.97,
95% CI: 0.96-0.99, p=.004). Patients with Medicaid and non-adenocarcinoma histologies
also had reduced odds of receiving erlotinib compared to patients with SCSEHP
(OR=0.29, 95% CI: 0.20-0.42, p<.001) and adenocarcinoma histologies (mixed/other
NSCLC OR=0.64, 95% CI: 0.46-0.91, squamous OR=0.36, 95% CI: 0.29-0.68, large cell
OR=0.28, 95% CI: 0.13-0.60, p<.001). Patients with at least one claim submitted by an
out-of-state provider were over two times more likely to receive erlotinib compared to
patients with only in-state claims (OR=2.03, 95% CI: 1.43-2.89, p<0.001). Lastly,
female patients and patients with molecular testing were more likely to receive erlotinib
compared to males and patients without molecular testing (OR=1.35, 95%CI: 1.00-1.81,
p=0.048 and OR=2.37, 95% CI: 1.16-4.85, p=0.018, respectively).
Erlotinib and overall survival
Overall survival for patients with erlotinib claims was longer than for patients
with no erlotinib claims (median OS=14 versus 7 months, p<0.001; Figure 6.2). The
censoring rate was slightly higher in the erlotinib group (10.13%) compared to the no
erlotinib group (9.31%).
Seven covariates were found to be predictors of overall survival. Univariable
HRs and corresponding 95% CIs are presented in Table 6.3. Significant covariates
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included age at diagnosis (p<.001), provider state (p<.001), stage (p<.001), grade
(p=.005), primary site (p=.001), molecular testing (p=.005), and erlotinib use (p<.001).
Age at diagnosis, provider state, stage, primary site, year of diagnosis, molecular
testing, and erlotinib use all remained significant predictors of overall survival in the
multivariable analysis (Table 6.3). Grade no longer remained significant (p=0.126),
however, year of diagnosis was a significant predictor of overall survival in the
multivariable model. A 10% increase in the risk of death was observed for each
additional decade of life (HR=1.01, 95% CI: 1.00-1.01, p<.007). Patients with at least
one claim submitted by an out-of-state provider had a 24% reduced risk of death
compared to patients with only in-state claims (HR=0.76, 95% CI: 0.68-0.85, p<.001).
As expected, patients diagnosed with stage IV disease had an increased risk of death
compared to those diagnosed with stage IIIB (HR=1.96, 95% CI: 1.73-2.23, p<.001).
Patients with a primary site of disease outside the lung lobe (main bronchus, overlapping
lesions, and lung/bronchus NOS) also saw an increased risk of death compared to patients
with a primary site of lung lobe (HR=1.20, 95% CI: 0.96-1.48, HR=1.36, 95% CI: 1.021.84, OR=1.18, 95% CI: 1.04-1.35, p=.010, respectively). Patients diagnosed prior to
2010 had a reduced risk of death compared to patients diagnosed in 2010 or later
(HR=0.87, 95% CI: 0.77-0.98, p=.020).
The risk of death for patients with molecular testing and for patients with erlotinib
claims did not largely change from the univariable model. Reduced risk of death was still
observed for those with molecular testing and erlotinib claims. The adjusted results
showed patients with molecular testing had 35% reduced risk of death compared to
patients with no molecular testing (HR=0.65, 95% CI: 0.45-0.95, p=.024). Patients with
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at least one erlotinib claim also had a 35% reduced risk of death compared to patients
with no erlotinib claims (HR=0.65, 95% CI: 0.56-0.75, p<.001).
Propensity score adjusted hazards
Propensity scores were calculated using multivariable logistic regression to
estimate the propensity for erlotinib given a set of covariates. Using weighted propensity
scores (inverse probability of treatment weights; IPTW) as a method of adjustment
increased the reduction in the risk of death in both scenarios. For the non-parsimonious
(all available covariates) and parsimonious models (variables deemed significant using
multivariable logistic regression), the risk of death was reduced by 41% and 43%,
respectively (HR=0.59, 95% CI: 0.48-0.73, p<0.001; HR=0.57, 95% CI: 0.46-0.71,
p<0.001), which was generally consistent with the adjusted results from the individual
covariate model (Table 6.4).
Discussion
Treatment for advanced stage, NSCLC is rapidly evolving. Targeted therapies
have delivered on increasing survival and decreasing toxicity in patients who otherwise
would have been treated with platinum-based chemotherapies. Our study assessed
predictors of targeted therapy (erlotinib) utilization and overall survival in a populationbased setting during the time period when erlotinib was only approved for use in
unselected patients with locally advanced or metastatic NSCLC. We found several
factors associated with increased odds of receiving any line erlotinib treatment, including
female sex, having at least one procedure claim submitted by an out of state provider, and
having any molecular testing. Our findings that females were more likely to receive
erlotinib are in alignment with results from recently published data evaluating the use of
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EGFR-specific molecular testing in 2012-2014 using MarketScan data, published by
Shen et al.113 These data also support the early clinical observations that responses to
drugs, such as erlotinib, were more likely in specific patient demographic cohorts,
including that of females.
The current study found a low rate of molecular testing overall (2.5%). While
erlotinib did not receive a FDA indication for use exclusively in patients with EGFR
mutated tumors until 2013, the link between EGFR mutation and benefit of drugs such as
erlotinib and gefitinib was described as early as 2004.92,94 Additionally, there were early
discussions of the clinical characteristics of patients more likely to benefit from EGFR
therapy even before the EGFR mutation relationship was confirmed. Thus, early
prescribers of erlotinib were likely aware of the rapidly evolving scientific literature
surrounding this class of drugs.
We found that patients were more likely to have treatment with erlotinib if they
had at least one procedure claim submitted by an out-of-state provider, however, this
result should be interpreted with caution for several reasons. First, we used a proxy
variable for provider state based on molecular testing procedure claims. We presumed
that if a patient travelled outside SC for molecular testing, they likely travelled outside
SC to receive treatment. Additionally, evaluation of molecular testing procedure claims
identified only three patients with molecular testing claims from an out-of-state provider,
thus, this result is based on very small numbers. Shen et al reported that geographic
region may influence EGFR testing, with patients diagnosed in the Western United States
more likely to have EGFR testing.113
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We also reported several factors associated with decreased odds of having at least
one erlotinib claim including increasing age, Medicaid insurance, and nonadenocarcinoma histology. We found an approximately 26% decreased risk of receiving
erlotinib for each decade of life. Our result was similar to the inverse association
(although non-significant) between age and erlotinib observed in a recent study.112
Younger patients may be more likely to be prescribed erlotinib for several reasons. They
may be more suitable for therapy overall and thus more likely to receive multiple lines of
therapy, increasing the likelihood of receiving erlotinib in the second-line setting and
beyond. Younger patients may also be more motivated to research and explore cuttingedge, novel therapies on their own and bring discussion of these options to their
physicians. Also, for working younger patients, an oral therapy, such as erlotinib, may be
more accommodating to their lifestyles than an IV chemotherapy regimen. Our result
that patients with non-adenocarcinoma history are less likely to be prescribed erlotinib is
similar to the Enewold and Thomas study and is likely to reflect the early use of clinical
characteristics in selection of appropriate patients by oncologists. Enewold and Thomas
also found patients with Medicaid coverage less likely to receive erlotinib,112 similar to
our results. Patients with Medicaid in our study were about 70% less likely to be
prescribed erlotinib compared to patients enrolled on SCSEHP. Patients with SCSEHP
coverage are likely to be higher SES, compared to Medicaid patients, and may be more
likely to have the resources to cover off-label copays. Additionally, SCSEHP plans may
have been more accommodating of off-label drug use requests.
Our results show a reduced risk of death for patients who received erlotinib and
for patients who had molecular testing regardless of EGFR mutation status. Patients who
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were treated with erlotinib had a 7-month increase in median OS compared to patients
with no erlotinib claims. This study evaluated erlotinib use early in its approval history.
Patients who received erlotinib early on may have received this drug as part of a clinical
trial, which may explain the similar survival length for patients in this study and patients
in unselected clinical trials.128,129,132
Limitations and Strengths
While we had information on some of the demographic and clinical
characteristics associated with increased response to erlotinib, which may impact
likelihood of erlotinib prescribing, we were lacking information on other important
characteristics identified through previous research, including never smoking status and
Asian race.92,94,160 We were also unable to assess line of therapy (e.g., first, subsequent)
in which erlotinib was administered. Additionally, we did not have information on the
provider geographic location for which the erlotinib claim was submitted and used
provider location for molecular testing as a proxy variable.
One strength of this study is that it included patients documented in a state-wide
cancer registry. This sample allowed us to evaluate predictors of erlotinib and its impact
on survival in a diverse group of cancer patients coming from a variety of different
treatment centers (e.g., academic, community-based). Additionally, this is the first study
to our knowledge to use IPTW propensity scores as an adjustment method for controlling
for baseline covariates in analyses of erlotinib survival. We found this method to result
in a similar, although slightly reduced, risk of death compared to other adjustment
methods where individual covariates were included in the model. Correcting imbalance
in baseline covariates in observational studies through the use of IPTW propensity scores
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as covariates appears to be a useful strategy for adjustment in samples of diverse cancer
registry patients.
Conclusions
Development, approval, and clinical use of targeted and immuno therapies is
rapidly changing the treatment of patients with NSCLC. Despite education attempts, the
adoption of molecular testing and precision medicine utilization are low in South
Carolina. Reasons for this include the high costs of molecular tests that are needed to
guide therapy decisions and the complexity of interpreting molecular reports. As
precision medicine becomes an increasingly major component of lung cancer diagnosis
and treatment, providers must find ways to keep abreast of evolving scientific literature
and new molecular discoveries. The use of clinical decision support tools and
involvement on molecular tumor boards is encouraged.
This study identified several non-clinical disparities in utilization of erlotinib,
including insurance type, that should be further examined. Additionally, we found a
reduced risk of death for patients treated with erlotinib. Future research could explore the
impact erlotinib on survival in among patients with and without EGFR mutation in the
population-based setting using national datasets.
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Tables and Figures
Table 6.1. Patient, physician, and disease characteristics for the overall population and erlotinib subgroups
All Patients
(N, %)

Patient/Physician Characteristics

Erlotinib
(N, %)

No Erlotinib
(N, %)

1623

100

227

13.99

1396

86.01

-

N

%

N

%

N

%

0.001*

Age at Diagnosis (years)

148

Mean (SD)

56.8

54.9

57.1

Median

57.0

56.0

57.0

Range

23-90

30-80

23-90
0.008*

Age at Diagnosis (years)
<52

452

27.9

71

31.3

381

27.3

52-57

420

25.9

70

30.8

350

25.1

58-62

385

23.7

53

23.4

332

23.8

63+

366

22.6

33

14.5

333

23.9

Sex

P-value

0.011*

Male

956

58.9

116

51.1

840

60.2

Female

667

41.1

111

49.0

556

39.8
0.701

Race
White

943

58.1

135

59.7

808

57.9

Black

663

40.9

89

39.2

574

41.1

Other

17

1.1

3

1.3

14

1.0
0.497

Hispanic
Non-Hispanic
149

1596

98.3

222

97.8

1374

98.4

Hispanic

12

0.7

3

1.3

9

0.6

Unknown

15

1.0

2

0.9

13

0.9
0.004*

Marital Status
Not married

827

51.0

97

42.7

730

52.3

Married

531

32.7

96

42.3

435

31.2

Unknown

265

16.3

34

15.0

230

16.6
<0.001*

Insurance
State health plan

299

18.4

74

32.6

225

16.1

Medicaid

1324

81.6

153

67.4

1171

83.9
0.361

Patient Metropolitan Status
Non-metropolitan

400

24.7

50

22.0

350

25.1

Metropolitan

1223

75.3

177

78.0

1046

74.9
0.035*

Provider State
Out of state

487

30.0

82

36.1

405

29.0

In state

1136

70.0

145

63.9

991

71.0

Disease Characteristics
150

0.210

AJCC Stage
IIIB

391

24.1

47

20.7

344

24.6

IV

1232

75.9

180

79.3

1052

75.4
0.357

Grade
Low

194

12.0

27

11.9

167

12.0

High

463

28.5

56

24.7

407

29.2

Unknown

966

59.5

144

63.4

822

58.9

Histology

<0.001*

Adenocarcinoma

607

37.4

125

55.1

482

34.5

Large cell

143

8.8

8

3.5

135

9.7

Squamous

389

24.0

33

14.5

356

25.5

Mixed or other NSCLC

484

29.8

61

26.9

423

30.3
0.969

Primary Site
Main bronchus

96

5.9

12

5.3

84

6.0

1155

71.1

164

72.3

991

71.0

Overlapping lesion

48

3.0

7

3.1

41

2.9

Lung and bronchus, NOS

324

20.0

44

19.4

280

20.1

Lobe

151

0.753

Year of Diagnosis
Prior to 2010

1152

71.0

159

70.0

993

71.1

2010 or later

471

29.0

68

30.0

403

28.9
0.002*

Molecular Testing
No

1583

97.5

214

94.3

1369

98.1

Yes

40

2.5

13

5.7

27

1.9

Abbreviations: N, number; NOS, not otherwise specified; NSCLC, non-small cell lung cancer; SD, standard deviation
*Significant at the p≤0.05 level.

Table 6.2. Univariable and multivariable logistic regression results for receiving erlotinib
Univariable Logistic Regression

Multivariable Logistic Regression

Unadjusted OR

95% CI

P-value

Adjusted OR

95% CI

P-value

0.97

0.96-0.99

0.001*

0.97

0.96-0.99

0.004*

Patient/Physician Characteristics
Age at Diagnosis (years)

0.010*

Sex
Male
152

Female

Reference
1.45

Reference

1.09-1.92

1.35
0.779

Race
White

Reference

Black

0.93

0.70-1.24

Other

1.28

0.36-4.52
0.557

Hispanic
Non-Hispanic
Hispanic

0.048*

Reference
2.06

0.55-7.68

1.00-1.81

Unknown

0.95

0.21-4.25
0.004*

Marital Status
Not married

Reference

Married

1.66

1.22-2.26

Unknown

1.11

0.73-1.68
<0.001*

Insurance
State health plan
Medicaid

Reference
0.40

153

0.84

Reference
0.031*
1.38

1.03-1.86

<0.001*
2.03

Reference

1.43-2.89
Reference

Disease Characteristics
AJCC Stage

0.20-0.42

0.60-1.18

Provider State

In state

0.29
0.324

Metropolitan

Out of state

Reference

0.29-0.54

Patient Metropolitan Status
Non-metropolitan

<0.001*

0.199

IIIB
IV

Reference
1.25

0.89-1.77
0.359

Grade
Low

Reference

High

0.85

0.52-1.39

Unknown

1.08

0.69-1.69
<0.001*

Histology
Adenocarcinoma

<0.001*

Reference

Reference
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Large cell

0.23

0.11-0.48

0.28

0.13-0.60

Squamous

0.36

0.24-0.54

0.44

0.29-0.68

Mixed or other NSCLC

0.56

0.40-0.78

0.64

0.46-0.91

0.964

Primary Site
Main bronchus

0.86

Lobe

0.46-1.62
Reference

Overlapping lesion

1.03

0.46-2.34

Lung and bronchus, NOS

0.95

0.66-1.36

0.738

Year of Diagnosis
Prior to 2010
2010 or later

Reference
1.05

0.78-1.43
0.001*

Molecular
No
Yes

0.018*

Reference
3.08

Reference

1.57-6.06

2.37

1.16-4.85

Abbreviations: CI, confidence interval; N, number; NOS, not otherwise specified; NSCLC, non-small cell lung cancer; OR, odds ratio
*Significant at the p≤0.05 level.
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Table 6.3. Univariable and multivariable Cox proportional hazards regression for overall survival
Univariable Cox Proportional Hazards
Regression

Multivariable Cox Proportional
Hazards Regression

Unadjusted HR

95% CI

P-value

Adjusted HR

95% CI

P-value

1.01

1.01-1.02

<0.001*

1.01

1.00-1.01

0.007*

Patient/Physician Characteristics
Age at Diagnosis (years)

0.080

Sex
Male

Reference

Female

0.91

0.82-1.01
0.768

Race
White

Reference

Black

0.96

0.87-1.07

Other

0.97

0.59-1.59
0.370

Hispanic
Non-Hispanic

Reference

156

Hispanic

0.67

0.35-1.28

Unknown

1.21

0.71-2.05
0.914

Marital Status
Not married

Reference

Married

0.98

0.87-1.10

Unknown

1.01

0.87-1.16
0.547

Insurance
State health plan
Medicaid

Reference
1.04

0.91-1.19

0.902

Patient Metropolitan Status
Non-metropolitan

0.99

Metropolitan

0.88-1.12
Reference
<0.001*

Provider State
Out of state

0.74

In state

0.66-0.83

<0.001*
0.76

Reference

0.68-0.85
Reference

Disease/Treatment Characteristics
<0.001*

AJCC Stage
157

IIIB
IV

Reference
1.82

Reference

1.60-2.06

1.96
0.005*

Grade
Low

Reference

High

1.28

1.07-1.54

Unknown

1.31

1.11-1.55
0.074

Histology
Adenocarcinoma

<0.001*

Reference

1.73-2.23

Large cell

1.20

0.99-1.45

Squamous

1.13

0.99-1.29

Mixed or other NSCLC

1.15

1.02-1.31
0.001*

Primary Site
Main bronchus

1.19

Lobe

0.96-1.48

0.010*
1.20

Reference

0.97-1.49
Reference

Overlapping lesion

1.38

1.02-1.85

1.37

1.02-1.82

Lung and bronchus, NOS

1.25

1.10-1.42

1.18

1.04-1.35

158

0.078

Year of Diagnosis
Prior to 2010
2010 or later

Reference
0.90

0.87

0.77-0.98

0.005*

No

0.024*

Reference
0.59

Reference

0.41-0.85

0.65

0.45-0.95

<0.001*

Erlotinib
No

Reference

0.80-1.01

Molecular

Yes

0.020*

Reference

<0.001*
Reference

Yes

0.68

0.59-0.79

0.65

0.56-0.75

Abbreviations: CI, confidence interval; HR, hazards ratio; N, number; NOS, not otherwise specified; NSCLC, non-small cell lung
cancer
*Significant at the p≤0.05 level.
Table 6.4. Comparison of adjustment methods for estimating the impact of erlotinib utilization on overall survival

Method

Comparison of Adjusted Cox Proportional Hazards
Regression Methods
Adjusted HR
95% CI
P-value

159

Cox PH model, individual
0.65
0.56-0.75
<0.001*
covariates
Propensity score,
0.57
0.46-0.71
<0.001*
parsimonious
Propensity score,
0.59
0.48-0.73
<0.001*
non-parsimonious
Abbreviations: CI, confidence interval; HR, hazards ratio; PH, proportional hazards
*Significant at the p≤0.05 level.

Abbreviations: NSCLC, non-small cell lung cancer; SCCCR, South Ca160rolina Central
Cancer Registry; SHP, State Health Plan
Figure 6.1. Lung cancer registry case and corresponding claims inclusion and
exclusion
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Figure 6.2. Overall survival for all non-small cell lung cancer patients, stratified by
whether they received (solid line) or did not receive (dashed line) erlotinib
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CHAPTER VII:
SUMMARY
Conclusion
This dissertation focused on two approaches to improving outcomes for patients
with lung cancer --- early diagnosis through screening with low-dose computed
tomography and utilization of precision medicine. The latter included two topics of
interest, molecular testing and targeted therapies, specifically administration of erlotinib.
Lung cancer screening with annual LDCT reduces all cause and lung cancer
mortality and is recommended by leading public health agencies. However, national
rates of LDCT utilization remain low and this impedes early diagnosis of lung cancer.
Family physicians reported feeling responsible for lung cancer screening discussions and
LDCT follow-up. While the majority of family physicians interviewed reported making
at least one LDCT referral, they acknowledged that their knowledge of lung cancer
screening is suboptimal. To ensure that patients are receiving the appropriate information
regarding the risks and benefits of lung cancer screening and are engaged in the decisionmaking process, educational outreach initiatives highlighting the importance of lung
cancer screening using LDCT in high risk patients, as well as the risks and benefits of
LDCT, are warranted. Additionally, education outlining the process for making a LDCT
referral and billing for both the lung cancer screening counseling visit and LDCT is
encouraged. Tools to assist clinicians both at the point of care, such as decision aids and
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copay estimators, and to make LDCT referrals (e.g., easy to use electronic order forms)
are likely to increase utilization of lung cancer screening in the primary care setting.
Along with early detention, new precision medicine tools are available to help
providers guide treatment decisions for patients with advanced lung cancer. Tumor
molecular testing was low in South Carolina (~2%), as was erlotinib utilization (~14%),
but patients who received these had a 7 month increase in survival over patients who did
not receive molecular testing or erlotinib. Educational efforts should be targeted towards
oncologists and oncology advanced care practioners and should focus on demonstrating
the importance of molecular testing to provide the information needed to select the most
appropriate treatment option. Additionally, institutional efforts to support oncologists,
such as molecular tumor boards, care pathways, and electronically accessible order
forms, should continue to be developed and implemented.
In a traditionally underserved disease area, we must continue to raise awareness
of the ability of emerging technologies, such as LDCT and molecular testing, to support
improved lung cancer outcomes. Additionally, we should advocate for insurance
coverage of these services. We should also continue to provide information to providers
and patients that these services are available and provide direction on how to access the
services.
Future Research
Additional research in the areas of lung cancer screening and molecular testing
are needed and this dissertation identified specific areas to target. Utilization rates for
both LDCT and molecular testing are low in South Carolina and nationally and reasons
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for this should be further explored. Additionally, utilization of molecular testing in other
cancer sites (e.g., colorectal) could be explored.
With regards to lung cancer screening, areas of further research interest include
identifying how family physician practices follow up with their patients after a referral
for a LDCT and determining the best approaches to documenting and billing for lung
cancer screening counseling visits. Additionally, future research could assess the
perspectives and practices of non-physician providers (e.g. nurse practioners, physician
assistants), who are also able to engage in shared decision-making discussions with high
risk patients and provide referrals for lung cancer screening.
Future research into precision medicine utilization in lung cancer should also
consider use of datasets that include patient level (e.g., smoking history, molecular test
results) and provider level variables (e.g., geographic location) that we were not able to
include in our analyses of molecular testing and erlotinib utilization. Now that new CPT
codes are available that provide additional detail on the specific genes tested, we
encourage additional research in this area using these codes in national datasets, such as
SEER-Medicare.
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APPENDIX A
FAMILY PHYSICIAN SURVEY ON LOW-DOSE CT LUNG
CANCER SCREENING

The Carolina Physicians’ Lung Cancer Screening Survey is a survey of family
physicians in North and South Carolina. In this survey, we request that you answer
questions about your attitudes and practices related to lung cancer screening procedures,
even if you are not currently recommending screening to your patients. This topic
has relevance for clinicians and health care researchers because lung cancer is the most
common cause of cancer-related death in the U.S. and our state.
All information you provide in this survey will remain confidential. Participation is
voluntary; however, we would greatly appreciate your participation since not responding
could affect the accuracy of our results, and your point of view may not be adequately
represented in the survey findings. We request you fill out the survey within one week of
receiving our invitation via email. You cannot save the survey and return to it later; it
must be completed in one session. All your information will be kept confidential and
results will only be reported in aggregate form. Your name will not be connected with
any information you provide.
If you have any questions, please call the study Principal Investigator Dr. Jan Eberth at
803-576-5770 or at jmeberth@mailbox.sc.edu. You can also contact Dr. Scott Strayer, a
fellow family practitioner, at Scott.Strayer@uscmed.sc.edu or Dr. Edward Kim, a
thoracic oncologist, at Edward.Kim@carolinashealthcare.org.
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By proceeding to the survey/questionnaire on the next page you are indicating that you
have read and understood this consent form and agree to participate in this research
study.
Thank you for your participation!
_______________________________________________________
Practice Setting and Demographics
1. Please select your practice setting:
[ ] Hospital
[ ] Private practice
[ ] Group practice
[ ] Health Maintenance Organization
[ ] Community health center
[ ] Medical school/university
[ ] Other; please specify:
_______________________________________________________
2. In which state and county do you practice?
State
County

3. Please select your gender:
[ ] Male
[ ] Female
4. Please select your race (Check all that apply)
[ ] White
[ ] Black or African American
[ ] American Indian or Alaska Native
[ ] Asian
[ ] Hawaiian/Pacific Islander
[ ] Other
4a. Do you consider yourself Hispanic/Latino?
[ ] Yes
[ ] No
5. Please select your age range:
[ ] 20-29
[ ] 60-69
[ ] 30-39
[ ] 70-79
177

[ ] 40-49
[ ] 50-59

[ ] 80+

6. What is your specialty?
[ ] Family medicine
[ ] General medicine
[ ] Internal medicine
[ ] Other, please specify:
LDCT Screening Recommendations & Guidelines
7. Which, if any, lung cancer screening test would you recommend for the
following patients? Assume that these patients have:
•
No symptoms of lung cancer
•
Never been screened for lung cancer before
•
Expressed no interest for lung cancer screening
•
Have no occupational exposure to lung carcinogens
No
Chest xLowscreening
ray
dose CT
50-year-old nonsmoker with:
• 30 years second-hand
smoke exposure from
spouse
50 year old current smoker
with:
• 20 pack-years of smoking
• Family history of lung
cancer
60 year old current smoker
with:
• 30-year pack history
70 year old former smoker
with:
• 30-year pack history
• Quit smoking 20 years ago
8. How often should patients at high risk for lung cancer be screened using lowdose CT (assuming low-dose CT is performed solely for lung cancer screening)?
[ ] Every 6 months
[ ] Every year
[ ] Every 2 years
[ ] Every 3 years
9. To the best of your knowledge, do the following organizations recommend the
use of low-dose CT for lung cancer screening in asymptomatic, high risk
patients? Check one box in each row.
178

Yes,
recommen
d

No, don’t
recommen
d

Not sure

U.S. Preventive Services
Task Force
American Cancer Society
National Comprehensive
Cancer Network
American College of
Radiology
American Academy of
Family Physicians
10. I have the time I need to stay abreast about current cancer screening guidelines.
[ ] Agree [ ] Disagree
Benefits and Risks of Screening
11. What do you consider to be the benefits of low-dose CT (for lung cancer
screening) for patients at high risk for lung cancer? Check all that apply.
[ ] Reduces lung cancer mortality
[ ] Increases the chances of finding lung cancer at an earlier stage
[ ] Low rate of false positives
[ ] It is beneficial for all patients, regardless of smoking history
[ ] No benefits
12. What do you consider to be the risks of low-dose CT for lung cancer screening
for patients at high risk for lung cancer? (Check all that apply)
[ ] Positive screening results rarely result in a lung cancer diagnosis
[ ] High rate of false negatives, leading to inaccurate reassurance given to people
with lung cancer
[ ] Psychological stress or anxiety for the patient
[ ] May lead to unnecessary diagnostic procedures
[ ] Exposure to radiation increasing cancer risk
[ ] No risks
Cost of Screening
13. Do Medicare/Medicaid cover the cost of low-dose CT for lung cancer screening
for high risk patients?
[ ] Yes
[ ] No
[ ] Not Sure
14. Do most private insurers cover the cost of low-dose CT for lung cancer screening
for high risk patients?
179

[ ] Yes
[ ] No
[ ] Not sure
Practice Patterns
15. During the past year did any of your patients ask if they can or should be
screened for lung cancer?
[ ] Yes
[ ] No

About how many patients?

16. How many patients have you referred for low-dose CT (for lung cancer
screening) in the past month? (Give your best estimate)

17. How many patients have you referred for low-dose CT (for lung cancer
screening) in the past year? (Give your best estimate)

18. Medicare/Medicaid require that patients considering LDCT screening for lung
cancer first have a shared decision-making visit with a healthcare provider. A
shared decision-making visit should include a discussion of the benefits and
harms of LDCT screening, follow-up diagnostic testing, over-diagnosis, the false
positive rate and total radiation exposure.
To what extent do you feel comfortable engaging in a discussion of this nature
with your patient?
[ ] I was not aware of this requirement
[ ] Very comfortable
[ ] Somewhat comfortable
[ ] Somewhat uncomfortable
[ ] Very uncomfortable
[ ] Unsure

19. Medicare/Medicaid require that providers counsel their patients on smoking
cessation, or encourage them to remain abstinent from smoking if former
smokers, before referring them for lung cancer screening.
To what extent do you feel comfortable engaging in a smoking
cessation/abstinence discussion with your patient?
[ ] I was not aware of this requirement
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[
[
[
[
[

] Very comfortable
] Somewhat comfortable
] Somewhat uncomfortable
] Very uncomfortable
] Unsure

20. How likely would you be to engage in this shared decision-making and smoking
cessation discussion with your patient if the visit took:
Very likely

Likely

Not
likely

Not very
likely

< 5 minutes
5-10 minutes
>10 minutes
21. How often to you discuss the risks and benefits of low-dose CT with patients you
recommend for lung cancer screening?
Always

Frequently

Sometimes

Infrequently

Never

22. Which best describes your practice style concerning low-dose CT for lung cancer
screening? (Please check only one box.).
Recommend screening to
patients without discussion of
risks and benefits
Discuss risks and benefits, then
recommend screening
Discuss risks and benefits, then
let patient decide to be screened
Discuss risks and benefits, then
recommend against screening
Do not discuss risks and
benefits or recommend
screening
Recommend against screening
23. If a patient recommended for low-dose CT initially declines screening, I still
encourage him/her to participate in the screening procedure.
[ ] Agree [ ] Disagree
Attitudes towards Screening
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24. Tell us about your opinions about low-dose CT for lung cancer screening. Check
one box per row.

Strongly Agree
Disagree
1
2
The benefits of low-dose CT
outweigh the risk for
patients at high risk for lung
cancer.
There is clear evidence that
low-dose CT for lung cancer
screening saves lives.
Low-dose CT screening for
lung cancer is cost-effective.
The rate of false positives
for low-dose CT is too high.
Low-dose CT creates
enough anxiety to negate the
value of screening.
The scientific evidence is
strong enough to warrant a
screening guideline for high
risk patients.
There is no need to educate
patients about low-dose CT
because in general they
want to be screened.
If cost were not an issue, I
would recommend low-dose
CT screening to my patients
at high risk for lung cancer.
I am not sure how to refer
my patients for LDCT
screening.
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Strongly
3

4

5

Management of LDCT Screening Results
25. If a patient is found to have a positive low-dose CT scan for lung cancer, to what
extent would you be comfortable managing the follow-up of your patient?
[ ] Very comfortable
[ ] Somewhat comfortable
[ ] Somewhat uncomfortable
[ ] Very uncomfortable
[ ] Unsure
Future Contact
26. Are you interested in being contacted at a later date to provide further
information on your opinions regarding lung cancer screening?
[ ] Yes
[ ] No
26a. If you answered yes to Question 26, please provide contact information that
you would like us to use to reach you in follow-up studies (name, address, phone
and email). Note that we will use this information solely to contact you for
gathering data in future studies, and we will not share your name or contact
information with any third parties or outside groups. Your name and contact
information will be stored securely by our study group.
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APPENDIX B
FAMILY PHYSICIAN INTERVIEW GUIDE
Introduction to physician via email (Initial contact attempt):
Greetings Dr. [INSERT NAME],
Last year, you participated in a survey on lung cancer screening through the [Carolinas
HealthCare System/South Carolina Academy of Family Physicians] and agreed to be
contacted to assist us with future research on lung cancer screening. If you recall, you
completed this survey [VIA AN ELECTRONIC SURVEY LINK/ON PAPER-SENT BY
CAROLINAS HEALTHCARE SYSTEM/SC ACADEMY OF FAMILY PHYSICIANSAT THE ANNUAL MEETING].
I am a graduate student working with University of South Carolina (USC), Medical
University of South Carolina (MUSC), and Levine Cancer Institute (LCI) researchers,
Jan Eberth, Scott Strayer, Kathleen Cartmell, and Edward Kim, to conduct a research
project on physician’s perceptions of low-dose CT screening for lung cancer and we
would like to hear more about your thoughts on this topic. It’s important that we learn
what physicians know and how they feel about screening patients for lung cancer using
low-dose CT, since there are inherent risks and benefits.
We realize that your time is valuable, and we are willing to provide an incentive for
participation in a telephone interview. We anticipate that the interview will take
approximately 30-45 minutes. Are you willing to participate in the telephone interview?
If so, please respond to this email with your preferred date/time of the interview. If you
do not wish to participate, please let us know and we will note this.
Thank you for your time and we look forward to hearing from you!
Jennifer L. Ersek, MSPH, PhD(c)
(704) 654-0884
ersek@email.sc.edu
Dr. Jan M. Eberth (USC)
Dr. Kathleen Cartmell (MUSC)
Dr. Scott Strayer (USC)
Dr. Edward Kim (LCI)
Introduction to physician via email (Follow-up contact attempt):
Greetings Dr. [INSERT NAME],
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We are following up to see if you received our email sent to you on [DATE]. If you
recall, you participated in a survey on lung cancer screening through the [Carolinas
HealthCare System/South Carolina Academy of Family Physicians] and agreed to being
contacted to assist us with future research on lung cancer screening. You completed this
initial survey [VIA AN ELECTRONIC SURVEY LINK/ON PAPER-SENT BY
CAROLINAS HEALTHCARE SYSTEM/SC ACADEMY OF FAMILY PHYSICIANSAT THE ANNUAL MEETING].
Please let us know if you are willing to participate in our telephone interview. For your
valued time, we will provide a gift card to you. If you agree, please respond to this email
with potential dates/times for the interview.
If you do not wish to participate, please also let us know and we will remove you from
our contact list.
Thank you again for your time. We look forward to hearing from you soon!
Jennifer L. Ersek, MSPH, PhD(c)
(704) 654-0884
ersek@email.sc.edu
Dr. Jan M. Eberth (USC)
Dr. Kathleen Cartmell (MUSC)
Dr. Scott Strayer (USC)
Dr. Edward Kim (LCI)
Reminder email to physician 1-3 days prior to scheduled interview:
Greetings Dr. [INSERT NAME],
I am looking forward to speaking with you soon about your thoughts on using low-dose
computed tomography for lung cancer screening. I just wanted to remind you that our
interview is scheduled for [Date/Time]. I will call you at [Phone number] / please call
me at (803) 580-5156.
Please let me know if you have any questions.
Thank you again for your time,
Jennifer L. Ersek, MSPH, PhD(c)
Introduction to receptionist answering phone (Final contact attempt or any attempt for
physicians who did not provide a valid email):
Hello, my name is Jennifer Ersek and I am calling from the University of South Carolina.
Last year, Dr. [INSERT NAME] participated in a survey on lung cancer screening
through the [Carolinas HealthCare System/South Carolina Academy of Family
Physicians] and agreed to being contacted for a phone interview. What is the best way to
schedule a few minutes with Dr. [INSERT NAME] to discuss this phone interview?
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Email/phone [EMAIL: Ask for email address.] Is he/she available to speak or could I
schedule another time to talk with Dr. [INSERT NAME] to discuss this interview?
Introduction to physician via phone:
Hi Dr. [INSERT NAME], my name is Jennifer Ersek and I am a graduate student at the
USC. We are contacting you today because you indicated interest in assisting us with
future research on lung cancer screening when you participated in our survey through the
Carolinas HealthCare System/SC Academy of Family Physicians last year. If you recall,
you either completed this survey [ELECTRONICALLY THIS YEAR OR IN PAPER
FORMAT AT THE SC ACADEMY OF FAMILY PHYSICIANS ANNUAL
MEETING/VIA EMAIL SURVEY LINKLAST YEAR].
I am working with University of South Carolina and MUSC researchers to conduct a
research project on physician’s perceptions of low-dose CT screening for lung cancer and
we would like to hear more about your thoughts on this topic. It’s important that we
learn what physicians know and how they feel about screening patients for lung cancer
using low-dose CT, since there are inherent risks and benefits.
We realize that your time is valuable, and we are willing to provide *AN INCENTIVE*
for participation in the interview. We anticipate that the interview will take
approximately 30-45 minutes. Are you willing to participate in the telephone interview?
We can schedule a more convenient time for you if you prefer or we can even do the
interview now.
If yes: Great! We are looking forward to learning about your thoughts and any
experience you may have with lung cancer screening in your practice.
If no: Thank you very much; I hope you have a pleasant day.
Consent: Let me quickly review a few specifics about this study before we continue.
Dr. Jan Eberth, a professor at the University of South Carolina, and her research team are
asking you to participate in this interview research study to learn more about your
thoughts and use of lung cancer screening. You are being asked to take part because you
are a family practice physician member of the South Carolina Chapter of the American
Academy of Family Physicians or an employee at the Carolinas HealthCare System and
you provided your contact information to us for future research.
Your participation in this study is completely voluntary. You should feel under no
pressure to be in the study. If you decide not to be in the study, your decision to not
participate will not in any way harm your relationship with the University of South
Carolina or the study investigator. You are free to stop being in the study if you change
your mind after starting the interview. As mentioned previously, for participation in this
study, you will receive *AN INCENTIVE*.
In this study, your interview responses (i.e., your study record) will be recorded. We will
then transcribe your recorded interview. We will not use your real name or any other
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identifying information in any manuscript or publication of any sort. The risks of
participation in this study are minimal but include the chance of study records being
compromised. However, the records of this study will be kept private to the best of our
ability. Your name and the name of your practice will not be associated directly with any
of the statements you make during the interview. The data generated from this study (i.e.
recorded interviews and transcripts) will be kept in a secure location. Benefits of this
study include the potential to better understand how physician’s view and utilize lung
cancer screening in South Carolina.
If you have any questions regarding the study, I will be happy to answer them today, or
via email in the future. The email address of the Principal Investigator of this study is
jmeberth@mailbox.sc.edu. If you have any questions regarding your rights as a study
participant, please feel free to contact the University of South Carolina Institutional
Review Board (IRB) by calling Lisa Marie Johnson, IRB Manager, Office of Research
Compliance, University of South Carolina at (803) 777-7095 or emailing her at
LisaJ@mailbox.sc.edu. Do you need me to repeat that phone number or email address? If
there are no questions, do I have your consent to proceed with the survey?
If yes: Great! We don’t expect you to know all of the answers to all of the questions we
have for you today. If you don’t know how to respond, please just let us know that.
If no: Thank you so much for your time today. We appreciate you taking the time out of
your busy day to take our phone call. Have a great day.
Interview Questions:
1. About Your Practice
1.1. How many physicians and advanced practioners, such as physician assistants or
nurse practioners, are in your practice? Do most practice full time?
1.2. Does your practice accept Medicare/Medicaid? What proportion of your patients
are covered by Medicare/Medicaid?
1.3. What can you tell me about the patients you see in your practice? Do you see
many cancer/lung cancer patients? Have you ever had any patients diagnosed
with lung cancer? If so, what can you tell me about them?
2. Current Evidence and Guidelines for LDCT Screening for Lung Cancer
First, we’d like to talk about current evidence and guidelines for lung cancer screening
with low-dose computed tomography.
2.1. How do you find out about new guidelines?
2.2. What can you tell me about the current lung cancer screening guidelines? What
is recommended? [Probe: If they don’t specifically mention the organizations
that make these recommendations ask, ‘What organization specifically
recommends the strategy you refer to?’]

187

2.3. What can you tell me about the type of person who should be recommended for
lung cancer screening? [Probe: Is screening recommended for everyone?
Former smokers?]
2.4. What can you tell me about the scientific evidence surrounding LDCT screening
for lung cancer? [Probe: Have you heard about the National Lung Screening
Trial or the Prostate Lung Colon Ovarian Cancer Screening Trial? If yes: What
have you heard? If no: PLCO-no mortality benefit with chest x-ray; NLST-20%
reduction in mortality with LDCT.]
3. Who to Talk to About Lung Cancer Screening in the Clinic
Next, let’s talk about who you talk to about lung cancer screening.
3.1. How do you make the decision on who to talk to about lung cancer screening?
[Probe: What types of patients would you discuss lung cancer screening with?
Do you have a way to systematically identify candidates for screening?]
3.2. What (if any) types of patients in your clinic ask on their own to be screened for
lung cancer or ask for your opinion about screening?
3.3. Patients considered to be high risk for lung cancer by the National
Comprehensive Cancer Network (Category B) are defined as those ages 55 to 80
years, asymptomatic, 30 pack year smoking history, current or have quit in past
15 years.]
How would you manage a patient who is not considered to be high risk, but is
requesting a referral for low-dose computed tomography screening? Are there
any circumstances where you would NOT recommend LCDT to someone who
may fit the definition of high risk?
4. Discussing LDCT in the Clinic
The goal of the next set of questions is to learn more about how you and your colleagues
recommend (or do not recommend) LDCT to patients in your offices, clinics.
4.1. To what extent do you think other healthcare providers in your region are
recommending LDCT?
4.2. What is your experience with recommending or not recommending LDCT
screening for high risk patients? [Probe: If they never use LDCT screening, why
not and do they intend to in the future? Can you describe the process for how you
discuss lung cancer screening with your patients? [Probe: Does this process
include shared decision making? Shared decision making is typically defined as
a ‘collaborative process that allows patients and their providers to make health
care decisions together”. SDM considers the best scientific evidence available,
as well as the patient’s values and preferences. Probe: Did you know that you
can bill for the shared-decision making visit? Describe how this communicationoriented visited that can be billed for Medicare beneficiaries and that the purpose
is for the patient and physician to discuss risks/benefits of screening, etc.] How
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comfortable are you with conducting a shared decision-making visit for lung
cancer screening with your patients, given the various pros and cons?
4.3. What are your thoughts on taking time during the patient’s appointment to
discuss lung cancer screening when the patient’s original purpose was a sick visit
or annual checkup?
4.3.1. How much time (if any) could you dedicate to this discussion? Would
you request the patient schedule a new appointment to talk specifically about
lung cancer screening?
4.4. How would you approach LDCT screening among patients who lack insurance?
[Probe: How would you discuss the costs of follow-up care and treatment if lung
cancer is found during screening?]
4.5. Do you feel that integrating lung cancer screening visit is feasible in your
clinic? If yes, what are some facilitators? If no, what are some barriers to
integration?
5.

Making the Low-Dose Computed Tomography Referral and Following Up
Next, let’s talk about making the LDCT referral and subsequent follow-up with the
patient.

5.1. How do you feel about the role primary care providers have in regard to lung
cancer screening?
5.1.1. Would you prefer to refer patients directly to a pulmonologist or
radiologist for the shared decision-making visit OR would you prefer to do it
yourself?
5.2. Have you ever referred anyone for LDCT screening? If yes, continue to 5.3. If
no, do you intend to do so in the future? What are the reasons why you would
not refer anyone? (Probe: Administrative reason, complexity with billing, etc)
5.3. For patients you have referred, did you have any difficulty making the LDCT
referral? [Probe: not know where to refer them, what to document on the referral
paperwork, etc…] Did you have any difficulty getting the scan reports?
5.4. What is the process for following-up with a patient with a positive lung nodule?
[Probe: What type of follow up would you recommend for a patient with a
pulmonary nodule? Is there a pulmonary nodule clinic in your area? Who do you
think should review the results with the patient?]
7/7/16 ADDITIONAL QUESTION--For physicians who do not appear to be supportive of
lung cancer screening with LDCT: What would kind of information or evidence would be
needed to gain your support for LDCT screening?
Conclusion:
Well, I think that about covers the questions we had for you today. Is there anything else
you would like to add or discuss? Do you have any questions for us?
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In the next few days, I will also be emailing you a document containing additional
information and resources for you about low-dose computed tomography screening.
One last thing, we think we will have enough physicians participating in these qualitative
interviews, however, in case some physicians change their mind about participating, do
you know of any other physicians that might like to participate? [If so, ask if they prefer
to reach out to the physician with our contact information or if they would like to provide
us with the physician’s contact information that is fine also.]
Thank you again, so much, for the time you spent with us today. Please feel free to
contact us if you have any questions about the study or lung cancer screening. We will
try to help you in any way!
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APPENDIX C
COMMON PROCEDURE TERMINOLOGY
BILLING CODES FOR MOLECULAR TESTING
Code

Short Description

83890 MOLECULE ISOLATE

83891 MOLECULE ISOLATE NUCLEIC
83892 MOLECULAR DIAGNOSTICS

83893 MOLECULE DOT/SLOT/BLOT

83894 MOLECULE GEL ELECTROPHOR
83896 MOLECULAR DIAGNOSTICS

83897 MOLECULE NUCLEIC TRANSFER
83898 MOLECULE NUCLEIC AMPLI EACH

83900 MOLECULE NUCLEIC AMPLI 2 SEQ

MOLECULE NUCLEIC AMPLI
83901 ADDON
83902 MOLECULAR DIAGNOSTICS
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Long Description
Molecular diagnostics; molecular
isolation or extraction, each nucleic
acid type (ie, DNA or RNA)
Molecular diagnostics; isolation or
extraction of highly purified nucleic
acid, each nucleic acid type (ie, DNA or
RNA)
Molecular diagnostics; enzymatic
digestion, each enzyme treatment
Molecular diagnostics; dot/slot blot
production, each nucleic acid
preparation
Molecular diagnostics; separation by
gel electrophoresis (eg, agarose,
polyacrylamide), each nucleic acid
preparation
Molecular diagnostics; nucleic acid
probe, each
Molecular diagnostics; nucleic acid
transfer (eg, Southern, Northern), each
nucleic acid preparation
Molecular diagnostics; amplification,
target, each nucleic acid sequence
Molecular diagnostics; amplification,
target, multiplex, first 2 nucleic acid
sequences
Molecular diagnostics; amplification,
target, multiplex, each additional
nucleic acid sequence beyond 2 (List
separately in addition to code for
primary procedure). Used in
conjunction with 83900
Molecular diagnostics; reverse
transcription

83903

83904

83905

83906

83907
83908

83909
83912
83913

83914
88384

88385

88386

Molecular diagnostics; mutation
scanning, by physical properties (eg,
single strand conformational
polymorphisms [SSCP], heteroduplex,
denaturing gradient gel electrophoresis
[DGGE], RNA'ase A), single segment,
MOLECULE MUTATION SCAN
each
Molecular diagnostics; mutation
identification by sequencing, single
MOLECULE MUTATION IDENTIFY segment, each segment
Molecular diagnostics; mutation
identification by allele specific
transcription, single segment, each
MOLECULE MUTATION IDENTIFY segment
Molecular diagnostics; mutation
identification by allele specific
translation, single segment, each
MOLECULE MUTATION IDENTIFY segment
Molecular diagnostics; lysis of cells
prior to nucleic acid extraction (eg,
stool specimens, paraffin embedded
LYSE CELLS FOR NUCLEIC EXT
tissue), each specimen
Molecular diagnostics; amplification,
NUCLEIC ACID SIGNAL AMPLI
signal, each nucleic acid sequence
Molecular diagnostics; separation and
identification by high resolution
technique (eg, capillary
electrophoresis), each nucleic acid
NUCLEIC ACID HIGH RESOLUTE
preparation
Molecular diagnostics; interpretation
GENETIC EXAMINATION
and report
Molecular diagnostics; RNA
MOLECULAR RNA STABILIZATION stabilization
Mutation identification by enzymatic
ligation or primer extension, single
segment, each segment (eg,
oligonucleotide ligation assay [OLA],
single base chain extension [SBCE], or
allele-specific primer extension
MUTATION IDENT OLA/SBCE/ASPE [ASPE])
Array-based evaluation of multiple
EVAL MOLECULAR PROBES 11-50
molecular probes; 11 through 50 probes
Array-based evaluation of multiple
molecular probes; 51 through 250
EVAL MOLECUL PROBES 51-250
probes
Array-based evaluation of multiple
molecular probes; 251 through 500
EVAL MOLECUL PROBES 251-500
probes

192

